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1.1 Thesis objective
In the late 1970s, a ubiquitously present protein was discovered to mediate protein 
turnover: ‘Most cellular proteins are in a dynamic state of constant turnover. The mechanism 
of protein breakdown […] is composed of several essential components. One of these, a small 
heat-stable polypeptide, was subsequently identified as ubiquitin, a universally occurring 
polypeptide of previously unknown function. Ubiquitin is covalently linked to protein 
substrates in an ATP-requiring reaction. […] This may be the initial signal event in protein 
degradation, since the ubiquitin-protein conjugates are degraded rapidly’ (quote from 
Hershko and Ciechanover, 19821).
Since the discovery of the ubiquitin proteasome system in the late 1970s – which 
was awarded with the 2004 Nobel Prize in Chemistry - it has become clear that the 
post-translational modification of proteins with ubiquitin has many more sophisticated 
functions than solely acting as a degradation signal to eliminate proteins from the cell. 
Therefore, ubiquitin is nowadays regarded as an important signaling molecule. 
Leukemia’s are cancer types that occur in both children and adults, and are still 
poorly curable in most adult cases. These cancer types are caused by malignant trans-
formation of cells in the hematopoietic system, our blood cell development system. 
Hematopoiesis is a tightly regulated process which balances apoptosis, cell proliferation 
and differentiation. Imbalances in these processes are the cause of malignant transforma-
tion, which can occur de novo, or by external factors such as toxic chemicals, infections 
or auto-immune diseases. The importance of ubiquitination has been shown in all three 
processes, which makes ubiquitination an interesting target to study during malignant 
transformation. The objective of this thesis is to study the signaling role of ubiquitina-
tion in normal and malignant hematopoiesis by using genome- and proteome-wide top 
down and dedicated bottom up approaches.
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1.2 Hematopoiesis
In daily life, we are constantly exposed to harmful pathogens. Our defense to infections 
of these pathogens relies on the highly efficient immune system: particular cells in the 
blood that move through our body on constant guard. Next to pathogen defense, the 
blood system is needed for transport of necessary nutrients and oxygen to all organs, and 
for transport of waste to the waste organs, the liver and kidneys. Furthermore, our blood 
system is involved in blood vessel repair after mechanical damage2.
All these different roles of the blood are performed by many different, highly 
specific blood cells. Most of these cells are only short-lived and therefore need to be 
replenished constantly. At the apex of the hematopoietic system are the hematopoi-
etic stem cells which give rise to all mature blood cells via a tightly regulated process, 
as explained below (paragraph 1.2.1)3. The mature blood cells can be subdivided in 
myeloid and lymphoid types. The myeloid lineage consists of cells involved in the 
innate immune system (e.g. monocytes, macrophages, granulocytes), the erythroblasts 
giving rise to the red blood cells and megakaryocytes that produce platelets needed for 
hemostasis. The lymphoid lineage contains the B- and T-cells, important in the adaptive 
immune system, and the NK cells, part of the innate immune system (figure 1.1).  
1.2.1 Regulation of Hematopoiesis   
During fetal development, hematopoiesis initially occurs in the yolk sac. Later during 
embryonic development, blood cell formation is regulated in the spleen, liver and 
lymph nodes. When bone marrow starts to be formed, it slowly takes over the process, 
resulting in a complete takeover after birth. However, maturation and activation of 
some lymphoid cells will remain a function of the secondary lymphoid organs (spleen, 
thymus and lymph nodes)2.
The hematopoietic stem cells (HSCs) reside in the bone marrow. In order to constitute 
the complete array of blood cells, they contain some important stem cell characteristics. 
This cell type is long-lived and quiescent, with both self-renewal capacities to retain a 
constant pool of these cells and pluripotent capacities to differentiate towards all different 
types of mature blood cells4. The balance between self-renewal and differentiation is a 
tightly regulated process. Deregulation of this process may have severe consequences 
as will be discussed below (paragraph 1.3). HSCs give rise to multipotent progenitors 
(MPPs): a group of proliferating cells which lose lineage potential by passing lineage 
restriction points as they progress during differentiation. Originally, it was suggested 
that MPPs make strict lineage decisions towards the common myeloid-erythroid 
progenitor (CMP) or the common lymphoid progenitor (CLP) (figure 1.1a). However, 
recent data suggest that such an absolute subdivision is not occurring. In contrast, it 
seems that HSCs can give rise to several MPPs with varying lineage restriction, such 
as EPLMs (early progenitors with lymphoid and myeloid potential)5 and LMPPs 
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Figure 1.1: Hematopoiesis
A. In the established model of hematopoiesis, the hematopoietic stem cell gives rise to myeloid 
and lymphoid progenitors, which further mature towards all mature blood cells. B. In recent 
models of hematopoiesis, there is no absolute separation of the myeloid and lymphoid lineage. In 
contrast, there are several progenitors, each with distinct differentiation capacities. In this model, 
most mature blood cells can originate from more than one progenitor. Abbreviations used: HSC, 
hematopoietic stem cell; MPP, multipotent progenitor; CLP, common lymphoid progenitor; 
CMP, common myeloid progenitor; NK, natural killer; ery, erythrocyte; GMP, granulocyte-
monocyte progenitor; DC, dendritic cell; LMPP, lymphoid-primed multi-potent progenitors; 
EPLM, early progenitor with lymphoid and myeloid potential. Figure 1.1b is adapted from 
Brown et al.3.
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(lymphoid-primed multi-potent progenitors)6,7 (figure 1.1b).
The differentiation of HSCs into MPPs and further on towards mature blood cells 
is regulated by the action of cytokines, including growth factors and chemokines. These 
extracellular proteins induce intracellular signaling pathways upon binding to their 
cognate receptors. This leads to altered transcription factor activity and thereby altered 
expression profiles. The altered expression programs will direct a cell to proliferate, 
apoptose, or differentiate. For example, the transcription factor CEBPα limits HSC 
self-renewal and commits progenitor cells towards a monocytic fate8.
1.3 Malignant hematopoiesis
The complexity of hematopoiesis is reflected by the multitude of hematopoietic ma-
lignancies. Broadly, hematological malignancies can be divided into two categories: 
myeloid and lymphoid neoplasms. Acute myeloid leukemia (AML) is the main subject 
of this thesis, which belongs to the class of myeloid neoplasms. A myeloid neoplasm is 
considered AML when the percentage of neoplastic cells in the peripheral blood or bone 
marrow exceeds 20%9.
1.3.1 Acute Myeloid Leukemia
AML is diagnosed in about 600 new patients each year in The Netherlands, and conse-
quently is among the 10 most occurring types of cancer in the adult population (data 
from the Dutch integrated cancer centers, www.iknl.nl). AML also occurs in children, 
albeit less frequently. Despite major research efforts in this disease, molecular knowledge 
has not been able to raise the overall five year survival rate above 40% for adults younger 
than 60 years10,11 (for children this is 65%12). In the elderly population (above 60 years), 
which represents the majority of the patients, outcome is very poor with less than 15% 
survival after five years13. 
In AML, the myeloid lineage is affected. The uncontrolled proliferation of the 
immature leukemic cells will outcompete the healthy bone marrow cells. Therefore, 
patients often suffer from fatigue and anemia, caused by lack of erythrocytes, bruising 
because of thrombocyte insufficiency, and high susceptibility to infections due to the 
lack of healthy white blood cells.
A multitude of underlying genetic defects has been identified in AML. At 
diagnosis, patients are subdivided in different classes of AML, depending on the genetic 
defects present and the cellular morphology of the leukemic cells. This latter gives 
information about the differentiation state of the malignant clone. Depending on the 
genetic background, the five year overall survival prediction can vary from up to 80% to 
less than 10%. Together with the morphological data, a suitable treatment regimen will 
be determined, which may include chemotherapy, bone marrow transplantations, and 
targeted therapies for specific genetic defects. 
Chapter 1
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1.3.2 The hierarchical organization of AML
AML is characterized by the clonal expansion of progenitor cells, which lack the 
intrinsic capacity to differentiate into more mature cells. There is much debate on the 
origin of leukemia and whether this disease is caused by malignant transformation of 
stem cells or progenitors. The fact that human AML cells can be subdivided into fractions 
that can or cannot induce leukemia in NOD/SCID mouse recipients shows that AML is 
hierarchically organized with self-renewing cells (which are often referred to as leukemia 
stem cells (LSCs)) at the apex of the organization14. At first, it was suggested that LSCs 
belong to a specific cellular fraction of the AML cells, the immature CD34+CD38- cells. 
However, recent data have shown that in several cases LSCs can also be found in more 
mature fractions, such as CD34+CD38+ cells15,16. These data pose a controversy to the 
definition leukemic stem cell, as these cells appear not to be equivalent to the normal 
CD34+CD38- hematopoietic stem cell. Although more mature fractions can show LSC 
activity, the leukemic organization remains hierarchical, as these more mature cells give 
rise to the same mature phenotype in secondary recipients but will never revert back 
to an immature phenotype. On the contrary, the more immature LSCs give rise to 
both immature and mature phenotypes in secondary recipients7. The fact that LSCs 
show different degrees of differentiation suggests that the ‘cell of origin’ (e.g. the normal 
hematopoietic cell that transforms into a malignant cell with stem cell characteristics) 
might be different between patients16,17. 
Identifying the true LSC is of great importance for the treatment of leukemia. 
Nowadays, treatments are directed to the bulk of leukemia cells. However, as the LSC 
is in a quiescent state, this cell might not be targeted by the current treatment strategies 
such as chemotherapy, explaining the high incidence of relapse. Ultimately, eradication 
of the LSC cell would lead to a cure. Therefore, effort has been made to understand the 
genetic background and function of these cells. For this, expression profiles of several 
AML LSC fractions have been compared to their normal counterparts. These studies 
showed that leukemic cells most closely resemble their normal progenitor counterparts, 
and not the HSCs. However, the LSCs show a self-renewal-associated expression 
program not observed in normal progenitors18. This self-renewal expression program 
represents the stemness of the LSCs and appears to influence clinical outcome in AML: 
patients that highly express stem-cell related genes show a worse prognosis compared to 
patients with lower expression of stemness genes15. 
Until now, a combined genetic, flow cytometric and functional characterization 
of the LSC at single cell level has been unrealizable. Therefore, the true LSC has not 
been identified yet. With the advancing technologies, I have confidence that it will be 
possible to fully characterize this cell type within the next ten years. Only then we will 
be able to determine which processes cause normal cells to transform into malignant 
clones, which likely will result in better understanding of the clinical diversity of the 
disease. 
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1.3.3 Acquired genetic abnormalities in AML
Although the issue of identifying the LSC in AML is not completely solved, much 
is known about genetic aberrations present in AML cells, making them distinct from 
normal hematopoietic cells. These aberrations include chromosomal translocations, 
inversions, duplications or deletions of complete or partial chromosomes, subtle point 
mutations and altered expression of particular genes. Based on diagnostic testing of 
recurrent chromosomal aberrations, specific point mutations and gene expression 
alterations, patients are currently classified into three prognostic groups with good, 
intermediate and poor prognosis10 (see table 1.1a and 1.1b). Despite improved prognos-
tications for genetic subgroups of AML, predicting the correct outcome of individual 
patients remains an elusive goal. In the last decade, global gene expression arrays have 
been conducted on large AML cohorts to gain better insight into the correlation of gene 
expression in AML blasts with disease outcome19,20. Indeed, specific gene expression 
profiles that correlate with survival have been identified via this approach. Profiling is 
still a promising technique to identify novel prognostic markers, as will be shown in 
chapter 3 of this thesis which describes the prognostic impact of BRE expression in 
AML. Deregulated expression of this gene was identified via global gene expression 
analysis.
1.3.4 Deregulated pathways involved in AML development
The genetic aberrations occurring in AML have a direct influence on important cellular 
pathways. The aberrations affect transcription factors, nuclear pore complexes, epigenetic 
regulators, signaling molecules, and more21-23. The altered activity of transcription 
factors caused by some of these aberrations (expression of AML-ETO, PML-RAR, and 
CBFb-MYH11 fusion genes due to chromosomal translocations, and CEBPA double 
mutations) leads to a global change in expression profile19,20. However, other mutations 
or translocations do not trigger common global expression alterations. In those cases, 
the affected pathways seem to have more subtle effects. Recently, several research lines 
have linked aberrant ubiquitination to the pathogenesis of AML, as several mutations 
and expression alterations in the ubiquitination machinery have been identified in 
AML24,25 (see table 1.2).
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Aberration Prognostic impact
ASXL1 mutation Poor prognosis190,191
BAALC high expression Poor prognosis192,193
cCBL mutation None194
CEBPA mutation Biallelic mutation: favorable prognosis195
cKIT mutation Poor prognosis among core binding leukemia’s196-198
DNMT3A mutation Poor prognosis199-201
EVI1 epxression Poor prognosis202
FLT3 Internal Tandem Duplication Poor prognosis203,204
FLT3 Tyrosine Kinase Domain mutation Controversial194
JAK2 mutation None194
KRAS mutation None23
MN1 high expression Poor prognosis205,206
NRAS mutation None23
NPM1 mutation In FLT3-ITD negative group: favorable prognosis207
RUNX1 mutation Poor prognosis208
TET2 mutation Poor prognosis in intermediate risk subgroup209 and 
cytogenetically normal AML210
TP53 mutation Poor prognosis211
WT1 mutation Uncertain23
Favorable prognosis Intermediate prognosis Unfavorable prognosis
•	inv(16) •	All entities not classified as 
favorable or unfavorable 
prognosis
•	abn(3q) excluding t(3;5)
•	t(15;17) •	 inv(3)/t(3;3)
•	t(8;21) •	add(5q), del(5q), -5
•	 -7, add(7q)/del(7q) (except cases with favorable 
karyotype)
•	 t(6;11)
•	 t(10;11)
•	11q23 aberrations (excluding t(9;11), t(11;19))
•	 t(9;22)
•	 -17/abn(17p)
•	Complex (≥4 unrelated abnormalities)
•	Monosomal karyotype189 (at least two chromosomal 
monosomies or one single monosomy in combination 
with at least one other structural abnormality)
Table 1.1A: Prognostic classification of aberrant karyotypes in AML 
Table 1.1B: Recurrent gene mutations and altered expression levels in AML
(adapted from Grimwade et al.10)
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1.4 Ubiquitination acts as a post-translational signaling role for cellular 
proteins
Protein activity is regulated at many levels. First of all, proteins are produced in a time-
dependent fashion by transcriptional and translational regulation. After translation, their 
activity and abundance can be regulated via several post-translational modifications, like 
phosphorylation and glycosylation. Another important post-translational modification 
is ubiquitination. In this process, one or more ubiquitin moieties are covalently attached 
to a cellular protein, the substrate (see paragraph 1.4.1). Initially, ubiquitination was 
regarded as a degradation mark for the substrate26. However, over the last decades, 
many more functions have been assigned to this modification, like protein trafficking 
and complex formation27 and ubiquitination is thereby more and more regarded as a 
modification with general signaling function (see paragraph 1.4.2).
1.4.1 The ubiquitination cascade
Ubiquitin is a small polypeptide of 76 amino acids. Four genes in the human genome 
encode a total of 14 ubiquitin mRNA copies, of which the majority is translated as 
ubiquitin polymers28. These polymers are processed into single ubiquitin peptides by 
the action of deubiquitinases (DUBs). Ubiquitin can then be attached to a cellular 
substrate protein in a three step cascade. First, ubiquitin is activated by an E1 activating 
enzyme in an ATP-dependent process. Next, the activated ubiquitin is transferred to an 
E2 conjugating enzyme, by forming a thio-ester bond between the C-terminal glycine 
of ubiquitin and the catalytic site cysteine of the E2. In the final step, the E2 binds to an 
E3 ligase, which recruits the substrate, thereby linking E2 and substrate. In the E2-E3-
substrate complex, the ubiquitin molecule is transferred from the E2 to an internal lysine 
(K) of the substrate, forming an isopeptide bond via the C-terminal glycine backbone of 
ubiquitin29 (figure 1.2a). Many E3 ligases contain a specific structural domain involved 
in E2 binding, like RING and HECT domains. Ubiquitin can be directly transferred 
from the E2 to the substrate as is the case for RING E3 ligase complexes. HECT 
E3 ligases, on the other hand, form an intermediate thio-ester with ubiquitin before 
transferring ubiquitin to the substrate. This latter property has recently been shown for 
members of the TRIAD class30 of RING ligases as well, which are characterized by two 
RING fingers interspersed by a RING-like domain (DRIL, double RING finger linked) 
(J. Smit et al., manuscript submitted and Wenzel et al. 201131). DUBs are not only 
involved in processing newly translated ubiquitin polymers, but are also able to reverse 
ubiquitination by hydrolyzing the covalent interaction of ubiquitin with its substrate. 
This enables a time dependent regulation of ubiquitination.
Within the ubiquitin cascade, the E2 determines which type of ubiquitin chain 
is formed (see paragraph 1.4.2) and the E3 is responsible for the substrate specificity 
of the modification. The human genome encodes only a few E1 enzymes. Over 40 E2 
Chapter 1
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enzymes have been identified, all containing the specific catalytic core UBC (UBiquitin 
Conjugating) domain. In contrast to this few E1s and E2s, hundreds of E3 ligases are 
encoded by the human genome32. It is currently assumed that a large proportion of 
the cellular proteome is subject to ubiquitination. This explains the presence of the 
hundreds of E3s, acting as the factors that introduce substrate specificity to this process. 
Still, the human proteome is much larger than the number of E3s, implying that a single 
E3 must be able to ubiquitinate more than one substrate, which is indeed known for 
many studied E3s33,34. 
1.4.2 Structurally different ubiquitin chains regulate different substrate outcomes
The ubiquitin peptide is attached to an internal lysine of the substrate. As ubiquitin 
itself contains seven lysines (K6, 11, 27, 29, 33, 48, and 63), it can be a substrate of its 
own modification: consecutive ubiquitin molecules can bind with their C-termini to 
lysines of their preceding counterparts, hence forming chains (figure 1.2a). Another type 
of chain is the head-to-tail chain (also known as linear chain), in which the C-terminus 
of one ubiquitin forms a covalent bond with the N-terminus of a preceding ubiquitin, 
resembling the ubiquitin polymers formed during translation. These options for chain 
formation induce much versatility. Some cellular proteins are marked with a single 
ubiquitin on a single lysine (mono-ubiquitination) or on multiple lysines (multiple 
mono-ubiquitination). Poly-ubiquitination involves the formation of chains. When 
a chain is formed via identical ubiquitin lysines or linear linkages, homotypic chains 
are formed. Mixed chains occur when multiple ubiquitin lysines are used within one 
chain35,36 (figure 1.2b). 
In theory, two other possibilities in substrate ubiquitination are conceivable: 
N-terminal substrate ubiquitination, using the αNH2-group of the substrate as ubiquitin 
acceptor site, or ubiquitination of cysteine, serine or threonine side chains, forming a 
thio- or oxy-ester linked modification. Although indirect data suggest that both modifi-
cation types exist, direct evidence and information on the physiological relevance is still 
limited37-40.
The internal ubiquitin lysine used for chain formation determines the structure of 
the chain. Currently, crystal structures of K11-, K48-, K63-linked and linear ubiquitin 
chains are available. Linear and K63-linked chains closely resemble each other being 
the most extended chains with open conformations, in contrast to the more compact 
K48- and K11-linked chains41-45. Depending on the chain structure, different effectors 
can bind and will determine the consequence of the modification for the substrate. 
K48-chains lead to the degradation of the substrate by the 26S proteasome. The 26S 
proteasome is composed of a regulatory multi-protein 19S subunit and a catalytic 
20S subunit. Ubiquitinated proteins associate with proteasome subunits containing 
ubiquitin binding domains (UBDs) specific for K48-linked chains. During proteasome 
association, the substrate is unfolded and degraded in the catalytic core, while ubiquitin 
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Figure 1.2: The ubiquitination cascade
A. The covalent attachment of ubiquitin to a cellular protein is achieved in a three step cascade, 
involving E1, E2 and E3 enzymes. Deubiquitinases (DUBs) are involved in the removal of 
ubiquitin from a substrate, making this modification reversible. Different types of chains can 
be formed, and will determine the outcome for the substrate. B. Ubiquitin can be attached to a 
substrate as monomer or as chains which are formed by internal lysine linkages. Chains can be 
formed via identical lysine linkages which are called homotypic chains or via usage of multiple 
lysines, which are called mixed chains. Abbreviations used in figure: K=lysine, C=cysteine.
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is recycled by DUBs that disassemble the ubiquitin chains46. 
K63-linked chains do not lead to proteasomal degradation, but serve a signaling 
role in cellular processes. This holds true for mono-ubiquitination as well. These processes 
involve, among others, receptor internalization, protein complex formation, and cellular 
translocation of substrates. K63-linked ubiquitination will be discussed in more detail 
in the following paragraphs. The role of the other ub-linkages is still under debate. 
Proteomic studies have shown that the abundance of all linkages, except K63-linked 
chains, increase after chemical inhibition of the 26S proteasome47-49, suggesting that all 
chains except K63-linked chains target substrates for degradation. K11-linked chains 
indeed seem to be bona fide degradation signals and are involved in protein degradation 
during cell cycle and endoplasmic-reticulum-associated degradation (ERAD)47,50,51. The 
physiological relevance of the other chains, however, remains unclear36.
1.4.2.1 K63-linked ubiquitin chains fulfill signaling functions for their substrates
K63-linked chains do not target substrates for proteasomal degradation, but alter the 
activity of the substrate protein. So far, the only E2 known catalyzing these chains 
is UBC1352,53. To function as E2, UBC13 needs a cofactor. Two cofactors have been 
identified so far, UEV1a and MMS2. These UEVs (Ubiquitin E2 variant) closely 
resemble E2 enzymes, though they are not catalytically active as they lack the active 
site cysteine. By elucidating the structure of the UBC13-MMS2-donor ubiquitin in-
termediate, the specificity of this E2 complex towards K63-linked chain catalysis could 
be explained54-56. The UEV binds the acceptor ubiquitin in such a conformation that 
lysine 63 is placed in close proximity to the E2 active site which is bound to the donor 
ubiquitin via a thio-ester bond. In this conformation, K63 of the acceptor ubiquitin can 
attack the thio-ester bond and forms an isopeptide bond with the donor ubiquitin. The 
process is then repeated as the donor ubiquitin will move across the E2 complex and 
will become the acceptor ubiquitin in the next round while a new donor ubiquitin will 
be attracted by UBC13.
The E2 variant cooperating with UBC13 depends on the biological context. 
Two important pathways that depend on K63-ubiquitination are DNA damage repair 
(see paragraph 1.5.2.1) and NF-κB signaling (see paragraph 1.5.2.2). The combination 
UBC13 and UEV1a is involved in NF-κB activation, as shown below52,57,58. In contrast, 
in the process of DNA damage repair, UBC13 uses MMS2 as cofactor52. However, it 
has been suggested that MMS2 and UEV1a are both dispensable for the DNA damage 
response, as depletion of both enzymes did not inhibit downstream signaling59.
Another important role of K63-linked chains is cell-surface receptor internaliza-
tion. These endocytic processes rely on the recognition of mono- or K63-ubiquitinated 
receptors by the ESCRT machinery60-63. Proteins can then be recycled back to the 
membrane or translocated to the lysosomes, where degradation will take place (see 
paragraph 1.5.2.3).
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1.4.3 Ubiquitin binding domains mediate ubiquitination function
The general principle for downstream effects of ubiquitination, either degradative or 
non-degradative, relies on ubiquitin recognition and binding by other proteins. Proteins 
that interact with ubiquitin are characterized by small ubiquitin binding domains 
(UBDs). There is much variety in UBDs with already more than twenty different 
structural UBD families identified to date. Among the major UBD families are the 
UIMs (ubiquitin interacting motifs) and UBA-domains (ubiquitin associated). Many 
of the domains display chain specificity43,64,65. Hence, UBDs mediate the functional 
outcome of ubiquitination. One of these domains, the UBD of TAB2, is subject of a 
methodological study to isolate K63-ubiquitinated proteins, described in chapter 7.
1.4.4 The application of mass spectrometry in studying ubiquitination
A major challenge in the field of ubiquitination is determining the ubiquitin chain ar-
chitecture on a protein. Currently, most information available on chain linkages comes 
from studies using chain-specific antibodies (available for mono- and poly-ubiquitin 
and K11-, K48-, and K63-specific poly-ubiquitin chains66-68) or studies using ubiquitin 
mutants lacking one or more lysines. Using these methods, specific chains have been 
identified on several substrates. 
The nature of the covalent interaction of ubiquitin with its substrate makes it 
suitable to study this modification by tandem mass spectrometry (tandem-MS). Trypsin 
digestion of an ubiquitinated lysine leads to a double glycine (diG) remnant of the 
C-terminus of ubiquitin, observed as a 114D mass shift in MS analysis of the parent-
peptide. In this way, the abundance of ubiquitin linkages has been quantified in cells47,69. 
The percentage of mono-ubiquitination varies from 30% to 80% of the total ubiquitin 
pool depending on organism and cell type70-72. This percentage includes -apart from true 
substrate mono-ubiquitination- free ubiquitin and end-capped ubiquitin, representing 
the last ubiquitin molecule in a chain. The current view is that K48-linked chains 
account for approximately 40% of the total poly-ubiquitin chain population, followed 
by K63- and K11-linked chains, which both account for 10-20% of the total chains. The 
other types of chains (linked via K6, K27, K29, and K33) are detectable, though much 
less abundant47,69,70. The drawback of MS-analysis of ubiquitination is that the protein 
configuration is disrupted by the trypsin digestion before measurement. Therefore, it 
is challenging to prove the existence of mixed chains. Researchers have claimed the 
presence of these chains by showing MS spectra of more than one ub-linkage per purified 
protein73,74. However, this does not provide proof for mixed chains, as there might be 
multiple populations of the protein containing different homotypic chains. The only 
real proof of the existence of mixed chains has been reported by Kim et al. They show 
diG-remnants on two neighboring ubiquitin-lysines within the same peptide. However, 
this has only been shown in extracellular in vitro ubiquitination assays75.
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The diG-remnant of ubiquitin on a modified lysine after trypsin digestion is used 
to identify the modified substrate lysines by MS analysis. As only one or few lysines of a 
particular substrate are ubiquitinated, the abundance of these modified peptides is only 
low in the total trypsin digested sample. Recently, a novel method was introduced to 
preselect peptides with diG-remnants using an antibody recognizing diG-remnants in 
immunoprecipitation experiments. This greatly enhanced the subsequent MS-mediated 
identification rate of modified lysines, with over 5,000 peptide identifications in single 
experiments49,76-78.  
1.4.5 Ubiquitin is part of a larger family of posttranslational modifiers
Ubiquitin adopts a three-dimensional structure that is found in several other proteins as 
well, which are called ubiquitin-like proteins (UBLs). Some of these proteins can also be 
used for post-translational modification, like SUMO, NEDD8 and ISG1579. In other 
cases, the UBL domain is part of a larger protein in which it serves as a binding site for 
other proteins. The role of the various UBLs is outside the scope of this thesis. 
1.5 The diverse role of ubiquitination in hematopoiesis
A wide cross-section of the cellular proteome is ubiquitinated at some point. This already 
suggests that virtually all cellular processes are somehow dependent on ubiquitination. 
Indeed, ubiquitination has been shown to be involved in cell cycle regulation, receptor 
signaling, autophagy, DNA damage repair, apoptosis and many more processes80. 
Aberrancies in protein ubiquitination can have serious consequences that can contribute 
to the pathogenesis of various diseases, including cancer.
The tight regulation of cell cycle progression, apoptosis and differentiation during 
hematopoiesis is on many levels dependent on ubiquitination. Several important he-
matopoietic regulators are well known subjects for ubiquitin mediated degradation, for 
example GFI181, GATA282, AML183, CEBPα84, and MLL85. Another important function 
of ubiquitination in hematopoiesis is cell surface receptor internalization. For example, 
two important receptors regulating cell expansion, the FLT3-receptor and c-KIT, are 
ubiquitinated by the E3 cCBL and consequently internalized86. 
1.5.1 Aberrant ubiquitination in malignant hematopoiesis
In hematopoiesis, cell cycle regulation needs to be properly controlled to balance differ-
entiation and self-renewal. Cell cycle regulation is highly dependent on ubiquitin, with 
an important role for the E3 ligase component FBW7, mutated in several hematological 
malignancies87-89 (see table 1.2). The importance of ubiquitination in growth factor 
receptor signaling is exemplified by mutations in the E3 ligase cCBL90,91 (table 1.2). 
A well studied protein in cancer development is p53, an important cell cycle 
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and apoptosis regulator. This protein is mutated in more than 50% of solid tumors. 
This is in strong contrast to hematopoietic malignancies that show p53 mutations in 
less than 10% of the patients92. This ‘gatekeeper of our genome’ is likely inactivated by 
other ways in leukemia’s in order to promote malignant transformation. Indeed, it has 
been suggested that p53 is inactivated in AML by increased proteasomal degradation 
mediated by the E3 ligase Mdm293,94, although a one to one correlation of p53 and 
Mdm2 levels could not be confirmed92. A specific inhibitor of the Mdm2-p53 complex 
restores normal p53 levels in AML and thereby opposes the malignancy, which makes 
this a promising therapeutic agent in AML95,96. 
The involvement of the ubiquitin system and it’s drugability in malignant 
hematopoiesis might be best exemplified in multiple myeloma (MM). This disease is 
Aberrations Protein function Disease Ref.
A20 inactivation DUB; regulation of NF-κB signaling 
(see par.1.5.2.2)
Various hematological 
malignancies
212
BRE over-
expression
Member of BRCA1 E3 ligase complex 
involved in DNA damage repair
AML, breast cancer this 
thesis;
32, 213
cCBL mutations E3 ligase; negative regulation of receptor 
tyrosine kinase activity
Myeloid neoplasms 91, 194
CYLD 
hemizygous 
deletions and 
mutations
DUB; regulation of NF-κB signaling 
(see par.1.5.2.2)
Multiple Myeloma 214, 215
Mutations in 
Fanconi Anemia 
genes
E3 ligase complex in DNA damage 
repair
Aplastic anemia
Myeloid leukemia
Squamous cell carcinomas
Gynecological cancers
216
FBW7 
mutations
E3 ligase; regulation of cell cycle, 
mTOR, cMyc, Jun
Various malignancies, 
incl. T-ALL (no other 
hematological malignancies)
87-89
MDM2 over-
expression
E3 ligase for p53 Various hematological 
malignancies
93, 94
TRIB1 gain 
of function 
mutations
Enhanced ERK phosphorylation and 
CEBPα degradation
Case study of Down 
syndrome-related acute 
megakaryocytic leukemia
217, 218
TRIB2 over-
expression
Enhanced CEBPα degradation AML 84, 219
USP9X  over-
expression
DUB; stabilization of pro-survival 
protein MCL1
Multiple Myeloma, diffuse 
large B-cell lymphoma
220
Table 1.2: Ubiquitin-modifiers involved in malignant hematopoiesis
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characterized by neoplastic proliferation of plasma cells. Therapies using the proteasome 
inhibitor bortezomib greatly improved patient outcome, resulting in complete clinical 
responses for patients with otherwise refractory and rapidly advancing disease97. 
Considering the countless pathways which depend on ubiquitination, it is not surprising 
that more aberrations in ubiquitination have consequences for malignant transforma-
tion. In table 1.2, a short overview can be found of ubiquitin related processes involved 
in malignant hematopoiesis. 
1.5.2 K63-linked ubiquitination in hematopoiesis
Different types of ubiquitination (e.g. mono, K48-, K63-linked ubiquitination) all 
have important roles in hematopoiesis. This thesis focuses on K63-non-proteolytic 
ubiquitination. Signaling dependent on K63-linked ubiquitination is involved in 
four pathways: DNA damage repair, NF-κB and MAP kinase signaling, and receptor 
turnover. Deregulated DNA damage repair is inextricably linked to virtually all malig-
nancies: underlying genetic defects, such as chromosomal translocations originate from 
misrepaired double strand DNA breaks (DSBs) or other types of DNA damage. The 
role of K63-linked ubiquitination in DNA damage repair will be explained in detail 
in paragraph 1.5.2.1. NF-κB signaling is shown to be hyperactive in leukemia stem 
cells98,99 and survival of these cells might depend on this type of signaling100. The role 
of K63-linked ubiquitination in this pathway is explained in more detail in paragraph 
1.5.2.2. Finally, deregulated receptor turnover, which is dependent on K63-linked 
ubiquitination, is involved in leukemia pathogenesis, as mutations in E3 ligases in this 
pathway occur in various hematologic malignancies (see paragraph 1.5.2.3). 
Based on the relationships between K63-linked ubiquitination and malignant 
hematopoiesis, research has been aimed at elucidating the role of UBC13 in normal 
hematopoiesis, using various mouse models. Ubc13-/- mice are embryonically lethal, 
emphasizing the importance of this gene101,102. To study the role of UBC13 in hema-
topoiesis and NF-κB signaling, inducible gene ablation techniques were used in mouse 
models. Ubc13 haploinsufficient mice, born at Mendelian frequencies, displayed 
resistance to LPS challenges, accompanied by reduced cytokine secretion101. In contrast 
to these data, another group found no impact of homozygous Ubc13 deletion on TNF- 
or LPS-induced IκB degradation in mouse embryonic fibroblasts (MEFs)102. Interest-
ingly, they only showed modest effects on NF-κB signaling, and more profound effects 
on MAP kinase signaling103. Although the downstream signaling effects seem different 
for the two systems, the overall effect is the same as also Ubc13-/- conditional knockout 
mouse macrophages show impaired TLR-induced cytokine production102.
Recently, a hematopoiesis-restricted inducible Ubc13 knockout mouse has been 
generated, displaying death within a two week period after Ubc13 depletion104. A severe 
reduction of white blood cells (of both myeloid and lymphoid origin) and platelets in 
the peripheral blood was observed. Erythrocyte numbers were also decreased, although 
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to a lesser extent. The loss of mature blood cells was explained by a reduced frequency 
of hematopoietic progenitors in the bone marrow of Ubc13-/- mice, which was partially 
caused by increased apoptosis of these cells. In adoptive bone marrow transplantations 
in which Ubc13+/+ and Ubc13-/- cells were mixed 1:1, it was shown that wildtype Ubc13 
cells completely outcompeted the knockout cells in all tested compartments of hemato-
poiesis (LSK, LK cells, B cells and myeloid cells), indicating a severe proliferation and 
differentiation disadvantage of UBC13-/- cells104.
An additional role for UBC13 might lie in myeloid differentiation as UBC13 was 
among the most down-regulated genes during gefitinib-induced granulocytic differen-
tiation of HL60 cells105. This promyelocytic cell line model can be differentiated towards 
granulocytes by several external stimuli106. The mechanism by which gefitinib induces 
differentiation in these cells is not understood. Originally, gefitinib was designed as a 
tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR)107. As HL60 
cells do not express EGFR, other, off-target mechanisms of action must apply in these 
cells. Chapter 6 will describe data on the role of UBC13 in myeloid differentiation.
All studies discussed above show an importance of UBC13 function in hemato-
poiesis. However, the molecular pathways and targets have not been identified, which 
might very well depend on cell type and stimulation. To better understand the multiple 
roles of K63-linked ubiquitination, the next paragraphs will review the four major 
pathways that depend on this type of ubiquitination.
1.5.2.1 K63-linked ubiquitination in DNA double strand break repair
Among a multitude of different DNA lesions, DNA double strand breaks (DSBs) are 
one of the most harmful ones as unrepaired DSBs can lead to chromosomal rearrange-
ments and consequently to tumorigenesis108. Fortunately, cells are equipped with highly 
specialized repair mechanisms to quickly and reliably repair the induced DNA damage 
to maintain chromosomal integrity. The first steps in the repair mechanism of DSBs are 
highly reliant on phosphorylation, which activates a second signaling pathway mediated 
via K63-linked ubiquitination. 
Double strand breaks are sensed by the MRE11/RAD50/NBS1 (MRN) complex 
via interaction of NBS1 with single stranded DNA109. This complex recruits the ATM 
kinase110,111, which phosphorylates surrounding histone H2AX at Ser139112,113. Phos-
phorylated H2AX (γH2AX) forms the binding platform for MDC1114,115, which is then 
also phosphorylated by ATM. This enforces a positive feedback loop115-119 and catalyzes 
downstream signaling initiated by binding of the RING finger E3 ligase RNF8120-122. 
Downstream of RNF8 are the activation of the 53BP1 and BRCA1 signaling 
E3 ligase complexes that regulate the actual repair mechanisms. Recruitment of both 
complexes is dependent on a catalytically active RNF8 protein, as deletion of its RING 
domain abolishes 53BP1 or BRCA1 recruitment to the damaged DNA. Although several 
E2s can bind to RNF8123, UBC13 seems to be the important E2 for DNA damage repair. 
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Figure 1.3: Ubiquitination 
regulates DSB repair
DNA double strand break (DSB) 
repair occurs in four steps. 1. The 
break is sensed by the MRN-
complex, which recruits MDC1 
and ATM. ATM phosphorylates 
MDC1, H2A, H2AX and itself. 
MDC1 phosphorylation leads 
to RNF8 binding. HERC2, a 
binding partner of RNF8 is also 
phosphorylated. This E3 complex 
catalyzes ubiquitination on 
H2A and H2AX in concert with 
UBC13. 2. RNF168 is recruited 
to the ubiquitin chains on 
H2A(X) 3. RNF168 amplifies the 
ubiquitination. 4. The ubiquitin 
chains form a binding platform 
for the BRCA1 E3 ligase complex 
and might lead to structural 
chromosomal reorganization 
and hence 53BP1 recruitment. 
These two complexes will activate 
downstream repair pathways. 
Throughout the pathway, several 
DUBs can inhibit ubiquitination 
by actively removing ubiquitin 
from the histones (USP3, 
BRCC36) or inhibiting the 
UBC13-RNF168 complex 
(OTUD1). Black arrows indicate 
phosphorylation, blue arrows 
indicate recruitment, green arrows 
indicate ubiquitination and red 
lines indicate deubiquitination.
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Indeed, either UBC13 or RNF8 depletion completely abolishes downstream signaling. 
As UBC13 is currently the only E2 known to catalyze regulatory K63-linked ubiquitin 
chains52, this indicates that DSB repair relies on this type of chain. RNF8 and UBC13, 
in combination with the cofactor MMS2 catalyze ubiquitination on surrounding H2A 
and H2AX, presumably in the form of di-ubiquitin chains120,122. An overview of the 
pathway is illustrated in figure 1.3. 
In the last few years, two other E3 ligases have been identified in DSB repair. A 
second RING finger protein, RNF168, is recruited to the damaged region by binding 
ubiquitinated H2A via its UIM, thereby responding to RNF8 activity124,125. This gene 
is mutated in patients suffering from the immunodeficiency RIDDLE syndrome124, a 
disease associated with defective DSB repair126. RNF168 depletion almost completely 
phenocopies the depletion of RNF8124,125. Resembling RNF8, RNF168 functions as 
an E3 ligase in conjunction with UBC13 and amplifies the RNF8-induced ubiquiti-
nation of H2A. Ubiquitination assays indicate that also RNF168 catalyzes ubiquitin 
K63-linked chain formation124,125. Recent data suggest that RNF168 is actually the 
main E3 ligase catalyzing K63-linked chains in this process, and RNF8 in addition 
is involved in K48-chain formation127,128. By marking substrates for degradation by 
K48-linked chains, RNF8 seems to regulate the activity of KU80, an effector protein 
in non homologous end joining (NHEJ) DNA repair and the checkpoint kinase 2 
(CHK2), an important cell cycle regulator127. These recent data suggest that these first 
steps of DNA damage sensing are not only dependent on K63-linked ubiquitination, 
but also on K48-linked ubiquitination. However, exact regulation and effects of RNF8 
activity are currently unknown.
In contrast to RNF168, that does not bind RNF8, the second newly identified 
E3 ligase, HERC2, forms a complex with RNF8 and facilitates UBC13-mediated 
K63-linked ubiquitin chain formation129. Cells depleted of HERC2 show impaired 
interaction of UBC13 and RNF8. This indicates that HERC2 is needed for RNF8 
and UBC13 complex formation. Whether HERC2 itself is acting as E3 ligase in this 
pathway is however still an unanswered question129.
A proper orchestration of the ubiquitination events in DSB repair is important. 
In addition, the removal of ubiquitin is equally important to prevent uncontrolled ac-
cumulation of the repair machinery in undamaged cells and to restore normal DNA 
replication and transcription once the DNA has been repaired. Several DUBs opposing 
the activity of RNF8 and RNF168 have been described, for example USP3, USP11, 
OTUB1 and BRCC36130-133. 
The RNF8-RNF168-HERC2 machinery forms a link between the upstream 
MRN, γH2AX and MDC1 early DSB sensors and the more downstream effector 
complexes of 53BP1 and BRCA1. Although 53BP1 recruitment is dependent on the 
ubiquitin signaling of RNF8/RNF168, it is currently unclear how 53BP1 senses these 
signals134-136. The recruitment of BRCA1 to the upstream RNF8-mediated ubiquitination 
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is much better understood, and depends on the formed K63-linked chains. BRCA1 
is part of the so-called BRCA1 A complex. Next to BRCA1, this complex involves 
RAP80, BRCC36, BRE, ABRAXAS and MERIT40137,138. Rap80 contains two UIMs 
that directly interact with ubiquitinated histones at DNA damage sites139-143. Rap80 
shows specificity to K6- and K63-linkages139,142, consistent with the chains formed by 
the RNF8/RNF168 machinery and the BRCA1 complex. BRCA1 itself represents an 
E3 ligase. Together with BARD1 it catalyzes formation of the unconventional ubiquitin 
K6-chains144,145. However, bona fide substrates are not identified yet. 
Another subunit of the BRCA1 complex is BRE, which is subject of chapter 3, 4 
and 5 of this thesis. This 45kD protein binds the BRCA1 complex by direct interaction 
with ABRAXAS137,138,146. It contains two putative UEV domains and is able to interact 
with ubiquitin chains138. However, it is not yet known whether the UEV domains are 
needed for ubiquitin binding. Knockdown of BRE induced increased sensitivity to 
ionizing radiation and diminished BRCA1 and MERIT40 foci formation, indicating a 
functional role for BRE in the DNA damage response137,138,146-148. Next to a role in DNA 
damage, it has been proposed that BRE functions in the TNF-receptor pathway as BRE 
overexpression suppressed TNFα and cycloheximide induced apoptosis149.
Although it is clear that ubiquitination is important in regulating the repair 
process of double strand breaks, some important issues remain unsolved, especially 
regarding the divergent substrates of RNF8 and RNF168, the recruitment of 53BP1 
and downstream substrates of BRCA1, and the role of K48-linked chains in this process. 
1.5.2.2 The role of linear and K63-linked ubiquitin chains in the regulation of NF-κB 
and MAP kinase pathways
The MAP kinase and NF-κB pathways are important mediators in cellular responses 
to danger signals. The two pathways share the first steps in their activation following 
cellular binding of pathogens or other danger signals. As will be described below, this 
activation is highly dependent on the signaling function of ubiquitination150.
NF-κB proteins are a class of transcription factors regulating immune responses 
and other cytokine related processes. The NF-κB signaling pathway can be stimulated 
by various agents, for example the pro-inflammatory cytokines TNFα and IL-1β or 
bacterial danger signals such as LPS (lipopolysaccharide). These extracellular molecules 
bind to their cognate receptors on the cell membrane. Upon ligand binding, RIP1, 
TRAF2, TRAF5, TRAF6 and cIAP1/2 are recruited to the receptor151-154. These E3 
ligases catalyze the formation of K63-linked ubiquitin chains in combination with the 
E2 complex UBC13-UEV1a67,155-157. Substrates of this modification are RIP1, TRAF2 
and TRAF6 itself and NEMO. Upon ubiquitination, a complex of TAK1, TAB2 and 
TAB3 is recruited via an interaction of the TAB-UBDs with the K63-linked chains 
on the ligases43,158. The recruitment and activation of this complex is essential for the 
activation of the Inhibitor of κB Kinase (IKK) complex. This complex, comprising two 
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catalytic domains, IKKα and IKKβ, and the regulatory subunit NEMO is recruited to the 
K63-linked chains present on RIP1159 and IKKβ is subsequently phosphorylated160,161. 
In an unstimulated setting, NF-κB dimers are bound to their inhibitor IκB and are 
thereby kept in the cytoplasm. Upon activation of the IKK complex, IκB is phosphory-
lated by IKKβ, followed by poly-ubiquitination with K48-linked ubiquitin chains and 
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Figure 1.4: Unconventional ubiquitination in the NF-κB pathway
NF-κB transcription factor activation is highly dependent on ubiquitination. Upon ligand 
binding to the cell surface receptor, several E3 ligases are recruited to the receptor (TRAFs, 
cIAPs, RIP1, LUBAC complex (HOIL, HOIP, Sharpin)). These E3 ligases auto-ubiquitinate or 
ubiquitinate other substrates (e.g. NEMO) with K63- or linear chains. The IKK complex (NEMO-
IKKα-IKKβ) is activated by linear chains on NEMO, which might lead to multimerization. 
Activated IKKβ phosphorylates IκB, which is then targeted for proteasomal degradation by K48-
ubiquitin chains. The released NF-κB subunits translocate to the nucleus where they will induce 
transcription of immune regulatory genes. 
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subsequent degradation162. The NF-κB subunits then are released and translocate to the 
nucleus to activate gene transcription.
The above described data suggest that this process is highly dependent on UBC13-
mediated K63-linked ubiquitination. It was therefore unexpected that conditional 
knockout of UBC13 or ubiquitin replacement studies using K63R mutants had only 
little effect on NF-κB activation, although the MAP kinase pathway was severely 
impaired102,163. These data indicate that other E2s might be involved in the K63-linked 
chain formation or that other types of ubiquitination are important. Indeed, the latter 
has been shown in the past years.
In 2006, Kirisako et al. described the formation of linear ubiquitin chains by 
LUBAC (linear chain assembly complex), a complex consisting of two TRIAD domain 
E3 ligases, HOIP and HOIL164. Overexpression of LUBAC, but not expression of either 
ligase alone, induces NF-κB activation in several cell line models165. SHARPIN was 
recently described as a third member of the linear ubiquitin ligase complex166-168. LUBAC 
interacts with and catalyzes linear chains on NEMO165. Importantly, NEMO contains 
a ubiquitin binding domain (UBAN domain) specific for K63- and linear chains, 
although this domain shows lower affinity for K63-linked chains169,170. The binding to 
linear chains on a neighboring NEMO-molecule might therefore be implicated in mul-
timerization of several NEMO-subunits, promoting the activation of IKK kinases169. 
In the early models of NF-κB activation, recruitment of NEMO was supposed 
to be dependent on K63-linked chains attached to RIP1. However, with the novel 
knowledge that K63-linked chains are dispensable for activation, it was unclear how 
NEMO is recruited and ubiquitinated upon ligand binding. Data from Haas et al. 
suggest simultaneous recruitment of the TAK1 complex, the IKK complex and 
LUBAC171. Once recruited, LUBAC ubiquitinates NEMO, leading to downstream 
signaling. An overview of the pathway can be found in figure 1.4.
All these data together propose a model in which the type of ubiquitin chain 
dictates the downstream signaling. Linear chains formed by LUBAC activate 
NF-κB signaling, whereas UBC13 mediated K63-linked chains activate the MAPK 
pathway102,165. However, the discrimination between these two pathways is not black 
and white, as crosstalk appears to happen172. 
To prevent improper activation of the NF-κB pathway, the pathway is negatively 
regulated by several DUBs. The two most studied DUBs in this pathway are A20 
and CYLD. However, others have been described as well, for example USP21173 and 
Cezanne174. Cezanne is a specific DUB for K11-chains, introducing another chain 
complexity contributing to NF-κB signaling41. The A20 DUB is rapidly upregulated 
upon NF-κB activation175 and might therefore be important for terminating NF-κB 
activation176. In contrast, CYLD is active in non-stimulated cells and thereby prevents 
spontaneous activation of the pathway177-179. However, after activation of NF-κB, this 
protein is inactivated by phosphorylation180,181, enabling full-blown NF-κB activation. 
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1.5.2.3 Membrane receptor turnover is regulated by K63-linked ubiquitination
Cells use a multitude of membrane associated proteins for environmental sensing. 
Strength and duration of downstream cellular signaling is in many cases regulated by 
membrane turnover of these proteins via endocytosis. Following activation, membrane 
proteins are often internalized in endosomes and consequently recycled back to the 
membrane in case of re-activation or further directed to the multivesicular bodies 
(MVB) and degraded in downstream lysosomes, which are, next to the proteasome, the 
most important protein degradation sites in the cell182. 
This sorting process is regulated by so-called ‘endosomal sorting complex required 
for transport’ (ESCRT) complexes 0 to III. Mono-ubiquitination of a cargo protein is 
sufficient for direct lysosomal sorting183, however, many examples show the involvement 
of K63-linked chains in this process, like for the turnover of EGFR, TrkA and MHC 
class 1 molecules61-63. The current view is that K63-linked chains greatly enhance the 
association of ubiquitinated proteins to the MVB compared to mono-ubiquitination184. 
Following ubiquitination of the membrane receptor, the modification is recognized by 
the UIM and VHS domains of Hrs and STAM185, which are part of the ESCRT-0 
complex. This is followed by recruitment of ESCRT-I, -II and –III that recognize the 
ubiquitinated protein via several ubiquitin binding domains in each complex, leading 
to translocation of the modified protein to the MVB186. Before lysosomal degradation 
of the proteins, ubiquitin is recycled via the action of the K63- and mono-ubiquitin 
specific DUBs AMSH187 and USP8188.
1.6 Outline of this Thesis
The work described in this thesis was aimed at studying the role of ubiquitination during 
normal and malignant hematopoiesis, emphasizing on K63-linked ubiquitination. For 
this, different approaches were undertaken. A genome-wide approach was used to study 
correlations between clinical outcome and altered expression of ubiquitin related genes 
in AML. Dedicated studies on the K63-specific E2 conjugating enzyme UBC13 were 
performed to study its role in myeloid differentiation and proteome-wide studies were 
applied for the identification of substrates modified with K63-linked ubiquitin chains. 
When studying correlations between gene expression and disease outcome in 
large patient cohorts, as described in chapter 3 and 5, it is important to obtain as much 
information as possible on the clinico-pathological data of the cohort, such as genetic 
abnormalities. Therefore, novel methods are being designed to screen for genomic 
aberrations in large cohorts with higher sensitivity, better reliability and reduced analysis 
time. Chapter 2 describes the application of High Resolution Melting (HRM) analysis 
as a fast and reliable technique for screening of the recently identified mutations in 
IDH1 and IDH2 in AML.
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In Chapter 3, differences in expression levels of genes encoding the ubiquiti-
nation machinery are correlated to disease outcome in AML. Using expression data 
of more than 1,600 ubiquitin related genes, high expression of the BRCA1-complex 
member BRE was identified as a favorable prognostic marker in AML, especially in 
patients with the recurrent chromosomal MLL-AF9 translocation. Chapter 4 describes 
the mutually exclusive expression of BRE with the poor prognostic factor EVI1 in AML. 
The data of these two chapters improve patient classification in AML.
The BRCA1-complex is well-known for its involvement in breast cancer, as 
mutations in BRCA1 occur in many familial breast cancer patients. We therefore studied 
whether BRE expression correlated with prognosis in breast cancer as well. Indeed, in 
chapter 5 we show that BRE expression predicted disease outcome in breast cancer. 
Depending on whether patients received radiotherapy or not as part of their primary 
treatment, high BRE expression at diagnosis predicted a favorable or an adverse outcome, 
respectively.
In chapter 6, the role of UBC13 is studied during myelopoiesis. UBC13 levels 
were downregulated during granulocytic and monocytic differentiation of different cell 
line models. Knockdown of UBC13 in the U937 cell line hampered monocytic dif-
ferentiation, indicating that the high expression in progenitor cells might be needed for 
subsequent differentiation.
Chapter 7 describes a novel method to isolate endogenous substrates of 
K63-linked ubiquitination. Until now, research has relied on overexpression of tagged 
ubiquitin mutants to study specific chain formation. However, overexpression and the 
use of tags introduce negative side effects. The novel method described in chapter 7 
is based on the isolation of proteins with K63-linked ubiquitin chains from cellular 
extracts using K63-specific ubiquitin binding domains. After isolation, protein identifi-
cation was achieved by mass spectrometry.
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Abstract
High resolution melting (HRM) analysis is a useful technique for rapid pre-
screening of recurrent mutations. Here we compared the performance of HRM 
analysis with direct sequencing for IDH1/2 mutation detection in acute myeloid 
leukemia. Direct sequencing detected IDH1/2 mutations in 32/168 (19%) cases. 
HRM analysis detected all mutations while the false positive discovery rate was 
only 4% (7/168). By determining IDH1 R132H allele frequencies, we observed 
that there were no samples with low frequencies that would be missed by HRM 
analysis. In conclusion, mutational pre-screening by HRM analysis, followed by 
sequencing of positive samples identified by HRM analysis, significantly increases 
the speed to detect recurrent mutations.
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Introduction
Screening for recurrent mutations in leukemia is becoming increasingly important 
because many of them have an impact on disease outcome. Nowadays, mutational 
detection is mostly based on DNA sequencing of PCR products or QPCR using allele 
specific probes. With the increasing number of recurrent mutations identified in cancer, 
the development of fast and efficient approaches for mutational screening is needed. 
An alternative technique for mutation detection is high resolution melting (HRM) 
analysis1. HRM analysis is a fast ‘single-well-technique’ which combines PCR using 
a fluorescent saturating dye that is intercalated in the DNA and melt curve analysis 
afterwards. As mutations cause changes in the melting property of the PCR product, 
they are identified when compared to non-mutated samples. Positive samples in HRM 
analysis can be sequenced subsequently to determine exact nucleotide changes. 
Recently, mutations in the NADP+-dependent isocitrate dehydrogenase genes 
IDH1 and IDH2 were identified in acute myeloid leukemia (AML), myeloid dysplastic 
syndromes and myeloproliferative diseases2-8. We study the application of HRM analysis 
and direct sequencing to screen for these mutations in a cohort of 168 AML patients 
using the real-time PCR platform of Applied Biosystems (Carlsbad, CA, USA). 
Materials and Methods
Patient material
168 adult AML patients treated in the department of Hematology of the Radboud 
University Nijmegen Medical Centre in Nijmegen and the Leiden University Medical 
Centre in Leiden, the Netherlands were included in this study. Paired bone marrow 
and peripheral blood samples were available from two patients. Samples were collected 
with informed consent of all patients and healthy individuals. The study was conducted 
according to the Declaration of Helsinki. Genomic DNA was isolated from bone 
marrow or peripheral blood, according to the manufacturers’ protocol (Qiagen, Hilden, 
Germany or Machery-Nagel, Düren, Germany). Molecular screening of 11q23 trans-
locations, FLT3, TET2 and NPM1 mutations and EVI1 overexpression was carried out 
using standard procedures.
HRM analysis of IDH1 and IDH2 mutations 
IDH1 R132 and IDH2 R140 and R172 mutations were detected by HRM analysis using 
the 7500 fast-real time-PCR platform of Applied Biosystems (Carlsbad, CA, USA). 
PCR was performed using 20 ng of genomic DNA, 6 pmol of forward and reverse 
primers (Supplemental table 2.3) and 10 μL MeltDoctor HRM Master Mix containing 
basic PCR ingredients (Applied Biosystems). PCR was followed by melting curve 
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measurements and data were analyzed using HRM software v1.0 (Applied Biosystems).
Sequence analysis of IDH1 and IDH2 mutations
Sequence analysis of IDH1 R132 mutations was carried out on purified PCR products 
generated during HRM analysis using M13 forward or reverse primers. For IDH2 
mutation detection by sequence analysis, a separate PCR was used. PCR was carried 
out with 50 ng genomic DNA, 7.5 pmol forward and reverse primers including M13-
sequences (Supplemental table 2.3), 5 mM MgCl2 and 0.25 mM dNTPs using Taqman 
Gold polymerase (Applied Biosystems). After purification, sequence analysis was carried 
out with forward or reverse M13 primers. All identified mutations were confirmed by 
independent analyses.
SNP array
Genomic DNA of the patient with a homozygous R140W IDH2 mutation was analyzed 
using a 250k SNP array (Affymetrix, Santa Clara, CA, USA) as described9. 
Allele frequency analysis of IDH1 and IDH2 mutations
Allele frequencies of IDH1 R132C and IDH2 R140Q mutations in the patient 
harboring both mutations were determined by pyrosequencing as described9 using 
primers indicated in supplemental table 2.4. Relative allele frequencies of IDH1 R132H 
mutations were measured on genomic DNA using an allele specific primer in QPCR 
(Supplemental table 2.3). Allele frequencies were normalized using an albumin QPCR10 
and the ΔCt method. QPCR was performed with Taqman Gold polymerase using an 
ABI Prism 7700 (Applied Biosystems). 
Results and Discussion
Sequence analysis detected IDH1 or IDH2 mutations in 32 out of 168 patients (19%) 
(supplemental tables 2.1&2.2). Using the methods as described, mutations could also 
be detected by HRM analysis (used primer combinations are indicated in supplemental 
table 2.3). Different primers with and without M13-sequences were tested, showing 
differential results for IDH1 or IDH2 mutations (figure 2.1). No mutations were 
missed by HRM analysis. For IDH1 R132, 12 mutated samples (7.1%) were found 
both by HRM and sequence analysis while an additional 3 positive samples (1.8%) 
were found only by HRM analysis. To elucidate whether the extra mutations found by 
HRM analysis were false positives, we compared the sensitivity of both techniques. For 
this, a dilution series of genomic DNA from a mutated sample was measured by HRM 
analysis and followed by direct sequencing. Positivity in HRM analysis was lost at an 
allele frequency of approximately 9%, whereas the mutation could still be detected at 
a frequency of 4% by sequencing (supplemental figure 2.1). As sequencing was more 
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sensitive, this suggested that the extra positive samples found by HRM analysis (which 
did not contain any SNPs), represented false positive results. 19 samples were positive 
for the IDH2 R140 mutation (11.3%) by sequence analysis. Initial HRM analysis for 
this mutation identified many false positive results. However, exclusion of samples 
with low PCR yields (Ct>26.8, 8 samples) significantly improved the discrimination 
between mutated and wild type samples. After exclusion, all positive samples found by 
sequencing were confirmed by HRM analysis while an additional two false positive cases 
were identified by HRM. R172 IDH2 mutations were found in two patients (1.2%) 
both by HRM and sequence analysis and two false positive samples were found by 
HRM (1.2%) (supplemental table 2.1&2.2). 
One patient showed both an IDH1 R132C and an IDH2 R140Q mutation. 
Allele frequencies of the mutations were measured by pyrosequencing to test whether 
the two mutations co-occur in the same leukemic clone (primer combinations 
are specified in supplemental table 2.4). The allele frequency of the IDH1 R132C 
Figure 2.1: Effect of addition of M13-sequence to primers used in HRM analysis
Representative HRM analysis of 30 samples using primer combinations for IDH1 R132 (A), 
IDH2 R140 (B) and R172 (C) with (right panel) or without the addition of M13-sequences 
to the primers (left panel). Samples with a mutation are shown in red, wild type samples in 
turquoise, as assigned by the HRM software. Addition of M13-sequences to the primers only 
minimally affected the discrimination between mutant and wild type IDH1, but negatively 
influenced the discrimination of IDH2 R140 and R172 mutations.
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mutation was 15.5%, while the IDH2 R140Q frequency was even lower (data not 
shown). Because IDH1 and IDH2 mutations are typically heterozygous and the total 
allele frequencies of both mutations was below 50%, we cannot conclude whether the 
mutations represent one and the same, or independent clones. One patient exhibited a 
homozygous IDH2 R140W mutation, identified by both sequence and HRM analysis 
(supplemental figure 2.2). SNP array analysis showed that the homozygous mutation 
was caused by uniparental disomy (UPD) on a large part of chromosome 15, including 
the IDH2 locus (supplemental figure 2.3). Of the 32 patients with IDH mutations, we 
found co-occurrences with other chromosomal aberrations confirming data of previous 
studies3,4,7,8,11. Furthermore, none of the IDH1 or IDH2 mutated patients showed over-
expression of EVI1 (supplemental table 2.1). 
Low frequencies of mutated alleles may be missed using sequencing or HRM 
analysis. To test whether IDH1 mutations occur at frequencies below the detection 
limit of HRM analysis, we designed an allele specific QPCR for the most frequently 
occurring IDH1 R132H mutation (for primer combinations, see supplemental table 
2.3). We tested genomic DNA of mutation positive samples and compared these to 
healthy control samples and AML samples negative for the IDH1 R132H mutation 
(figure 2.2). Using healthy control samples, low allele frequencies were observed 
as represented by large ΔCt values between the housekeeping gene albumin and the 
allele specific IDH1 QPCR. These low allele frequencies are likely caused by aspecific 
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Figure 2.2: Relative allele frequencies of 
IDH1 R132H mutations
DNA samples of AML patients with or 
without (WT) IDH1 R132 mutations 
and donor samples were measured using 
an R132H specific QPCR. A more 
than 8-fold difference was observed 
between the sample with the lowest allele 
frequency among the R132H mutants 
compared to the sample with the highest 
allele frequency among the WT samples. 
Data are represented as relative quantity 
adjusted to albumin using the ΔCt method 
(arbitrary units (AU)), plotted in a box and 
whiskers plot (box: extends from the 25% 
to the 75% percentiles, with a line at the 
median; whiskers: minimal and maximal 
value). The p-value was calculated using 
an unpaired student’s t-test. 
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annealing of the mutant specific primer to wild type sequences. Importantly, the allele 
frequencies of healthy controls and AML patients lacking the IDH1 R132H mutation 
were comparable. In contrast, the mutated R132H samples showed low ΔCt values 
representing high allele frequencies. The minimal difference between the lowest value of 
the IDH1 R132H mutated samples and the highest value of the wild type AML samples 
was 8.3 fold. Allele frequencies within the group of patients with the IDH1 R132H 
mutation showed a minimal difference of only three-fold. As the mutation positive 
samples were all detected by HRM analysis, and there were no samples with intermedi-
ate allele frequencies, i.e. between the IDH1 R132H positive and negative groups, we 
conclude that HRM analysis is sensitive enough to detect all positive samples for this 
mutation, without false negative results. During the preparation of this manuscript, 
HRM analysis of IDH1 and IDH2 mutations in brain tumors was described using 
the less frequently used Roche platform (Lightcycler, Roche Applied Science, Basel, 
Switzerland)12. As the Applied Biosystems QPCR platform used by us is among the 
most frequently used platforms in diagnostic laboratories, HRM analysis would be 
widely applicable.
We conclude that HRM analysis is a fast and efficient way to screen patients 
for IDH1 and IDH2 mutations. After DNA isolation, HRM analysis is fast, using a 
closed, single well system, without any post-PCR processing. Afterwards, only samples 
positive in HRM analysis need to be sequenced to identify the base pair changes using 
the same PCR product, thereby significantly reducing time consuming sequencing work 
especially when large cohorts need to be addressed. HRM analysis might be a useful 
alternative for the detection of other recurrent mutations (e.g. in NPM1, FLT3 and 
CEBPA) as well.  
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Karyotype 11q23a FLT3 
ITD
FLT3 
TKD
TET2 NPM1 EVI1
O.E.b
IDH1 
R132
IDH2 
R140
IDH2 
R172
1 normal POS wt wt wt wt neg R132Cd R140Qd wt
2 normal neg wt MUT wt MUT neg R132C wt wt
3 47, XXY neg wt wt wt MUT neg R132C wt wt
4 normal neg MUT wt wt wt neg R132H wt wt
5 normal neg wt wt wt MUT neg R132H wt wt
6 normal neg MUT wt wt wt neg R132H wt wt
7 NDc NDc MUT wt wt MUT neg R132H wt wt
8 NDc NDc wt wt wt MUT neg R132H wt wt
9 normal neg wt wt wt MUT neg R132H wt wt
10 normal neg MUT wt wt MUT neg R132H wt wt
11 normal neg MUT wt wt NDc neg R132H wt wt
12 9q- neg wt wt wt wt neg R132L wt wt
13 normal neg MUT wt wt MUT neg wt R140Q wt
14 normal neg wt wt SNPg MUT neg wt R140Q wt
15 normal neg MUT wt wt MUT neg wt R140Q wt
16 normal neg wt MUT wt MUT neg wt R140Qe wt
17 der(7;12(q10;q10)
7p(der(7;12))
neg wt wt wt wt neg wt R140Q wt
18 normal neg MUT NDc wt MUT neg wt R140Q wt
19 47XX,der(7;10), 
+10,+11
neg wt wt wt NDc neg wt R140Q wt
20 normal neg MUT wt wt wt neg wt R140Q wt
21 NDc NDc wt wt wt wt neg wt R140Q wt
22 normal neg wt wt wt NDc neg wt R140Q wt
23 normal neg wt wt wt wt neg wt R140Q wt
24 normal neg wt wt wt MUT neg wt R140Q wt
25 46, XY[10] NDc wt wt wt MUT neg wt R140Q wt
26 NDc neg wt wt wt MUT neg wt R140Q wt
27 normal neg wt wt NDc NDc NDc wt R140Q wt
28 NDc NDc MUT wt NDc MUT NDc wt R140Q wt
29 NDc NDc wt wt wt MUT neg wt R140Q wt
30 NDc NDc MUT wt wt MUT neg wt R140Wf wt
31 NDc NDc wt wt MUT wt neg wt wt R172K
32 NDc NDc wt wt wt wt neg wt wt R172K
Supplemental table 2.1: Characteristics of patients with IDH1/IDH2 mutations
a11q23 translocations;
bEVI1 overexpression;
cNo data available;
dPatient 1 harbors a mutation at IDH1 R132 as well as at IDH2 R140;
eMutation found in bone marrow and peripheral blood sample;
fPatient 28 harbors a homozygous mutation at IDH2 R140;
gMutation found in AML blasts, but also in T-cells: mutation is probably a single 
nucleotide polymorphysm (SNP).
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Samples screened Wild type Mutated False positive Omitteda
IDH1 R132 170b 155 12 3 0
IDH2 R140 170b 139 20c 2 8
IDH2 R172 168b 164 2 2 0
Supplemental table 2.2: HRM data of IDH1 and IDH2 mutations in 168 AML patients
aSamples omitted based on high Ct values, reflecting inefficient PCR product amplification;
bSamples of 168 or 166 patients including two patients with bone marrow and peripheral blood samples;
c20 samples of 19 patients including one patient with a paired bone marrow and blood sample.
M13-IDH1 forward 5’-tgtaaaacgacggccagtGGCACGGTCTTCAGAGAAGC-3’
M13-IDH1 reverse 5’-caggaaacagctatgaccCAACATGACTTACTTGATCCCCATAA-3’
IDH2-R140 forward 5’-AGTTCAAGCTGAAGAAGATGTGGAA-3’
IDH2-R140 reverse 5’-CGTGGGATGTTTTTGCAGATG-3’
IDH2-R172 forward 5’-GCCCATCATCTGCAAAAACATC-3’
IDH2-R172 reverse 5’-AGGATGGCTAGGCGAGGAG-3’
Supplemental table 2.3: Primer combinations for mutation detection of IDH1 R132, 
IDH2 R140 and R172
A. optimal primer combinations for HRM analysis
B. primers for Sanger sequencing
M13-forward 5’-tgtaaaacgacggccagt-3’
M13-reverse 5’-caggaaacagctatgacc-3’
M13-IDH2-R140 forward 5’-tgtaaaacgacggccagtCGTCTGGCTGTGTTGTTGCTT-3’
M13-IDH2 reverse 5’-caggaaacagctatgaccAGGATGGCTAGGCGAGGAG-3’
C. primers and probe for IDH1 R132H allele specific QPCR
IDH1-Cons-F 5’-GGGTGGCACGGTCTTCAG-3’
IDH1-R132H-R2 5’-ACTTACTTGATCCCCATAAGCATCAT-3’
IDH1-FAM-MGB probe 5’-TTATCTGCAAAAATATCC-3’
Bases in Italics: M13 forward or reverse sequence;
Bases underlined: 2 mismatches compared to wild type IDH1, 1 mismatch compared to R132H mutation. The extra 
mutation was incorporated in the reverse primer to enhance discrimination between wild type and mutated samples.
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IDH1 
R132
PCR IDH1-R132-forward-
primer
5’-GTGGCACGGTCTTCAGAGAAG-3’
IDH1-R132-reverse-
primer-Univ1
5’-AGCGCTGCTCCGGTTCATAGATT-
TGCCAACATGACTTACTTGATCC-3’
Univ1-Biotin 5’-Biotin-GCTGCTCCGGTTCATAGATT-3’
Pyro-
sequencing
IDH1-R132-forward-seq 
primer
5’-GGGTAAAACCTATCATCATA-3’
IDH2 
R140
PCR IDH2-R140-forward-
primer
5’-CGTCTGGCTGTGTTGTTGC-3’
IDH1-R140-reverse-
primer-Univ1
5’-AGCGCTGCTCCGGTTCATAGATT- 
AGACAGTCCCCCCCAGGAT-3’
Univ1-Biotin 5’-Biotin-GCTGCTCCGGTTCATAGATT-3’
Pyro-
sequencing
IDH1-R140-forward-seq 
primer
5’-AAGTCCCAATGGAACTATC-3’
Supplemental table 2.4: Primer combinations used for pyrosequencing
Bases in Italics: universal sequence in reverse primer and in biotin-primer to add biotin label to PCR product using 
three primers in the PCR.
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100 15.5 Variant 1 Variant 1 mutant mutant
66.7 10.3 Variant 1 Variant 1 mutant mutant
53.3 8.3 Variant 1 Variant 2 mutant mutant
40 6.2 Variant 2 Variant 2 mutant mutant
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6.7 1.0 Variant 2 Variant 2 WT WT
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C
Supplemental figure 2.1: Comparing sensitivity of HRM analysis and sequencing 
Genomic DNA from an IDH1 R132C positive sample (allele frequency of 15.5%, as measured 
by pyrosequencing) was diluted in genomic DNA of an EBV-immortalized cell line with wild 
type IDH1 in a concentration range as indicated in (A). Samples were measured in duplo with 
HRM analysis (B) or sequencing analysis (C). The HRM software autocalling showed discordant 
calling between duplicates at a dilution of 53.3% (allele frequency of 8.3%). Direct sequencing 
discriminated the mutated allele at a dilution of 26.7% (allele frequency of 4.1%) and was lost 
at a dilution of 13.3% (allele frequency of 2.1%).
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Supplemental figure 2.2: HRM and sequence analysis of a patient harboring a 
homozygous R140W IDH2 mutation
A. HRM analysis showed a clear difference in the melting temperature of wild type samples (blue 
lines) and the homozygous mutation (red line). The heterozygous mutations (green lines) showed 
a double melt temperature as expected for heterozygous samples. B. Sequence analysis revealed 
a single homozygous T peak in the TGG codon (red marking), causing an Arg (CGG) to Trp 
substitution at codon 140 in the PCR product of IDH2.
Region of UPD:
Chromosome 15:
Supplemental figure 2.3: The homozygous IDH2 R140W mutation is caused by UPD
The patient with the homozygous IDH2 R140W mutation was screened for loss of heterozygosity 
using a 250k SNP array, showing UPD of a large part of chromosome 15 and a small deletion 
at 15q11. Red dots represent loss (signal<0) or gain (signal>0) of individual SNPs. Green lines 
represent heterozygous SNPs found. UPD is indicated with a blue bar.
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High BRE expression predicts favorable 
outcome in adult acute myeloid 
leukemia, in particular among 
MLL-AF9 positive patients
Sylvie M. Noordermeer, Mathijs A. Sanders, Christian Gilissen, Evelyn 
Tönnissen, Adrian van der Heijden, Konstanze Döhner, Lars Bullinger, Joop 
H. Jansen, Peter J.M. Valk, and Bert A. van der Reijden
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Chapter 3
Abstract 
Aberrations in protein ubiquitination have recently been identified in the patho-
genesis of acute myeloid leukemia (AML). We studied whether expression changes 
of over 1600 ubiquitination related genes correlated with clinical outcome in 525 
adult AML patients. High expression of one of these genes, BRE, was observed 
in 3% of the cases and predicted favorable prognosis independently of known 
prognostic factors (5-year overall survival: 57%). Remarkably, unsupervised 
expression profiling showed that 86% of high BRE expressing patients were confined 
to a previously unrecognized cluster. High BRE expression was mutually exclusive 
with FLT3 ITD, CEBPA, IDH1 and IDH2 mutations, EVI1 overexpression, and 
favorable karyotypes. In contrast, high BRE expression co-occurred strongly 
with FAB M5 morphology and MLL-AF9 fusions. Within the group of MLL-AF9 
positive patients, high BRE expression predicted superior survival, while normal 
BRE expression predicted extremely poor survival (5-year overall survival of 80% 
versus 0%, respectively, p=0.0002). Both the co-occurrence of high BRE expression 
with MLL-AF9 and its prognostic impact were confirmed in an independent cohort 
of 436 AML patients. Thus, high BRE expression defines a novel subtype of adult 
AML characterized by a favorable prognosis. This work contributes to improved 
risk stratification in AML, especially among MLL-AF9 positive patients. 
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BRE expression as prognostic factor in AML
Introduction
Acute myeloid leukemia (AML) is a heterogeneous disease characterized by recurrent 
genetic lesions that have different prognostic impact. These lesions affect various 
biological processes like gene transcription, nuclear transport, epigenetics, and signal 
transduction1-3. Recently, mutations in genes that are involved in ubiquitination have 
been identified in AML pathogenesis as well4. Ubiquitination is a post-translational 
modification of cellular proteins. In this process, the small ubiquitin protein is conjugated 
to substrate proteins as a single moiety or as ubiquitin chains. This may mark substrates 
for degradation by the 26S proteasome or may alter the substrate’s functional activity, 
depending on the type of ubiquitin chain that is attached4. Substrate ubiquitination 
is catalyzed via a three step cascade involving E1 activating enzymes, E2 conjugating 
enzymes, and E3 ligases. Like other post-translational modifications, ubiquitination is a 
reversible process, as deubiquitinases (DUBs) remove ubiquitin chains from substrates. 
Because of its versatile role in many biological pathways, it is not surprising that 
changes in protein ubiquitination contribute to cancer development including malignant 
hematopoiesis4,5. For example, mutations in the E3 ligase c-CBL have been described in 
AML and other myeloid neoplasms6,7. Mutations in this important negative regulator 
of receptor tyrosine kinases lead to prolonged receptor signaling and hence enhanced 
proliferation. Apart from gene mutations, altered expression of proteins that regulate 
ubiquitination can also contribute to leukemogenesis. An example is TRIB2 overexpres-
sion which triggers proteasomal degradation of CEBPα. This results in impaired myeloid 
differentiation and the onset of leukemia in mouse models8. Independent research lines 
have shown the potential of interfering with the ubiquitination process as anti-cancer 
therapy. Several of these therapies are currently tested in clinical trials for hematological 
malignancies9-12.
Recurrent mutations in AML have an impact on disease outcome. Treatment 
decisions are therefore dependent on the presence or absence of these mutations. Since 
expression levels of certain genes, like EVI113, are significantly associated with disease 
outcome, the type of treatment is also guided by expression levels of individual genes. 
In the last decade, gene expression profiles of large AML cohorts have been generated. 
By combining these expression data with clinical data, new prognostic AML subgroups 
have been identified14-16. Despite improved molecular based risk stratification, the 
survival within prognostic subgroups still shows large variation. The identification of 
novel recurrent mutations or expression markers with prognostic value may therefore 
improve individualized treatment strategies. 
Here we studied whether changes in expression of genes involved in ubiquitina-
tion (hereafter referred to as Ub-genes) correlated with disease outcome using outlier 
gene expression analysis. With this type of analysis, genes that are differentially expressed 
in a subset of patients are identified. By comparing the expression data of these genes 
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with clinical parameters of the patients, correlations with survival can be studied. Since 
gene expression data of large AML cohorts are available nowadays, outlier analysis has 
great potential in the identification of novel prognostic factors. Indeed, by applying this 
approach for Ub-genes, we identified a novel prognostic factor in AML. This work may 
add to the risk stratification of AML patients.
Materials and Methods
Selection of Ub-genes
The interpro database (www.ebi.ac.uk/interpro/) was used to generate a list of structural 
protein domains involved in ubiquitination, using several enzyme classes as search terms 
(e.g. E2 conjugating enzyme, E3 ligase, deubiquitinating enzyme, proteasome), as well as 
the overall term ‘ubiquitin’. The list of interpro codes was subsequently filtered manually 
for domains with a clear link to ubiquitination, including UBA (ubiquitin associated) 
and UBL (ubiquitin like) domains, resulting in a total of 121 individual codes, (supple-
mental table 3.1A). Using the gene ontology database, GO-terms involving ubiquitina-
tion were collected as well (75 GO-terms, supplemental table 3.1B). 
By use of the biomart database (www.biomart.org/biomart/martview/) genes 
containing the relevant interpro domains and GO-terms were identified. To ensure 
maximal completeness, this list of unique refseq entries was merged with a list of 
Ub-genes previously published by W. Harper and colleagues17 and an overview of human 
deubiquitinases (DUBs) generated by S. Urbé and S. Hayes (personal communication). 
Gene expression profiling of AML samples
For the present study, our previously published cohort of 525 AML patient samples, 11 
CD34+ donor samples, and 5 normal bone marrow (NBM) control samples was used18. 
Details on clinical data and experimental procedures of the micro-array profiling on the 
Affymetrix HG-U133 plus 2.0 arrays (Santa Clara, CA, USA) can be found elsewhere18. 
The array data are accessible online at the Gene Expression Omnibus (GSE14468).
To validate observed findings in an independent cohort, 40k cDNA array data 
(arrays manufactured by the Stanford Functional Genomics Facility) of a second 
previously published cohort of 436 AML patients were analyzed, including 11 MLL-AF9 
positive patients (GSE16432)19. In addition, Affymetrix HG-U133 2.0 plus array data of 
14 adult MLL-AF9 positive AML patients were used for data validation. These samples 
were provided by the German-Austrian AML Study Group (AMLSG) with patient 
informed consent obtained in accordance with the Declaration of Helsinki and institu-
tional review board approval from all participating centers. Patients were entered into 
AML HD93, AML HD98A, AMLSG 06-04 and AMLSG 07-04 treatment protocols. 
For the validation MLL-AF9 data set (n=25), BRE expression data of the 
63
BRE expression as prognostic factor in AML
3
HG-U133 plus 2.0 arrays (11 MLL-AF9 samples) and the 40k cDNA arrays (14 
MLL-AF9 samples) were combined. Data normalization and filtering for well expressed 
genes was performed separately for the cDNA and Affymetrix data sets as previously 
described20,21. Subsequently, data sets were combined following (i) the averaging of the 
expression of multiple clones/probe sets measuring the same gene (based on the gene 
symbols), and (ii) the mean-centering of the cDNA and Affymetrix data in order to 
reduce platform specific effects. Normalized BRE expression data of these 25 patients are 
available in supplemental table 3.2.
Cell isolation
For the isolation of primary donor blood cells, mononuclear cells were first isolated 
from buffy coats using ficoll 1077 gradients (GE Healthcare, Chalfont St. Giles, UK). 
Subsequently, T cells were isolated by magnetic cell sorting (MACS) using anti-CD3 
micro beads (Miltenyi Biotec, Bergisch Gladbach, Germany). From the remaining 
fraction, monocytes, NK cells and B cells were isolated by fluorescence activated cell 
sorting (FACS) using CD14 (Becton Dickinson, Franklin Lakes, NJ, USA), CD19 
(DAKO, Glostrup, Denmark) and CD56 (Becton Dickinson) antibodies, respectively. 
Granulocytes were isolated from total blood samples by MACS using anti-CD14 micro 
beads (Miltenyi Biotec). Cell purity of the hematopoietic fractions was confirmed to 
be 90% or higher by flow cytometric analyses. In addition to primary cells, the t(9;11) 
positive cell lines Molm13, Monomac-6 and THP1 were used. Isolation of AML cells, 
RNA purification, and cDNA preparation have been described before18,20. 
BRE QPCR and MLL-AF9 fusion gene detection
BRE expression was measured by QPCR on cDNA samples using a commercially available 
primer/probe set (Applied Biosystems, Carlsbad, CA, USA, Hs01046283_m1), and data 
were normalized by PBGD or beta-ACTIN QPCR22. MLL-AF9 breakpoint PCR on the 
cohort of 525 patients was performed as described before23,24. For the validation cohort, 
conventional chromosome banding and fluorescence-in-situ-hybriization (FISH) for 
MLL-AF9 translocations was performed as previously described25.
Statistical analyses
Genes with outlier expression were defined as probe sets that showed expression values 
of more than four times the standard deviation above or below the mean expression of 
all AML samples for at least one sample. As this analysis does not involve a discernible 
null-hypothesis, a p-value is not obtained. It is therefore unattainable to perform 
corrections for multiple testing. For survival analyses we selected probe sets detecting 
outlier expression in at least ten patients since this accounts for at least 2% of the 
patients, a percentage that we consider biologically and clinically relevant. In addition, 
the likelihood that correlations are found by chance would increase in smaller groups.
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The Cox proportional hazard model was used for multivariate analyses to identify 
whether genes were independent prognostic factors for overall survival (OS) and event 
free survival (EFS) (with events defined as: relapse, death by any cause, and no complete 
remission), including known prognostic factors in the model (that is, age (continuous 
variable), white blood cell count (WBC, continuous variable), FAB M5 morphology 
(positive versus negative), stem cell transplantation status, favorable karyotypes (t(8;21), 
t(15;17), inv(16)), CEBPA double mutations, FLT3 ITD, and NPM1 mutations). 
Before performing multivariate analyses, the proportional hazard assumption was tested 
for high BRE expression and no indication of non-proportionality was found.
Differences between variables of patient subgroups were statistically tested by 
performing χ2 tests, Fisher exact tests, or Mann-Whitney U-tests. Survival differences 
were visualized using Kaplan-Meier plots. Significance of survival differences between 
patient groups was calculated using the log rank method. All analyses were performed 
two-tailed. Because we anticipated that only small numbers of patients were identified 
with outlier expression per probe set, we considered p<0.05 as statistically significant.
Results
Identification of genes with prognostic impact in AML using outlier analysis
To study the expression of genes encoding proteins involved in ubiquitination, we selected 
these proteins based on the presence of catalytic domains used in the ubiquitin pathway 
and relevant GO-terms. In total, 1,618 proteins (based on HGNC nomenclature) 
were selected, which are encoded by 2,608 refseq entries (table 3.1). The Ub-genes are 
represented by 2,890 probe sets on the used Affymetrix HG-U133 plus 2.0 micro-array.
Since the introduction of micro-arrays to study gene expression in AML, novel 
prognostic subclasses have been identified based on similarities in expression profiles. 
Here, we conducted outlier expression analysis on a cohort of 525 AML patients as 
an alternative approach to study whether distinct expression of individual Ub-genes 
in subsets of patients correlated with survival. Outlier expression was defined as an 
expression level of more than four times the standard deviation above or below the mean 
expression of all AML samples (see Materials and Methods). In total, fifteen probe sets 
were identified that showed outlier expression in at least ten patients (supplemental 
table 3.3). Subsequently, overall survival of patient groups exhibiting outlier expression 
was compared to the remaining AML patients. Of these fifteen probe sets, three 
showed a significant correlation with OS (supplemental figure 3.1). One of these probe 
sets represented EVI1, which is a known prognostic factor in AML13. The other two 
represented BRE (Brain and Reproductive organ-Expressed), a member of the BRCA1 
E3 ubiquitin ligase complex. 
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High BRE expression correlates with FAB M5 morphology and the MLL-AF9 fusion
By outlier analysis, twelve high BRE expressing samples were identified based on the 
cut-off used for outlier expression. Figure 3.1 shows that these twelve samples actually 
belong to a distinct group of fourteen patients with high BRE expression (which all 
showed BRE expression higher than 3 x the standard deviation above the mean), 
representing 3% of the total AML cohort of 525 samples (figure 3.1A). Two samples 
showed intermediate expression and the remaining patients showed limited variation in 
BRE expression. To validate the BRE array expression data, a BRE specific QPCR was 
performed. The QPCR confirmed the array data as a good correlation between the two 
types of data was observed (linear regression r2>0.8, p<0.001, supplemental figure 3.2). 
We also studied whether BRE was differentially expressed during normal hematopoiesis. 
Its expression was measured in CD34+ cells, total bone marrow, and several mature blood 
cell fractions from healthy donors (T-, B-, NK- cells, granulocytes, and monocytes). All 
fractions showed BRE expression comparable to levels observed in the majority of the 
AML samples, and no high BRE expression was observed (Supplemental figure 3.3). 
Evaluating the co-occurrence of high BRE expression with known parameters in 
AML revealed high co-occurrence with FAB M5 morphology (p<0.001, figure 3.1B, table 
3.2). Furthermore, co-occurrence was found with the t(9;11) translocation (p<0.001), 
and a relatively young age (p=0.006). In contrast to these positive correlations, high BRE 
expression was mutually exclusive with FLT3 ITD mutations (p=0.027). High BRE 
expression was also mutually exclusive with favorable karyotypes, CEBPA mutations, 
Protein Family Structural domains # Refseq IDs # HGNC proteinsa
E1 activating enzymes Ubiquitin activating domain40 9 4
E2 conjugating enzymes UBC core domain41 78 43
E3 ligases RING42
TRIAD43
HECT44
PHD45
U box46
562
33
45
290
42
334
22
28
173
31
E3 complex formation SOCS box47 54 39
Substrate recruitment F-box48
BTB49
115
273
72
188
Proteasome complex 85 68
DUB UCH, USP, OUT, Josephin, 
JAMM50
98 86
Table 3.1: Representation of important ubiquitination core enzyme families in the human 
genome
DUB indicates deubiquitinating enzyme.
aNumber of proteins based on protein nomenclature by the HGNC: HUGO Gene Nomenclature Committee.
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EVI1 overexpression, and IDH1 and IDH2 mutations. The corresponding p-values were 
not significant in this cohort, likely due to low sample numbers (table 3.2).
High BRE expression was strongly associated with t(9;11) translocations as 
shown above. This translocation, leading to the MLL-AF9 fusion gene, can be missed 
by routine cytogenetic analysis. Therefore, we re-analyzed the complete cohort for the 
presence of the MLL-AF9 fusion by RT-PCR. All samples that were t(9;11) positive 
based on cytogenetic findings were also positive for the MLL-AF9 fusion in the PCR 
reaction. However, eight additional MLL-AF9 positive samples were identified by PCR 
(supplemental figure 3.4). This yielded a total incidence of 3.5% of AML cases with 
MLL-AF9 fusions (table 3.2). Five of the newly identified MLL-AF9 positive samples 
showed high BRE expression. In total, ten out of fourteen samples with high BRE 
expression contained the MLL-AF9 fusion, one had an MLL-ENL translocation, one 
had an MLL-AF10 translocation and the other two were 11q23 negative (table 3.2, 
figure 3.1C).
normal BRE 
expressing patients
high BRE 
expressing patientsa
P
Sex (N=518), no. (%) 0.788b
Male 252 (50) 6 (42.9)
Female 252 (50) 8 (57.1)
Age (N=518), years 0.006c
median (range) 47 (14-77) 37.5 (17-49)
WBC (N=518), x 109/L 0.500c
median (range) 28.6 (0.3-510) 68 (1-240)
Transplantation status (N=525), no. (%) 0.130b
No transplantation  302 (59.1) 5 (35.7)
Autologous transplantation 68 (13.3) 2 (14.3)
Allogeneic transplantation 141 (27.6) 7 (50)
FAB classification (N=509), no. (%) <0.001d
M0 17 (3.4) 1 (7.1) 0.400b
M1 100 (20.2) 0 (0) 0.083b
M2 130 (26.3) 1 (7.1) 0.130b
M3 23 (4.6) 0 (0) 1.000b
M4 93 (18.8) 0 (0) 0.084b
M5 104 (21.0) 12 (85.7) <0.001b
M6 7 (1.4) 0 (0) 1.000b 
Other/unknown 21 (4.2) 0 (0) 1.000b
Table 3.2: Characteristics of patients with high BRE expression (#14 patients)
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High BRE expression but not MLL-AF9 is an independent factor for favorable OS and EFS
To determine whether high BRE expression was an independent predictor for favorable 
OS, a multivariate analysis with the Cox proportional hazard model was performed, 
including known prognostic factors (see Materials and Methods section). First, analyses 
were performed comparing the survival of the twelve patients with outlier-high BRE 
expression to the survival of the remaining cohort. Using this cut-off, high BRE 
expression was an independent factor for both OS and EFS (hazard ratio’s: 0.15 and 
0.13, p-value’s=0.003 and 0.002 for OS and EFS, respectively) (table 3.3A). Afterwards, 
the analysis was repeated, but now by comparing the fourteen patients with the highest 
BRE expression (which showed distinct BRE expression) to the rest of the cohort. Also 
in this analysis high BRE expression was an independent factor for OS and EFS (hazard 
ratio’s: 0.3 and 0.26, p-value’s=0.047 and 0.023 for OS and EFS, respectively). In 
contrast, the presence of the MLL-AF9 fusion did not correlate significantly with OS or 
normal BRE 
expressing patients
high BRE 
expressing patientsa
P
Cytogenetics, no. (%)
t(15;17) (N=522) 25 (4.9) 0 (0) 1.000b
t(8;21) (N=522) 38 (7.5) 0 (0) 0.613b
inv(16) (N=522) 42 (8.3) 0 (0) 0.617b
11q23 (N=522) 21 (4.1) 12 (85.7) <0.001b
MLL-AF9 (N=522) 8 (1.6) 10 (71.4) <0.001b
MLL-AF10 (N=522) 2 (0.4) 1 (7.1) 0.080b
MLL-ENL (N=522) 0 (0) 1 (7.1) 0.027b
Other genetic aberrations, no. (%)
FLT3 ITD mutations (N=525)  143 (28.0) 0 (0) 0.015b
FLT3 TKD mutations (N=523) 51 (10.0) 2 (14.3) 0.643b
NPM1 mutations (N=525) 157 (30.7) 1 (7.1) 0.075b
CEBPA single mutations (N=525) 12 (2.3) 0 (0) 1.000b
CEBPA double mutations (N=525) 26 (5.1) 0 (0) 1.000b
EVI1 overexpression (N=518) 52 (10.3) 0 (0) 0.380b
IDH1 mutations (N=522) 38 (7.5) 0 (0) 0.613b
IDH2 mutations (N=522) 49 (9.6) 0 (0) 0.382b
Table 3.2 (continued)
WBC indicates white blood cell count; FAB, French-American-British.
aCut-off used for high BRE expression was mean of all AML + 3 x standard deviation;
bp-values are based on Fisher exact tests; 
cp-values are based on Mann-Whitney U-tests; 
dp-values are based on χ2 tests.
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EFS in the complete AML cohort (table 3.3A-B).
Among intermediate and high risk AML groups, patients with MLL-AF9 trans-
locations have been reported to show a relatively good prognosis26,27, although others 
have not been able to confirm this28. To address this issue in the cohort studied here, 
we determined the effect of the presence of an MLL-AF9 fusion on OS and EFS in 
intermediate and high risk patients (excluding patients with favorable karyotypes and 
CEBPA double mutations). This showed that MLL-AF9 positivity did not correlate 
significantly with favorable OS or EFS (figure 3.2A). As all fourteen patients with high 
BRE expression also belonged to the intermediate and high risk prognostic groups, we 
visualized the predictive value of high BRE expression on survival among these patients 
as well. In contrast to MLL-AF9 positivity, both OS and EFS of the fourteen patients 
with high BRE expression were significantly better compared to the remaining patients 
(5-year OS of 27.5±2.3 vs. 57.1±13.2%, p-value=0.04 and 5-year EFS of 20.0±2.1 
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Figure 3.1: High BRE expression correlated 
strongly with FAB M5 morphology and 
MLL-AF9 rearrangements 
A. Gene expression profiling showed that high 
BRE expression, as represented by the probe 
set intensity of 212645_x_at, occurred in 14 
out of 525 AML patients, accounting for 3% 
of the cohort. Donor CD34+ and normal bone 
marrow cells did not show high BRE expression. 
B. High BRE expression correlated with FAB 
M5. BRE expression is visualized per FAB 
morphology class. C. High BRE expression co-
occurred with the presence of the MLL-AF9 
fusion. BRE expression is represented by the 
fluorescent intensity of probe set 212645_x_at. 
Other probe sets representing BRE (205550_s_
at and 211566_x_at) showed comparable results 
(data not shown). The mean per subclass is 
represented by a horizontal line. Dotted lines 
represent the mean of all AML samples plus 3 
or 4 x the standard deviation of BRE expression, 
used as values for outlier analysis and cut-off for 
high BRE expression, assigning 14 or 12 samples 
with high expression, respectively.
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vs. 57.1±13.2%, p-value=0.01 for patients with normal and high BRE expression, re-
spectively) (figure 3.2B). In conclusion, high BRE expression correlated with favorable 
outcome in poor and intermediate risk prognostic groups and was an independent 
factor for clinical outcome in AML.
OS EFS
HR 95% CI P HR 95% CI P
High BRE 0.15 0.042-0.52 0.003 0.13 0.038-0.47 0.002
MLL-AF9 1.82 0.81-4.1 0.15d 1.52 0.68-3.4 0.31d
Favorable karyotypea 0.30 0.21-0.43 <0.001 0.32 0.23-0.44 <0.001
CEBPA double mutation 0.26 0.14-0.50 <0.001 0.28 0.16-0.50 <0.001
NPM1 mutation 0.45 0.34-0.59 <0.001 0.41 0.31-0.53 <0.001
FLT3 ITD 1.60 1.2-2.1 <0.001 1.55 1.2-2.0 0.001
Transplantation statusb 0.68 0.60-0.78 <0.001 0.75 0.66-0.85 <0.001
FAB M5 1.05 0.80-1.4 0.73 1.00 0.77-1.3 0.98
Agec 1.01 1.0-1.0 0.080 1.00 1.0-1.0 0.52
WBCc 1.00 1.0-1.0 0.097 1.00 1.0-1.0 0.027
Table 3.3: High BRE expression is an independent prognostic factor for OS and EFS, 
based on the multivariate Cox regression hazard model
A. High BRE expression based on mean of all AML + 4x standard deviation (12 patient samples)
B. High BRE expression based on mean of all AML + 3x standard deviation (14 patient samples)
OS EFS
HR 95% CI P HR 95% CI P
High BRE 0.30 0.094-0.98 0.047 0.26 0.08-0.83 0.023
MLL-AF9 1.29 0.52-3.22 0.58d 1.11 0.46-2.7 0.82d
Favorable karyotypea 0.31 0.22-0.45 <0.001 0.33 0.24-0.46 <0.001
CEBPA double mut 0.28 0.15-0.52 <0.001 0.30 0.17-0.52 <0.001
NPM1 mut 0.47 0.36-0.62 <0.001 0.43 0.33-0.56 <0.001
FLT3 ITD 1.54 1.2-2.0 0.001 1.48 1.1-1.9 0.003
Transplantation statusb 0.70 0.61-0.80 <0.001 0.76 0.67-0.87 <0.001
FAB M5 1.09 0.83-1.4 0.54 1.05 0.81-1.4 0.72
Agec 1.01 1.0-1.0 0.059 1.00 1.0-1.0 0.43
WBCc 1.00 1.0-1.0 0.32 1.00 1.0-1.0 0.13
Mut indicates mutation; FAB, French-American-British; WBC, White Blood Cell count; OS, Overall Survival; EFS, 
Event Free Survival; HR, Hazard Ratio; CI, confidence interval.
aFavorable karyotype: t(8;21), t(15;17), and inv(16);
bTransplantation status: either no transplantation, autologous transplantation or allogeneic transplantation;
cContinuous variables;
dThe p-value of MLL-AF9 is mainly affected by co-occurrence with high BRE expression (based on correlation of 
regression coefficients, data not shown).
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Figure 3.2: High BRE expression correlated with superior OS in intermediate and poor 
risk patients
A. Kaplan-Meier plots for OS (left panels) and EFS (right panel) showed that MLL-AF9 
positivity did not correlate significantly with a good OS or EFS among the intermediate and poor 
risk AML patients (i.e. excluding patients with t(15;17), t(8;21), inv(16) and CEBPA double 
mutations) (5-year OS of 27.2±2.4 vs. 44.4±11.7%, p-value=0.17 and 5-year EFS of 20.2±2.1 vs. 
44.4±11.7%, p-value=0.067 for MLL-AF9 negative and positive patients, respectively). B. In the 
group of intermediate and poor risk AML patients, patients with high BRE expression exhibited 
a significantly better OS and EFS (5-year OS of 27.5±2.3 vs. 57.1±13.2%, p-value=0.04 and 
5-year EFS of 20.0±2.1 vs. 57.1±13.2%, p-value=0.01 for patients with normal and high BRE 
expression, respectively). C. Within the group of MLL-AF9 positive patients, high BRE expression 
correlated with a significantly better OS and EFS (5-year OS of 0% vs. 80%, p-value=0.0002 and 
5-year EFS of 0% vs. 80%, p-value=0.0001 for patients with normal and high BRE expression, 
respectively). P-values were determined with the logrank test. The number of patients included 
in the analyses is shown in brackets.
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Figure 3.3: An independent AML cohort 
confirmed the positive effect of high BRE 
expression on prognosis
A. BRE expression was high in a subset of a 
second cohort of 436 AML patients and co-
occurred strongly with MLL-AF9 translocations 
(p<0.001 based on Fisher Exact tests). 40k 
cDNA expression array data of BRE (clone: 
IMAGE:739993) were log transformed and 
mean centered. Patients were subdivided into 
three groups based on MLL-AF9 and 11q23 
positivity. Dotted lines represent the mean of 
all AML samples plus 3 or 4 x the standard 
deviation of BRE expression, used as values 
for outlier analysis and cut-off for high BRE 
expression. B. High BRE expression accounts 
for good OS within an independent MLL-AF9 
cohort (5-year OS of 7.1±6.9 vs. 63.6±14.5%, 
p=0.0089 for patients with normal and high 
BRE expression, respectively). BRE array 
expression data of two cohorts of MLL-AF9 
positive patients were combined by log transformation and mean centering of the data. Based 
on the cut-off used for high BRE expression in figure 3.3A (mean of 436 AML samples + 3 x 
standard deviation), MLL-AF9 patients were subdivided into two groups: high and normal BRE 
expression (see supplemental table 3.2). P-values were determined with the logrank test. The 
number of patients included in the analyses is shown in brackets.
High BRE expression correlates with superior survival within MLL-AF9 positive AML 
patients
Of the eighteen MLL-AF9 positive AML samples, ten cases showed high BRE expression 
(table 3.2, figure 3.1C). We therefore questioned whether BRE expression predicted 
disease outcome within the group of MLL-AF9 positive patients. This analysis showed 
that MLL-AF9 positive patients with high BRE expression exhibited a superior survival 
while the remaining MLL-AF9 positive patients did very poor (figure 3.2C), both with 
respect to OS and EFS (5-year OS and EFS of 0% vs. 80% for patients with normal and 
high BRE expression, respectively, p=0.0002 (OS) and p=0.0001 (EFS)).
Validation of the prognostic value of BRE expression in an independent AML cohort
When studying the statistical impact of large numbers of genes, correlations can be 
found by chance. Therefore, we studied an independent cohort of 436 AML patients19. 
All non-predictive outliers identified in the first cohort did not predict outcome in the 
second cohort either (data not shown). With regard to BRE, outlier expression was 
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also observed in a subset of this second cohort (figure 3.3A). Patients with high BRE 
expression (3 times the standard deviation above the mean of the complete cohort) had 
a favorable outcome compared to the remaining intermediate and high risk patients in 
this cohort as well (5-year OS of 25.6±2.6 vs. 71.4±17.1%, p=0.039 for patients with 
normal and high BRE expression, respectively) (supplemental figure 3.5). Despite the 
clear prognostic effect, we were unable to confirm the independent prognostic value 
of high BRE expression in this cohort. This could be explained by the low number of 
BRE RBKS
MRPL33
Novel AML 
cluster with high 
BRE expression 
Figure 3.4: Patients with high BRE expression were confined to a novel AML subclass
Pairwise correlations of 525 AML patients based on optimal clustering as described before16 
identified several clusters of patients with similar expression profiles which can be recognized by 
the red blocks showing high correlation along the diagonal. One of these clusters was represented 
by a high incidence (86%) of patients with high BRE expression (left three black bars show the 
relative intensity of the three probe sets representing BRE expression on the array). The other 
three black bars show the relative expression intensity of the probe set for MRPL33 and two 
probe sets for RBKS as indicated in the figure, revealing co-expression of these chromosomal 
neighbors with BRE. The MLL-AF9 status of the samples is represented in the green bar (green: 
negative, red: positive, blue: ND). 
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high BRE expressing patients and lack of sufficient molecular data of more than 50% 
of the patients. Furthermore, the co-occurrence with MLL-AF9 in this cohort was even 
stronger than in the primary cohort (6 out of 7 high BRE patients were MLL-AF9 
positive, p<0.001, figure 3.4A). 
To validate the effect of BRE expression on survival within MLL-AF9 patients, 
we combined the BRE expression data of the eleven MLL-AF9 positive patients in this 
cohort with an additional group of fourteen MLL-AF9 positive patients. These 25 
patients were subdivided according to normal and high BRE expression based on the 
cut-off used in the second AML cohort of 436 samples. Also in this MLL-AF9 cohort, 
the OS of the patients with high BRE expression was significantly better than the OS 
of the remaining MLL-AF9 positive patients (5-year OS of 7.1±6.9 vs. 63.6±14.5%, 
p=0.0089 for patients with normal and high BRE expression, respectively) (figure 3.3B). 
We conclude that high BRE expression is a good prognostic factor, especially among 
MLL-AF9 positive cases, based on data from two large independent AML cohorts. 
Patients with high BRE expression are confined to a new subclass in AML
Unsupervised cluster analysis of gene expression profiles in the first AML cohort 
revealed that patients with high BRE expression were confined almost completely to 
a previously uncharacterized cluster (twelve of the fourteen patients with high BRE 
expression) (figure 3.4). Two additional samples without high BRE expression belonged 
to this cluster as well. MLL-AF9 positivity was overrepresented in this cluster (ten of the 
eighteen MLL-AF9 positive patients) as was expected because of its co-occurrence with 
high BRE expression. However, the correlation of the cluster with MLL-AF9 positivity 
was less than the correlation with high BRE expression. The OS of the patients within 
this cluster was significantly better than the remaining cohort, as could be anticipated 
based on the overrepresentation of patients with high BRE expression (data not shown).
Discussion
Several mutations and changes in expression of Ub-genes are implicated in the patho-
genesis of AML4,6-8. By correlating outlier expression of Ub-genes with clinical outcome 
in 525 AML patients, we identified differentially high expression of EVI1 and BRE as 
prognostic factors. Previous research has already shown that high EVI1 expression is an 
independent poor prognostic factor13, providing proof-of-principle that outlier analysis 
is a powerful approach to identify prognostic factors. 
BRE is a subunit of the BRCA1-BARD1 DNA damage repair ubiquitin E3 
ligase complex and enhances its activity29,30. BRE also downregulates TNFα signaling 
by binding death receptors31 and overexpression of BRE inhibits apoptosis31-33. Differ-
entially high BRE expression occurred in 3% of the AML patients, while the remaining 
patients showed only small differences in BRE expression. No high BRE expression was 
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found in donor CD34+ cells, total bone marrow or several mature blood cells, nor in 
several t(9;11) cell lines tested by us (supplemental figure 3.3) or others23. Importantly, 
the differential expression found in AML was an independent factor for both favorable 
OS and EFS (table 3.3). High BRE expression co-occurred with FAB M5 morphology, 
a relatively young age and MLL-AF9 fusions. In contrast, high expression was mutually 
exclusive with favorable karyotypes, CEBPA mutations, FLT3 ITD, EVI1 overexpression, 
and IDH1 and IDH2 mutations in the studied cohort (table 3.2). The co-occurrence of 
high BRE expression with MLL-AF9 fusions and its favorable prognostic value in AML 
was validated in an independent cohort of 436 patients. 
T(9;11) translocations can be missed by routine cytogenetic analysis. Indeed, 
re-analysis of the 525 AML samples by MLL-AF9 RT-PCR identified eight additional 
MLL-AF9 positive samples (total=18 samples), indicating that 44% of the cases were 
missed by cytogenetic analysis. Previous research in various cohorts showed that the 
prognostic value of MLL-AF9 positivity in AML is controversial26-28. In the cohort 
studied here, the total group of MLL-AF9 positive patients showed an intermediate 
survival, which was not significantly different compared to the remaining intermediate 
and high risk patients. Importantly, our data suggest that the MLL-AF9 positive group 
actually consists of two prognostic groups that are characterized by the level of BRE 
expression: MLL-AF9 positive patients with high BRE expression showed a superior 
survival while patients without high BRE expression showed a very poor outcome (figure 
3.2C). The prognostic impact of high BRE expression was reinforced by showing the 
favorable effect of high BRE expression on overall survival in an independent cohort of 
MLL-AF9 positive patients. Thus, patients with high BRE expression constitute a novel 
favorable prognostic group in AML. 
During the preparation of this manuscript, Balgobind et al. showed correlations 
of high BRE expression with favorable relapse free survival (RFS) in pediatric AML23. 
They did not observe correlations with OS and EFS, as described here for adult AML. 
In their study, high BRE expression was associated with FAB M5 morphology and 
11q23 translocations (primarily t(9;11)) as well. They showed a favorable RFS of MLL 
rearranged pediatric patients with high BRE expression, compared to the remaining 
MLL rearranged patients without high BRE expression. However, they did not address 
survival among MLL-AF9 patients, as was done in this study. Nevertheless, high BRE 
expression is a prognostic factor both in pediatric and adult AML, although the effect of 
high BRE expression on clinical outcome is different for adults and children. Additional 
studies are required to determine whether this is caused by differences in treatment 
regimens.  
Genome wide expression profiling supported the fact that patients with high 
BRE expression constitute a new subtype in AML, since unsupervised cluster analysis 
showed that most patients with high BRE expression were confined to a distinct cluster 
(figure 3.4). This indicates that these patients shared global expression profiles. In this 
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cluster no recurrent genetic aberrations were identified other than the expected partial 
co-occurrence with the MLL-AF9 fusion. Within this cluster, high BRE expression 
was more frequently observed than MLL-AF9 positivity, proposing a better correlation 
of high BRE expression than MLL-AF9 positivity with this cluster. In addition, BRE 
appeared to be among the most discriminatively expressed genes when comparing this 
cluster to the other AML samples (data not shown).
The frequent co-occurrence of high BRE expression and MLL-AF9 fusions 
could suggest that BRE is a direct target of the oncogenic fusion protein. However, 
independent mouse studies did not identify BRE as MLL-AF9 target in untransformed 
or transformed cells34,35. We observed that about half of the MLL-AF9 positive patients 
did not show high BRE expression, strongly suggesting that it is not a direct target 
in all cases. Furthermore, the unique expression profile characteristic for patients with 
high BRE expression co-occurred only partially with MLL-AF9 positivity (figure 3.4). 
This could suggest that other factors than MLL-AF9 determine this profile. Although 
we observed no correlations between BRE expression and known MLL-AF9 target 
genes such as HoxA7, HoxA9 and MLL (data not shown), we did observe an inverse 
correlation with the MLL-AF9 target MEIS1 (supplemental figure 3.6). This could 
suggest that MLL-AF9 uses separate tumor dependent co-factors to activate different 
gene programs, one including BRE, the other including MEIS1. Whether MLL-AF9 
binds different regulatory DNA sequences depending on the availability of co-factors 
needs to be addressed in future research.
By studying genes that showed co-expression with high BRE expression, we found 
that two co-expressed genes, RBKS and MRPL33, are located directly upstream of BRE 
on chromosome 2 (2p23.2) (figure 3.4). High BRE expression was inextricably linked 
with high RBKS and MRPL33 expression. Reversely, high RBKS or MRPL33 expression 
did not necessarily co-occur with high BRE expression. Genes more up- or downstream 
of BRE did not show this co-expression (data not shown). These data might indicate 
that a larger chromosomal locus is deregulated in patients with high BRE expression. To 
our knowledge, no small aberrations in the chromosomal region comprising the BRE 
locus have been identified in AML patients so far36-39. Therefore, it will be important to 
determine in more detail whether the high expression of the three consecutive genes on 
this locus is due to local changes in transcriptional regulation or whether this is caused 
by chromosomal aberrations. 
We conclude that unbiased statistical outlier analyses of Ub-gene expression 
distributions in AML allowed us to identify high BRE expression as a novel prognostic 
factor. Furthermore, we identified a previously unrecognized subtype in AML with 
favorable outcome, represented by the differentially high BRE expression. These findings 
provide new insights into the risk stratification of AML, especially within the group of 
MLL-AF9 positive patients. 
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Interpro code Interpro short description
IPR000011 Ubiquitin-activating enzyme, E1
IPR000127 Ubiquitin-activating enzyme repeat
IPR000306 Zinc finger, FYVE-type
IPR000315 Zinc finger, B-box
IPR000426 Proteasome alpha-subunit, conserved site
IPR000449 Ubiquitin-associated/translation elongation factor EF1B, N-terminal
IPR000569 HECT
IPR000594 UBA/THIF-type NAD/FAD binding fold
IPR000608 Ubiquitin-conjugating enzyme, E2
IPR000626 Ubiquitin
IPR001232 SKP1 component
IPR001334 E6 early regulatory protein
IPR001353 20S proteasome, A and B subunits
IPR001370 Proteinase inhibitor I32, inhibitor of apoptosis
IPR001373 Cullin, N-terminal region
IPR001394 Peptidase C19, ubiquitin carboxyl-terminal hydrolase 2
IPR001496 SOCS protein, C-terminal
IPR001578 Peptidase C12, ubiquitin carboxyl-terminal hydrolase 1
IPR001607 Zinc finger, UBP-type
IPR001680 WD40 repeat
IPR001810 Cyclin-like F-box
IPR001841 Zinc finger, RING type
IPR001965 Zinc finger, PHD-type
IPR001975 Ribosomal protein L40e
IPR002004 Polyadenylate-binding protein/Hyperplastic disc protein
IPR002083 MATH
IPR002714 Tumour suppressor protein, von Hippel-Lindau disease
IPR002867 Zinc finger, C6HC-type
IPR002906 Ribosomal protein S27a
IPR003105 SRA-YDG
IPR003126 Zinc finger, N-recognin
IPR003153 Adaptor protein Cbl, N-terminal helical
IPR003185 Proteasome activator pa28, REG alpha subunit
IPR003323 Ovarian tumour, otubain
IPR003613 U box
IPR003649 B-box, C-terminal
IPR003653 Peptidase C48, SUMO/Sentrin/Ubl1
Supplemental table 3.1A: Interpro codes of ubiquitination related domains
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IPR003892 Ubiquitin system component Cue
IPR003903 Ubiquitin interacting motif
IPR003977 Parkin
IPR004162 Seven in absentia protein
IPR004170 WWE
IPR004806 UV excision repair protein Rad23
IPR004854 Ubiquitin fusion degradation protein UFD1
IPR004939 Anaphase-promoting complex, subunit 10
IPR005062 SAC3/GANP/Nin1/mts3/eIF-3 p25
IPR005176 Protein of unknown function DUF298
IPR005375 Ubiquitin-like, Ufm1
IPR005607 BSD
IPR006285 E1-like protein-activating enzyme Gsa7p/Apg7p
IPR006575 RWD
IPR006615 Ubiquitin carboxyl-terminal hydrolase, N-terminal region 1
IPR006746 26S proteasome non-ATPase regulatory subunit Rpn12
IPR006928 Peptidase C76, herpesvirus UL36 UL36 deubiquitinylating peptidase
IPR007192 Cdc23
IPR007397 F-box associated region
IPR007527 Zinc finger, SWIM-type
IPR007901 MoeZ/MoeB
IPR008401 Apc13p
IPR008402 Anaphase-promoting complex, Apc15p-like
IPR008974 TRAF-like
IPR009060 UBA-like
IPR009109 Ran-GTPase activating protein 1, C-terminal
IPR010309 E3 ubiquitin ligase, region of unknown function DUF908
IPR010314 E3 ubiquitin ligase, region of unknown function DUF913
IPR010460 Ubiquitin carboxyl-terminal hydrolase, N-terminal region 2
IPR010606 Mib-herc2
IPR011011 Zinc finger, FYVE/PHD-type
IPR011016 Zinc finger, variant RING-type
IPR011333 BTB/POZ fold
IPR012462 Peptidase C78, ubiquitin fold modifier-specific peptidase 1 and 2
IPR013010 Zinc finger, SIAH-type
IPR013069 BTB/POZ
IPR013083 Zinc finger, RING/FYVE/PHD-type
IPR013246 Sgf11, transcriptional regulation
IPR013322 TRAF-type
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IPR013323 SIAH-type
IPR013896 Ubiquitin-associated region 2
IPR013956 E3 ubiquitin ligase, BRE1
IPR014645 Target of Myb protein 1
IPR014741 Adaptor protein Cbl, EF hand-like
IPR014742 Adaptor protein Cbl, SH2-like
IPR014761 UV excision repair protein Rad23, C-terminal
IPR014764 Defective in cullin neddylation
IPR014786 Anaphase promoting complex subunit 2
IPR014857 Zinc finger, RING-like
IPR014891 DWNN domain
IPR014929 E2 binding
IPR015036 USP8 interacting
IPR015063 Region of unknown function DUF1873
IPR015133 E3 ubiquitin ligase, AvrPtoB
IPR015155 PFU (PLAA family ubiquitin binding)
IPR015221 Ubiquitin related modifier 1
IPR015228 Ubiquitin-associated
IPR015342 Peroxisome biogenesis factor 1, N-terminal
IPR015343 Peroxisome biogenesis factor 1, alpha/beta
IPR015458 MDM4/MDMX protein
IPR015459 Ubiquitin-protein ligase E3 MDM2
IPR015496 Ubiquilin
IPR015580 RUB1 conjugating enzyme Ubc12
IPR015581 Ubiquitin-conjugating enzyme
IPR015582 Ubiquitin-conjugating enzyme E2 H10
IPR015940 Ubiquitin-associated/translation elongation factor EF1B, N-terminal, eukaryote
IPR015943 WD40/YVTN repeat-like
IPR016010 Parkin, C-terminal
IPR016072 SKP1 component, dimerisation
IPR016073 SKP1 component, POZ
IPR016135 Ubiquitin-conjugating enzyme/RWD-like
IPR016157 Cullin, conserved site
IPR016158 Cullin homology
IPR016159 Cullin repeat-like
IPR016398 E3 ubiquitin-protein ligase p28
IPR016615 Ubiquitin thioesterase Otubain
IPR016652 Ubiquitinyl hydrolase
IPR016806 COP9 signalosome complex, subunit 9
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IPR016897 E3 ubiquitin ligase, SCF complex, Skp subunit
IPR017073 Ubiquitin binding protein, Hrs/VPS27
IPR017134 Ubiquitin-protein ligase E6-AP
IPR017335 E3 ubiquitin ligase, RNF8
IPR017390 Ubiquitinyl hydrolase, UCH37 type
Supplemental table 3.1B: GO terms of ubiquitin related processes
GO term code GO term name
GO:0000151 ubiquitin ligase complex
GO:0000152 nuclear ubiquitin ligase complex
GO:0000153 cytoplasmic ubiquitin ligase complex
GO:0000209 protein polyubiquitination
GO:0000502 proteasome complex
GO:0000835 ER ubiquitin ligase complex
GO:0000836 Hrd1p ubiquitin ligase complex
GO:0004221 ubiquitin thiolesterase activity
GO:0004839 ubiquitin activating enzyme activity
GO:0004842 ubiquitin-protein ligase activity
GO:0004843 ubiquitin-specific protease activity
GO:0005838 proteasome regulatory particle
GO:0005839 proteasome core complex
GO:0006511 ubiquitin-dependent protein catabolic process
GO:0006513 protein monoubiquitination
GO:0008537 proteasome activator complex
GO:0008538 proteasome activator activity
GO:0008539 proteasome inhibitor activity
GO:0008641 small protein activating enzyme activity
GO:0010390 histone monoubiquitination
GO:0010498 proteasomal protein catabolic process
GO:0010860 proteasome regulator activity
GO:0016567 protein ubiquitination
GO:0016574 histone ubiquitination
GO:0016578 histone deubiquitination
GO:0016579 protein deubiquitination
GO:0016925 protein sumoylation
GO:0019005 SCF ubiquitin ligase complex
GO:0019773 proteasome core complex, alpha-subunit complex
GO:0019783 small conjugating protein-specific protease activity
GO:0019787 small conjugating protein ligase activity
GO:0022624 proteasome accessory complex
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GO:0031145 anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic 
process
GO:0031146 SCF-dependent proteasomal ubiquitin-dependent protein catabolic process
GO:0031371 ubiquitin conjugating enzyme complex
GO:0031386 protein tag
GO:0031396 regulation of protein ubiquitination
GO:0031397 negative regulation of protein ubiquitination
GO:0031398 positive regulation of protein ubiquitination
GO:0031461 cullin-RING ubiquitin ligase complex
GO:0031462 Cul2-RING ubiquitin ligase complex
GO:0031593 polyubiquitin binding
GO:0031597 cytosolic proteasome complex
GO:0031624 ubiquitin conjugating enzyme binding
GO:0031625 ubiquitin protein ligase binding
GO:0032434 regulation of proteasomal ubiquitin-dependent protein catabolic process
GO:0032435 negative regulation of proteasomal ubiquitin-dependent protein catabolic process
GO:0032436 positive regulation of proteasomal ubiquitin-dependent protein catabolic process
GO:0033182 regulation of histone ubiquitination
GO:0033522 histone H2A ubiquitination
GO:0033523 histone H2B ubiquitination
GO:0034450 ubiquitin-ubiquitin ligase activity
GO:0042787 protein ubiquitination during ubiquitin-dependent protein catabolic process
GO:0043130 ubiquitin binding
GO:0043161 proteasomal ubiquitin-dependent protein catabolic process
GO:0043161 proteasomal ubiquitin-dependent protein catabolic process
GO:0043162 ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway
GO:0043248 proteasome assembly
GO:0051436 negative regulation of ubiquitin-protein ligase activity during mitotic cell cycle
GO:0051437 positive regulation of ubiquitin-protein ligase activity during mitotic cell cycle
GO:0051438 regulation of ubiquitin-protein ligase activity
GO:0051439 regulation of ubiquitin-protein ligase activity during mitotic cell cycle
GO:0051443 positive regulation of ubiquitin-protein ligase activity
GO:0051444 negative regulation of ubiquitin-protein ligase activity
GO:0051865 protein autoubiquitination
GO:0055105 ubiquitin-protein ligase inhibitor activity
GO:0055106 ubiquitin-protein ligase regulator activity
GO:0070086 ubiquitin-dependent endocytosis
GO:0070530 K63-linked polyubiquitin binding
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GO:0070534 protein K63-linked ubiquitination
GO:0070535 histone H2A K63-linked ubiquitination
GO:0070536 protein K63-linked deubiquitination
GO:0070537 histone H2A K63-linked deubiquitination
GO:0070844 polyubiquitinated protein transport
GO:0070845 polyubiquitinated misfolded protein transport
sample array type BRE expressiona
1 cDNA -2.22
2 U133plus2.0 -2.04
3 cDNA -1.94
4 cDNA -1.88
5 U133plus2.0 -0.99
6 U133plus2.0 -0.94
7 U133plus2.0 -0.88
8 U133plus2.0 -0.73
9 cDNA -0.61
10 U133plus2.0 -0.56
11 U133plus2.0 -0.50
12 cDNA -0.30
13 U133plus2.0 -0.29
14 U133plus2.0 -0.05
15 cDNA 0.52
16 cDNA 0.83
17 cDNA 1.18
18 cDNA 1.20
19 cDNA 1.31
20 U133plus2.0 1.32
21 U133plus2.0 1.52
22 U133plus2.0 1.53
23 U133plus2.0 1.84
24 cDNA 1.90
25 U133plus2.0 1.93
aLog transformed BRE expression data of the Affymetrix HG U133 plus2.0 array were mean centered and averaged from 
three independent probe sets (212645_x_at, 211566_x_at, and 205550_s_at). For the cDNA array samples, the data of 
clone IMAGE:739993 were log transformed and mean centered. Afterwards, the data of the two arrays were combined. 
The cutoff for high BRE expression (grey shaded samples) was obtained from analyses in the second cohort of 436 AML 
patients profiled on the cDNA array.
Supplemental table 3.2: Normalized BRE expression data of the validation cohort of 25 
MLL-AF9 positive patients
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Probe set (gene name) Number of 
outlier samplesa,b
Mean expression 
of outliers ± SDc
Mean expression of remaining 
AML samples ± SDc
202318_s_at (SENP6) 10 1306 ± 85 503 ± 123
205550_s_at (BRE) 10 3253 ± 672 347 ± 152
205856_at (SLC14A1) 10 457 ± 90 41 ± 57
207600_at (KCNC3) 10 27 ± 5 5.3 ± 3.0
209962_at (EPOR) 10 889 ± 206 54 ± 76
209963_s_at (EPOR) 10 322 ± 64 31 ± 31
210638_s_at (FBXO9) 10 3448 ± 655 588 ± 299
210885_s_at (TRIM15) 10 53 ± 12 4 ± 5
243526_at (WDR86) 10 239 ± 53 13 ± 24
36564_at (RNF19B) 10 1794 ± 324 247 ± 182
37986_at (EPOR) 10 606 ± 108 68 ± 71
211566_x_at (BRE) 11 2489 ± 538 226 ± 121
221884_at (EVI1) 11 648 ± 145 16 ± 51
212645_x_at (BRE) 12 2581 ± 551 228 ±111
213038_at (RNF19B) 12 1392 ± 259 213± 137
Supplemental table 3.3: Ubiquitin related probe sets with 10 or more outlier samples
aOutlier expression is defined as an expression value more than four times the standard deviation above or under the mean 
expression of all AML samples;
bWhen performing the outlier analysis on the complete array dataset, 302 probe sets containing 10 or more outlier 
samples were identified;
cSD: standard deviation.
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A
B Supplemental figure 3.1: High expression of 
BRE and EVI1 correlated with OS
The OS of the patients with BRE (A) or EVI1 (B) 
expression higher than the mean + 4 x standard 
deviation was significantly different compared to 
the rest of the AML cohort as shown in the Kaplan-
Meier plots. The number of patients in each group is 
shown in brackets. P-values were calculated with the 
log rank test. The third and last probe representing 
BRE on the array - also positive in our outlier analysis 
(212645_x_at) - showed a nearly significant p-value when analyzing OS of outliers compared to 
all other AML samples (p=0.055, data not shown). The survival curve differences for the different 
BRE probes were caused by the number of patients that were regarded as outlier (expression>4 
x standard deviation above the mean), as this varied from 10 to 12 patients, depending on the 
probe set (see supplemental table 3.3).
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Supplemental figure 3.2: Correlation of 
BRE array and QPCR expression data 
BRE expression measured by probe 
212645_x_at on the HGU133 plus2.0 
array was compared with QPCR data of the 
same samples using PBGD as housekeeping 
gene. Samples included for analysis were all 
samples with high BRE expression, as well 
as the intermediate BRE expressing samples 
and a subset of samples with normal BRE 
expression according to the array data. A good 
correlation was found with an r2 of 0.84 and p<0.001 as calculated by the Spearmann’s correlation 
coefficient. Comparable correlations were found for the other two BRE probe sets of the array 
versus the QPCR data (r2=0.84 for 211566_x_at vs. QPCR and r2=0.81 for 205550_s_at vs. 
QPCR, p<0.001, data not shown).
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Supplemental figure 3.3: BRE expression in hematopoietic sub fractions and t(9;11) cell 
lines 
BRE expression was measured by QPCR on cDNA of various hematopoietic sub fractions and 
three t(9;11) positive cell lines (Molm13, Monomac-6, THP1). As a comparison, representatives 
of normal and high BRE expressing AML samples were included in this graph. All data were 
normalized by β-ACTIN and represented as ΔCt (2ΔCt). 
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Supplemental figure 3.4: MLL-AF9 breakpoint PCR on high BRE expressing samples and 
11q23 positive samples
MLL-AF9 breakpoint RT-PCR was performed on all samples. The gel image shows the resulting 
PCR products representing the samples with high BRE expression, intermediate BRE expression 
and samples with an 11q23 translocation. The table below the gel image shows the original 
karyotyping results. The arrows indicate the samples that were positive for the MLL-AF9 
breakpoint PCR but were t(9;11) negative based on routine cytogenetic analyses. In addition 
to the results shown here, three more MLL-AF9 positive samples were identified after RT-PCR. 
These samples showed normal BRE expression levels.
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Supplemental figure 3.5: High BRE expression predicts favorable OS in an independent 
cohort of intermediate and high risk AML patients
The OS of intermediate and high risk patients (excluding t(8;21), inv(16), and t(15;17) patients) 
with normal or high BRE expression of a second, independent cohort was visualized by Kaplan 
Meier curves. The cut-off used for high BRE expression was based on the mean of all AML patients 
in this cohort plus 3 x the standard deviation. Patients with high BRE expression had a better 
prognosis than patients with normal BRE expression (5-year OS of 25.6±2.6 vs. 71.4±17.1%, 
p=0.039 for patients with normal BRE and high BRE expression, respectively). P-values were 
based on logrank tests. The number of patients included in the analysis is shown in brackets.
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Supplemental figure 3.6: BRE expression is inversely correlated to MEIS1 expression in 
MLL-AF9 positive patients
Array expression data of BRE (probe set: 212645_x_at) and MEIS1 (probe set 1559477_s_
at) showed an inverse correlation within MLL-AF9 positive patient samples. The calculated 
Spearmann correlation coefficient is -0.61 with a p-value of 0.007. Similar data were obtained 
when using other probe sets representing MEIS1 on the Affymetrix micro-array.
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Abstract
Acute myeloid leukemia (AML) is a heterogeneous disease with many different 
underlying genetic aberrations, which are often associated with disease development 
and clinical outcome. AML patients with MLL-AF9 fusions are currently classified 
as intermediate risk. Recently, we showed that MLL-AF9 positive patients can be 
subdivided into a favorable and a poor prognostic subgroup based on high or 
normal BRE expression, respectively. As BRE expression differences are relatively 
small between the two groups, testing BRE expression for diagnostic purpose is 
difficult using commonly available techniques such as QPCR. In this chapter we 
show mutually exclusive expression of BRE and EVI1 within MLL-AF9 positive 
patients. Only few patients were double negative for both genes. High EVI1 
expression is a poor prognostic marker in AML, and thereby explains the adverse 
prognosis of the majority of patients with normal BRE expression levels. Molecular 
screening for both high EVI1 expression and MLL-AF9 is therefore of importance 
for proper risk stratification. To study intrinsic differences between the two 
subtypes of MLL-AF9 positive AML, global gene expression profiles of high BRE 
and high EVI1 expressing MLL-AF9 positive samples were compared. Patients with 
high EVI1 expression did not share similar global expression profiles, in contrast 
to patients with high BRE expression. This indicates that MLL-AF9 by itself does 
not provoke global expression differences. The MLL-AF9 fusion encodes a mutated 
transcription regulator. EVI1 is a direct target gene of the fusion protein but was not 
upregulated in all MLL-AF9 patients. We show that this phenomenon also applied 
to two other direct targets of MLL-AF9, HOXA9 and MEIS1. These data suggest 
that additional mechanisms and/or factors are involved in deregulating expression 
of MLL-AF9 target genes.
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Introduction
AML is a heterogeneous disease at the molecular level, with a variety of genetic 
aberrations. Many of these aberrancies influence disease development and consequently 
prognosis. However, disease outcome often differs substantially between patients within 
genetically defined subgroups. Therefore, knowledge on discriminating prognostic 
factors within those subgroups is needed for improved classification and risk dependent 
treatment.
Recently, we identified high BRE expression in 3% of AML patients, which 
associated with a favorable prognosis. The majority of the patients with high BRE 
expression was positive for the MLL-AF9 translocation (±70%)1. The five-year overall 
survival (OS) rate of AML patients positive for the MLL-AF9 fusion gene is approxi-
mately 40%2,3. Based on BRE expression, patients could be further subclassified into a 
favorable and an adverse prognostic subcategory: MLL-AF9 positive patients with high 
BRE expression exhibited a superior outcome (five-year OS of 80% and 64% for two 
independent cohorts, respectively) while patients with normal BRE expression exhibited 
a very poor outcome (five-year OS of 0% and 7%)1. Genome-wide expression profiling 
identified a common global expression profile for more than 85% of the patients with 
high BRE expression1.
Remarkably, 50% of the MLL-AF9 patients showed high BRE expression. 
Therefore, there was only partial co-occurrence with the global expression profile char-
acterized by high BRE expression1. These data suggest that the MLL-AF9 translocation 
does not induce a common genome-wide expression program. In this chapter, we study 
whether MLL-AF9 positive, BRE negative patients can be further characterized, and 
what the contribution of the MLL-translocation is on altered gene expression. 
The Mixed Lineage Leukemia (MLL) gene encodes a methyltransferase, that 
is responsible for H3K4 (Histone 3 Lysine 4) methylation. This modification marks 
genes for active transcription4,5. In MLL-translocations, the methyltransferase activity 
is lost6. More than 50 fusion partners of MLL have been identified so far in acute 
leukemia’s. AF9, ELL and ENL are the most frequently occurring partners in adult 
AML6. MLL-fusion proteins such as MLL-AF9 form a large complex including 
DOT1L and pTEFb7. DOT1L is a methyltransferase for histone 3 lysine 79 (H3K79), 
inducing an open chromatin formation for gene transcription. Recent data have shown 
that MLL-AF9 positive cells show aberrant H3K79 methylation patterns8. However, 
deletion of DOT1L resulted in upregulation of only a small part of the genes showing 
the aberrant methylation, indicating no absolute correlation of the H3K79 activation 
mark and gene transcription. The deregulated genes identified were highly enriched 
for genes to which the MLL-fusion protein binds, often referred to as the direct 
targets, including MEIS1 and HOXA97,8. Both genes are highly expressed in MLL-AF9 
transformed mouse hematopoietic cells9,10. These data suggest a one to one correlation 
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of MLL-AF9 transformation and expression of these targets.
Recently, also EVI1 has been identified as a direct target of MLL-AF911. High EVI1 
expression occurs in approximately 10% of AML cases and is associated with an inferior 
outcome12,13. High EVI1 expression can be a direct consequence of 3q chromosomal 
aberrations, affecting the EVI1 gene locus. However, EVI1 overexpression also occurs 
in cells without 3q aberrations. For these cases, co-occurrence has been observed with 
MLL rearrangements including MLL-AF911-13. However, not all MLL-AF9 rearranged 
samples show high EVI1 expression. This seems to impose a discrepancy with the data 
reporting EVI1 as a direct target of MLL-AF9.
High BRE and EVI1 expression both correlate partially with MLL-AF9 trans-
locations, but predict opposite disease outcome for patients. We therefore questioned 
whether high expression of these genes was mutually exclusive among MLL-AF9 positive 
cases. We also studied the expression of the known MLL-fusion target genes HOXA9 
and MEIS1 in individual MLL-rearranged AML cases to investigate whether these direct 
targets are highly expressed in all patients.
Materials and Methods
Patient samples and micro-array analyses
For this study, three previously published and publically available micro-array studies 
were re-analyzed. AML cohort 1 consisted of 525 AML patients, including 18 MLL-AF9 
positive samples and 15 samples with other 11q23 aberrations (GSE14468)14. Gene 
expression was analyzed using the Affymetrix HG-U133 plus 2.0 array platform (Santa 
Clara, USA). Cohort 2 contained 436 AML patients, including 11 MLL-AF9 samples 
and 4 other MLL-rearranged samples (GSE16432)15. For gene expression analyses, 40k 
cDNA arrays were used (manufactured by the Stanford Functional Genomics Facility). 
For both cohorts, 11q23 aberrations were analyzed by conventional chromosome banding 
and specific breakpoint PCR or FISH, as described elsewhere1. To validate MEIS1 and 
HOXA9 expression in MLL-rearranged cases, a third, publically available cohort of 
542 AML patients was used, including 38 MLL-rearranged cases (GSE13159)16. Gene 
expression profiling of this cohort was performed using the Affymetrix HG-U133 plus 
2.0 array platform. Array data normalization was performed separately for the three 
cohorts.
Statistical analyses
Positive or negative correlations between expression of two genes were statistically tested 
using Spearmann rank correlation tests. Unsupervised clustering analyses were performed 
as described before17 and represented as a correlation view between the different samples 
included in the clustering.
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Figure 4.1. Mutual exclusive expression of BRE and EVI1 in MLL-AF9 AML
A. BRE expression was plotted against EVI1 expression for MLL-AF9 positive cases in two separate 
MLL-AF9 cohorts14, 15. In cohort 1 (left plot), 33% (6/18) of the samples showed high EVI1 
expression, and 55.6% (10/18) showed high BRE expression. In cohort 2 (right plot), 27.3% 
of the samples showed high EVI1 expression (3/11), and 54.5% showed high BRE expression 
(6/11). Both cohorts contained two patients with neither high BRE nor high EVI1 expression. 
High BRE expression was defined as described before1. High EVI1 was defined as the upper 10% 
of the total cohort. P-values for negative correlation were calculated using Spearmann correlation 
tests. B. Kaplan-Meier plots showed that patients characterized by high BRE expression had 
significantly better overall survival compared to patients with high EVI1 expression among MLL-
AF9 positive cases. P-values were determined with the log-rank test. The number of patients 
included in the analyses is shown in brackets. C. Unsupervised genome-wide clustering of MLL-
AF9 patients from cohort 1 showed that EVI1-positive patients clustered apart from high BRE 
expressing patients. EVI1-positive patients showed less similar expression profiles compared to 
high BRE expressing patients. Unsupervised clustering was performed as described elsewhere9 
and clustering is represented as pairwise correlations between samples with red indicating a high 
correlation and blue a poor correlation. Black bars represent BRE (212645_x_at) and EVI1 
(221884_at) expression, as indicated.
Chapter 4
96
4
Results and Discussion
High BRE and EVI1 expression co-occur with MLL-AF9 translocations, yet both 
predict opposite disease outcome1,11-13. We therefore hypothesized that the expression 
of these two genes would be mutually exclusive in MLL-AF9 rearranged AML cases. 
To determine the correlation between BRE and EVI1 expression, we re-analyzed two 
MLL-AF9 cohorts for which we previously reported high BRE expression1,14,15. This 
showed that high BRE and high EVI1 expression are indeed mutually exclusive, with 
only a few cases that did not show high BRE or EVI1 expression (figure 4.1A). As the 
number of these double negative patients was low, the poor prognosis of the majority 
of patients lacking high BRE expression was explained by high EVI1 expression (figure 
4.1B). Additional studies with larger patient numbers are required to determine the 
prognosis of the double negative patients. 
In our previous study, 40% of MLL-AF9 positive cases were missed by routine 
cytogenetics1. In addition, MLL-AF9 positive cases with high EVI1 expression lack 
chromosomal rearrangements encompassing the EVI1 locus on chromosome 312,13. 
Therefore, molecular screening for MLL-AF9 and EVI1 or BRE overexpression is strongly 
recommended to improve risk stratification in these patients. As the fold differences 
of BRE expression between patients with high and normal levels are relatively small1, 
screening for EVI1 overexpression is diagnostically more feasible, as diagnostic tests are 
already available.
To study whether the mutually exclusive BRE and EVI1 expression represented 
global expression differences, we performed unsupervised genome-wide gene expression 
clustering analysis within MLL-AF9 positive samples. Although the EVI1-positive 
patients were separated from the BRE-positive patients (figure 4.1C), they did not share 
highly similar expression profiles, while BRE-positive patients did1. Indeed, in an unsu-
pervised clustering analysis of the total AML cohort, MLL-AF9 positive patients with 
high EVI1 expression clustered only partially, showing modest similarities in expression 
profiles (figure 4.2). Thus, MLL-AF9 positive patients with high BRE expression seem 
to represent a specific molecular AML subclass with highly similar expression profiles, 
while the MLL-AF9 positive patients with high EVI1 expression do not.
As EVI1 has been shown to be a direct target of MLL-AF911 but was only highly 
expressed in a subset of MLL-AF9 rearranged patients, target gene transcription might 
not exclusively depend on the fusion protein. To study whether this phenomenon also 
applied to two other direct MLL-AF9 target genes, MEIS1 and HOXA98, we compared 
their expression as well as the expression of BRE and EVI1 in individual MLL-AF9 
or other MLL-rearranged AML patients in cohort 1 (figure 4.3). In general, there 
was an overall higher expression of all four genes in both MLL-AF9 and other MLL-
rearranged samples compared to the remaining AML samples, validating data described 
before1,10,11,18,19 (figure 4.3A). However, analysis of individual samples showed that none 
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of the four genes was consistently overexpressed in all MLL-rearranged patients. In fact, 
of the 33 patients with any type of MLL-rearrangement, a significant percentage of 
patients showed expression levels comparable to, or lower than the mean of non MLL-
rearranged AML cases (18% for MEIS1, 12% for HOXA9, 58% for EVI1 and 39% for 
BRE, figure 4.3). In addition, several patients showed high expression of HOXA9, but 
lacked high expression of MEIS1 (for example, open yellow boxes within the MLL-AF9 
group, samples indicated by *, figure 4.3A) or vice versa (for example, open blue triangles 
within the 11q23 group, samples indicated by *, figure 4.3A). Indeed, there was no 
correlation of MEIS1 and HOXA9 expression within MLL-rearranged samples (p=0.2, 
figure 4.3B). 
1 2 3 4
1. MLL-AF9 status
2. 11q23 status
3. BRE expression
4. EVI1 expression
Figure 4.2: Unsupervised clustering of 525 AML patients
Unsupervised clustering of the total AML cohort 1 showed that MLL-AF9 patients with high 
BRE expression clustered together almost completely, as described before1 (chapter 3 of this 
thesis). This was in contrast to EVI1-positive MLL-AF9 patients, which showed partial clustering 
in the total cohort. This graph was adapted from a previously published figure1, by including 
EVI1 expression (221884_at). MLL-AF9 status, 11q23 status and BRE and EVI1 expression are 
indicated along the pairwise correlation graph by the numbers 1-4, respectively.
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To confirm these data in another cohort, we studied the expression of MEIS1, 
HOXA9, EVI1 and BRE in a third, large AML cohort, including 38 MLL-rearranged 
cases (figure 4.4)16. Also in this cohort, the overall expression of the four genes was 
higher in MLL-rearranged cases (figure 4.4A). Still, a number of individual cases showed 
expression levels of MEIS1, EVI1 and BRE comparable to the mean of the non MLL-
rearranged cases. In this cohort, HOXA9 was almost exclusively high in MLL-rearranged 
cases (figure 4.4A). Remarkably, more than 60% of non MLL-rearranged cases showed 
high MEIS1 (expression value >0.25) and HOXA9 expression (expression value >0.4) 
(figure 4.4B). In cohort 1, this was the case for less than 35% of the samples (expression 
value of MEIS1 >200, expression value HOXA9 >600, figure 4.3). Despite the differences 
between the cohorts, the data imply that high expression of both targets is not a distinct 
phenomenon for MLL-rearrangements. Importantly, in pediatric AML, the correlation 
of high MEIS1 and HOXA9 expression to MLL-rearrangements seems stronger, as in a 
study on 23 MLL-rearranged versus 56 non-MLL pediatric AML cases, all rearranged 
cases showed high expression of both genes20.
The above described data suggest that there are large differences in target gene 
expression between individual patients with MLL-AF9 translocations or other 11q23 
aberrations. In combination with the observation that MLL-AF9 patients with high 
BRE expression share a similar expression profile, in contrast to the remaining MLL-AF9 
patients, this suggests that global gene expression regulation is not solely dependent on 
the MLL-AF9 fusion gene. Although studying molecular mechanisms of MLL-transfor-
mation in mouse models, including epigenetic regulation and resultant gene expression 
profiling, has yielded much information on MLL-AF9 mediated transformation, it seems 
unlikely that there will be only one molecular mechanism of malignant transformation 
applicable to all MLL-AF9 positive or other MLL-rearranged patients. It is more likely 
that MLL-translocations can provoke various altered expression programs depending 
on, for example, different cofactors or the differentiation status of the transformed cells. 
Figure 4.3: Comparison of MEIS1, HOXA9, EVI1, and BRE expression among 11q23 
AML patients (left page)
A. Gene expression data of MEIS1, HOXA9, EVI1 and BRE are represented for cohort 1 (525 
AML samples and 16 control samples (CD34 or normal bone marrow (NBM)). Individual 
MLL-AF9 and other 11q23 patients are indicated by different colors and open or closed symbols. 
Micro-array probesets used for analyses are indicated on the y-axis. The black line indicates the 
mean expression of the samples. * indicates samples mentioned in main text which show opposite 
expression levels of MEIS1 and HOXA9. B. HOXA9 expression was plotted against MEIS1 
expression in the total cohort (left panel) or within 11q23 rearranged samples only (right panel). 
MLL-AF9 and remaining 11q23 patients are indicated in red and green, respectively. Although 
MEIS1 and HOXA9 expression showed a positive correlation in the total cohort (p<0.001), there 
is a poor correlation between MEIS1 and HOXA9 expression within 11q23 (including MLL-
AF9) patients, based on Spearman rank correlation testing (p=0.2).
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Figure 4.4: Comparison of MEIS1, HOXA9, EVI1, and BRE expression among 11q23 
AML patients in an independent cohort
A. Gene expression data of MEIS1, HOXA9, EVI1 and BRE are represented for cohort 3 
comprising 542 AML patients, including 38 MLL-rearranged cases, and 73 control samples 
(healthy or non-leukemic bone marrow samples)16. Micro-array probesets used for analyses are 
indicated on the y-axis. The black line indicates the mean expression of the samples. B. HOXA9 
expression was plotted against MEIS1 expression for the total cohort. MLL-rearranged cases are 
indicated in grey. Of the remaining AML cohort, 63% of the samples showed simultanleously 
high expression of MEIS1 and HOXA9 (expression level above 0.25 and 0.4 for MEIS1 and 
HOXA9, respectively).
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Abstract
Breast cancer is one of the leading causes of cancer mortality in women. Recent 
advances in gene expression profiling have indicated that breast cancer is a het-
erogeneous disease and that the current prognostication using clinico-pathological 
features is not sufficient to fully predict therapy response and disease outcome. In 
this retrospective study, we show that expression levels of BRE, which encodes a 
member of the BRCA1 DNA damage repair complex, predicted disease free survival 
in non-familial breast cancer patients. The predictive value of BRE expression 
depended on whether patients received radiotherapy as part of their primary 
treatment. In radiotherapy treated patients, high BRE expression predicted a 
favorable disease free survival (hazard ratio (HR)=0.47, 95% confidence interval 
(CI)=0.28-0.78, p=0.004), while in non-treated patients, high BRE expression 
predicted an adverse prognosis (HR=2.59, 95% CI=1.00-6.75, p=0.05). Among ra-
diotherapy treated patients, the prognostic impact of BRE expression was confined 
to patients with smaller tumors (HR=0.23, 95% CI=0.068-0.75, p=0.015), and it 
remained an independent factor after correction for the other prognostic factors 
age, tumor size, lymph node involvement and histological grade (HR=0.50, 
CI=0.27-0.90, p=0.021). In addition, high BRE expression predicted a favorable 
relapse free survival in a publicly available dataset of 2,324 breast cancer patients 
(HR=0.59, CI=0.51-0.68, p<0.001). These data indicate that BRE is an interesting 
candidate for future functional studies aimed at developing targeted therapies. 
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Introduction
Despite great improvements in diagnostic imaging techniques and treatment, breast 
cancer remains one of the leading causes of cancer mortality in women. Prognostication 
of breast cancer patients nowadays relies highly on classical clinico-pathological features, 
such as tumor size, histological grade, age and lymph node metastases1. However, it 
remains a challenge to accurately predict disease outcome based on these parameters, 
which is necessary in order not to under- or over-treat patients.
Over the last twenty years, there has been great interest in developing prognostic 
patient classification methods based on molecular screenings. Genome-wide gene 
expression screens have identified expression profiles that predict disease outcome and 
therapy response. For example, in several large patient studies, a 70-gene signature 
called the ‘MammaPrint’ (Agendia, Amsterdam, The Netherlands) has been shown 
to outperform classical prognostication methods2-4. Together with other molecular 
classification methods5,6, these data indicate that the identification of differential 
gene expression has great potential for improved prediction of disease outcome and 
subsequent treatment decisions.
DNA double strand breaks (DSBs) are one of the most cytotoxic types of DNA 
damage. The importance of proper repair of these breaks to maintain genomic integrity 
is exemplified by recurrent mutations of genes involved in DSB repair in various cancers, 
for example BRCA1 mutations which occur in approximately 20% of the familial breast 
cancer cases7-9. The importance of the BRCA1 multi-protein complex has been illustrated 
by the identification of polymorphisms and haplotypes within other BRCA1 complex 
members, such as RAP80 and ABRAXAS, both in BRCA1/2 mutated and non-mutated 
familial breast cancer patients. However, the clinical impact of these polymorphisms 
remains to be confirmed10-15. Furthermore, BRCA1 expression levels seem to predict 
breast cancer outcome in non familial cases16-19, although data are not consistent20. 
Recently, it has been shown that high expression of BRE (Brain and Reproduc-
tive organ-Expressed), another member of the BRCA1 complex21-24, denotes a favorable 
prognosis in acute myeloid leukemia (AML)25,26. In this study, we demonstrate that 
BRE expression levels in breast cancer tumor tissue contained prognostic information 
in a cohort of 229 non-familial breast cancer patients, establishing the relevance of this 
DNA damage repair factor in breast cancer.
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Materials and Methods
Breast cancer samples
Frozen breast cancer tissue sections were available of two independent cohorts of in 
total 229 patients who had undergone resection of their primary tumor, as described 
before27-29. Patients were treated by surgical resection of the tumor which was followed 
by adjuvant systemic treatment and/or radiotherapy for part of the cohort. Patient char-
acteristics can be found in table 5.1. The median follow-up period of censored patients 
was 107.5 months. This study was performed according to REMARK guidelines30.
BRE QPCR
Tissue collection, mRNA isolation and cDNA preparation have been described before28. 
BRE expression was measured in both cohorts by QPCR using a commercially available 
primer/probe set (Hs01046283_m1, Life Technologies, Carlsbad, CA, USA) and 
normalized to expression of the housekeeping gene PBGD, as described26. Normalized 
QPCR data were mean centered per analyzed cohort and afterwards the data of the 
cohorts were combined to increase patient numbers for further analyses.
Statistical analyses
To statistically test the correlation of BRE expression with clinical parameters, the 
complete cohort was subdivided into two equally sized groups based on BRE expression. 
Differences in patient characteristics were tested by χ2, Fisher exact, or Mann Whitney U 
tests, as indicated. Disease free survival (DFS; with an event defined as the diagnosis of 
recurrent or metastatic disease) was used as feature for disease outcome. The prognostic 
impact of BRE expression was visualized using Kaplan-Meier plots and statistically 
tested via the logrank method and univariate or multivariate Cox regression analyses. 
Statistical analyses were carried out using Graphpad (La Jolla, CA, USA) or SPSS (IBM 
Corporation, Armonk, NY, USA) software.
Results
BRE expression correlates with tumor size
To study the prognostic effect of BRE expression in breast cancer, BRE mRNA levels 
were measured in tumor tissues collected at diagnosis of a cohort of 229 breast cancer 
patients by QPCR. Given the association of BRE with DNA damage repair, we 
subdivided the patient cohort a priori in two groups based on whether they had received 
radiotherapy as part of their primary treatment. BRE levels were gradually distributed 
and no difference was observed between radiotherapy treated or non-treated patients 
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(p=0.25). The dynamic range of expression was less than 50-fold (5.4Ct) and levels were 
normally distributed (based on a Kolmogorov-Smirnov test) (see figure 5.1a). This is in 
contrast to AML in which BRE is highly expressed in a distinctive subset of patients, 
while the remaining patients show little variation26. 
Comparisons of BRE expression with known clinico-pathological factors showed 
that BRE expression correlated with tumor size (p=0.014), but not with any of the other 
parameters (table 5.1). The correlation of BRE expression with tumor size was only 
observed in radiotherapy treated patients in which high BRE expression was more often 
found in smaller tumors (p=0.005, table 5.1).
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Figure 5.1: BRE expression predicts disease 
free survival in breast cancer
A. BRE expression was gradually distributed 
among 229 breast cancer patients. No significant 
differences were observed between radiotherapy 
(RT) and non-radiotherapy treated (no RT) 
patients. BRE expression was measured using 
QPCR and normalized to the housekeeping 
gene PBGD by the ΔCt method. Data shown 
are mean centered. Expression levels between 
radiotherapy treated and non-treated patients 
did not differ significantly (p=0.25 based on 
student’s T-test). B. For Kaplan Meier analyses, 
the total cohort was divided into two equally 
sized groups based on BRE expression (high: 
solid line; low: dashed line, as indicated). BRE 
expression had opposing prognostic impact 
in non-radiotherapy treated (no RT: upper 
panel) and radiotherapy treated (RT: lower 
panel) patients. In non-radiotherapy treated 
patients, the 5-year DFS was 86.6 ± 6.2% and 
75.5 ± 8.7% for low and high BRE expression, 
respectively (HR=2.59, CI=1.00-6.75, p=0.05). 
In radiotherapy treated patients, the 5-year DFS 
was 60.2 ± 5.5% and 78.3 ± 4.5% for low and 
high BRE expression, respectively (HR=0.47, 
CI=0.28-0.78, p=0.004). Patient numbers 
included in the analyses are indicated in brackets. 
P-values, HR’s and CI’s were calculated using 
the logrank method. Subdividing the cohort 
into three groups based on BRE expression 
obtained comparable results (data not shown).
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BRE expression predicts disease free survival in breast cancer 
Gradual differences in BRE expression (using continuous QPCR data) did not correlate 
with disease free survival (DFS) or overall survival (OS) in the total cohort, as tested 
by univariate Cox regression analysis (DFS: table 5.2, OS: data not shown). However, 
when the cohort was subdivided into radiotherapy treated and non-treated patients, BRE 
expression (tested as continuous variable) had prognostic impact on DFS within both 
groups (table 5.2). Remarkably, BRE expression showed opposite effects on prognosis. 
In the radiotherapy treated group (n=169), which accounted for the majority of the 
patients, high BRE expression correlated with a favorable DFS (Hazard ratio (HR)=0.72, 
95% confidence interval (CI)=0.53-0.97, p=0.030), while in the non-radiotherapy 
treated group (n=59), high BRE expression correlated with a poor prognosis (HR= 1.79, 
CI=1.11-2.87, p=0.016, table 5.2). Similar results were obtained when subdividing 
patients into two or three groups based on BRE expression, instead of using gradual 
QPCR data (table 5.3, and data not shown).
The effect of BRE expression on DFS was visualized using Kaplan Meier plots by 
subdividing the total cohort into two groups using median BRE expression as cutoff. 
Among the patients that did not receive radiotherapy, high BRE expression predicted 
an adverse prognosis validating the Cox regression analysis (HR=2.59, CI=1.00-6.75, 
p=0.05). High BRE expression predicted a favorable prognosis among the patients 
that received radiotherapy (HR=0.47, CI=0.28-0.78, p=0.004) (figure 5.1b). Interest-
ingly, within the radiotherapy treated patients, a significant correlation between BRE 
expression and disease free survival was only observed for the group of patients with 
smaller tumors (HR=0.23, CI=0.068-0.75, p=0. 015), which contained relatively more 
high BRE expressing patients (table 5.1, figure 5.2). No significant prognostic impact 
was observed in patients with larger tumors (figure 5.2).
BRE expression is an independent prognostic factor in radiotherapy treated patients
To determine whether BRE expression was an independent prognostic factor for DFS 
in breast cancer, multivariate Cox regression analyses were performed. These analyses 
showed that BRE expression was a prognostic factor within the group of radiotherapy 
treated patients, independent of the other prognostic factors age, tumor size, lymph 
Total cohort Non-radiotherapy 
treated patients
Radiotherapy treated 
patients
P HR (95% CI)a P HR (95% CI)a P HR (95% CI)a
BRE expression 
(QPCR data)
0.342 0.877 
(0.67-1.15)
0.016 1.79 
(1.11-2.87)
0.030 0.72 
(0.53-0.97)
Table 5.2: Univariate analysis of the correlation of BRE expression with DFS
aHR: hazard ratio; CI: confidence interval.
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node involvement and histological grade (HR=0.50, CI=0.27-0.90, p=0.021, table 5.3). 
Of note, also age, tumor size and the number of involved lymph nodes were independent 
prognostic factors in this group of patients. For non-radiotherapy treated patients, BRE 
expression did not significantly correlate with DFS in the multivariate analysis (table 
5.3). 
BRE expression predicts outcome in a large independent breast cancer cohort
We extended our studies to an independent cohort of breast cancer patients by evaluating 
the predictive value of BRE expression in a large publicly available micro-array dataset 
of 2,324 patients (see figure 5.3, Kaplan Meier Plotter31 (www.kmplot.com)). This 
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Figure 5.2: BRE expression predicts 
favorable DFS in radiotherapy-treated 
patients with small tumors
In radiotherapy-treated patients, BRE 
expression predicts DFS in patients with small 
tumors (pT1, upper panel). The 5-year DFS was 
72.7 ± 9.5% and 92.6 ± 4.1% for the groups 
with low and high BRE expression respectively 
(HR=0.23, CI=0.068-0.75, p=0.015). For 
patients with larger tumors (pT2 and pT3/4), 
no statistically significant prognostic effect of 
BRE expression was observed. For this analysis, 
patients were subdivided into two groups based 
on BRE expression, as explained in figure 5.1. 
P-values, HR’s and CI’s were calculated using 
the logrank method.
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cohort showed a favorable prognosis for patients with high BRE expression (upper 50% 
of the patients), and an adverse survival for patients with low BRE expression (lower 
50%) (HR= 0.59, CI=0.51-0.68, p <0.001 after correction for multiple testing). As no 
data regarding radiotherapy treatment were available, the impact of BRE expression on 
disease outcome within these subgroups could not be determined.
Non-radiotherapy treated patients Radiotherapy treated patients
Univariate Multivariatea Univariate Multivariatea
P HR 
(95% CI)b
P HR 
(95% CI)b
P HR 
(95% CI)b
P HR 
(95% CI)b
BRE 
(2 groupsc)
0.059f 2.51 
(0.97-6.53)
0.083f 2.38
(0.89-6.35)
0.004 0.46 
(0.27-0.79)
0.021 0.50 
(0.27-0.90)
Age 
(continuous)
0.349 0.98 
(0.95-1.02)
0.616 0.99 
(0.95-1.03)
0.112 0.98
(0.96-1.00)
0.020 0.97
(0.95-1.00)
Menopausal status 
(post- vs. 
premenopausal)
0.838 1.07 
(0.57-1.99)
0.140 0.81 
(0.62-1.07)
Tumor sized
(pT1 vs. pT2 vs. 
pT3/4)
0.422 1.39
(0.62-3.09)
0.465 1.56 
(0.47-5.15)
<0.001 2.01
(1.42-2.84)
0.014 1.70
(1.11-2.59)
Histological grade
(I vs. II vs. III vs. 
NDe)
0.941 0.97
(0.39-2.42)
0.895 1.01 
(0.86-1.19)
0.032 1.70
(1.05-2.74)
0.313 0.95
(0.86-1.05)
Involved lymph nodes
(0 vs. 1-3 vs. ≥4)
0.002 5.63
(1.84-17.3)
0.034 3.92 
(1.11-13.8)
0.001 1.87
(1.30-2.68)
0.013 1.66
(1.11-2.48)
Estrogen receptor 
status
(positive vs. negative)
0.680 0.82
(0.31-2.15)
0.362 0. 78 
(0.45-1.34)
Progesterone receptor 
status
(positive vs. negative)
0.866 0.92 
(0.36-2.39)
0.839 0.95
(0.55-1.62)
Table 5.3: Multivariate Cox regression analysis of BRE expression correlation with DFS
aFactors included in multivariate analysis: BRE expression, age, tumor size, histological grade and involved lymph 
nodes;
bHR: hazard ratio; CI: confidence interval;
cThe two groups are defined by BRE expression above or below the median expression of the total cohort, respectively;
dpT1: tumor size≤2cm, pT2: tumor size of 2-5cm, pT3/4: tumor size >5cm and/or direct extension to chest wall or 
skin;
eAs data on histological grading were missing for a substantial number of patients, this group (ND: Not Done) was 
included in the multivariate analyses as separate group, next to histological grade I, II or III;
fIn non-radiotherapy treated patients, BRE expression lost its significance when the median expression was used to 
divide patients based on BRE expression. When subdividing patients into three groups based on BRE expression, BRE 
was a significant predictor for DFS in both univariate and multivariate models.
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Discussion
High expression of the BRCA1 complex member BRE has recently been identified in a 
subgroup of AML patients in whom it defines favorable prognosis25,26. Here, we show 
that the expression of this gene also predicted disease outcome in a cohort of 229 non-
familial breast cancer patients. Interestingly, the predictive value of BRE expression at 
diagnosis on disease free survival depended on whether the patient received subsequent 
radiotherapy treatment. In radiotherapy treated patients, high BRE expression predicted 
a favorable disease outcome, whereas in non-radiotherapy treated patients it correlated 
with an adverse outcome (see figure 5.1, table 5.3). To extend our studies, BRE 
expression was evaluated in a publicly available dataset of 2,324 breast cancer patients31. 
In this large cohort, high BRE expression predicted a favorable relapse free survival. As 
this cohort represented a collection of previously published gene expression datasets, 
integral data on clinico-pathological factors were unavailable. Therefore, we were unable 
to determine the impact of BRE expression on disease outcome with regard to radio-
therapy treatment. The identification of prognostic impact of BRE expression in two 
independent cohorts warrants further studies in large cohorts to validate the effects 
found in radiotherapy treated and non-treated patients. 
The fact that BRE expression predicted opposing effects on disease outcome 
depending on radiotherapy treatment might imply that there are intrinsic differences in 
breast cancer patients who are treated or not treated with radiotherapy. Alternatively, there 
might be a direct effect of high BRE expression on radiotherapy response. The decision 
for radiotherapy treatment is closely related to the surgical treatment and depends on 
multiple factors, like tumor size and the involvement of axillary lymph nodes. As the 
patients were consequently not randomly assigned for treatment, it was not possible to 
100
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0
0 5 10 15 20
R
FS
 (%
)
Time (years)
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low BRE expression (50%)
high BRE expression (50%)
Figure 5.3: BRE expression predicts relapse 
free survival in a cohort of 2,324 breast 
cancer patients
A publicly available database (Kaplan Meier 
Plotter31) was used to investigate the effect of 
BRE expression on relapse free survival (RFS) 
in a cohort of 2,324 breast cancer patients. 
Micro-array data (BRE probe set 211566_s_
at) of these patients were used to divide 
patients into two equally sized groups. High 
BRE expression predicts a favorable prognosis 
(HR=0.51, CI=0.51-0.68, p<0.001). P-value, 
HR and CI were calculated using the logrank 
method. The p-value was corrected for 
multiple testing by Bonferroni correction.
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explain the opposing effect of BRE expression on the prognosis of radiotherapy treated 
versus non-treated patients in this cohort. Therefore, it would be of particular interest to 
test BRE expression in a cohort of patients that received radiotherapy in a randomized 
fashion, to evaluate a direct effect of BRE expression on therapy outcome.
BRE is a member of the BRCA1 complex, involved in DNA double strand break 
repair21-24. This complex is recruited to DNA damaged sites via binding of the complex 
member Rap80 to ubiquitin chains which are generated upon DNA damage32-34. 
Mutations in DNA repair factors are closely linked to familial breast cancer, as 25% 
of the cases is characterized by mutations in DNA damage repair factors, like BRCA1, 
BRCA2, PTEN, CHEK2, and ATM7-9,35-38. However, in non-familial breast cancer, these 
mutations are rare. In non-familial cases, associations between low BRCA1 expression 
with poor prognosis have been identified16-19, resembling the observations we made for 
BRE expression in radiotherapy treated patients. 
Depletion of BRE abrogates BRCA1 foci formation, indicating that BRE is 
needed for complex formation and downstream DNA repair22-24,39. Several studies have 
described an increased radio-sensitivity of cells upon BRE depletion21,22. Next to a role 
in the BRCA1 complex, BRE is also involved in death receptor mediated apoptosis, 
as it binds TNFα and FAS receptors and overexpression of BRE caused resistance to 
apoptosis induction by various stress-related stimuli40. This indicates that BRE serves 
an anti-apoptotic role following different types of stress. It was therefore unexpected to 
find a correlation between high BRE expression and a favorable breast cancer outcome 
in relation to radiotherapy. High expression would enhance DNA repair and hence 
would render cells resistant to radiotherapy. Indeed, this reasoning seems to be true for 
BRCA1, as radiotherapy has been shown to be especially beneficial for patients with low 
BRCA1 levels, whereas there was no benefit for patients with high BRCA1 levels41. On 
the other hand, high expression of the Mre11/Rad50/Nbs1 complex, also involved in 
DNA damage repair, predicts a good response to radiotherapy42, indicating that DNA 
repair proteins can contribute differentially to radiotherapy response. In this case, high 
BRE expression might attenuate the DNA damage repair pathway following radio-
therapy. The data described in this study indicate that BRE is an interesting candidate 
for functional studies in breast cancer to test its effect on radiotherapy responses.  
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6 Abstract
The E2 ubiquitin conjugating enzyme UBC13 catalyzes the formation of lysine 
63 (K63) specific ubiquitin chains. Ubiquitin chains linked through K63 play an 
active role in various signaling routes. Conditional knockout of Ubc13 in the he-
matopoietic system of mice impairs normal hematopoiesis affecting the survival of 
stem cells and early progenitors. In this study, we investigated the role of UBC13 in 
human myeloid differentiation models. We observed that UBC13 protein levels were 
downregulated during granulocytic as well as monocytic differentiation in several 
cell line models. The UBC13 cofactors MMS2 and UEV1a were also downregulated 
during differentiation. Silencing of UBC13 in U937 cells decreased PMA-induced 
monocytic differentiation, based on lower CD11b expression as read-out. However, 
UBC13 depletion did not affect apoptosis or cell cycle progression. These findings 
warrant further studies on the identification of proteins modified with K63-linked 
ubiquitin chains during myeloid differentiation.
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Introduction
Ubiquitination is a post-translational modification that plays a pivotal role in many 
biological pathways. Within the process of modifying proteins with poly-ubiquitin 
chains, E2 conjugating enzymes dictate the type of ubiquitin chain formed. E3 
ubiquitin ligases, which interact with E2s, determine which proteins are marked with 
ubiquitin. During ubiquitination, E2 enzymes first form a thio-ester bond with the 
C-terminus of ubiquitin via their catalytic site cysteine. Within the E2-E3-substrate 
complex, the E2-bound ubiquitin can attack lysine residue side chains, resulting in an 
isopeptide bond between ubiquitin and substrate protein. As ubiquitin itself contains 
seven lysine residues, ubiquitin chains can be formed via the covalent interaction of the 
C-terminus of a donor ubiquitin to an internal lysine of the acceptor ubiquitin. The E2 
conjugating enzyme UBC13 is currently the only identified E2 that specifically catalyses 
the formation of K63-linked chains1,2. UBC13 activity depends on the cooperation 
of either one of its cofactors, MMS2 or UEV1a. These ubiquitin E2 variants (UEVs) 
lack the catalytic cysteine needed for thio-ester formation. However, they are able to 
bind ubiquitin non-covalently, thereby positioning the acceptor ubiquitin in such a way 
that the donor ubiquitin, bound to UBC13, can only attack the K63 side chain of the 
acceptor3-5.
K63-linked ubiquitin chains play a role in several pathways including DNA 
damage responses, NF-κB and MAP kinase signaling and receptor trafficking6. All 
four pathways are involved in blood cell development, suggesting a role for UBC13 in 
hematopoiesis. The importance of UBC13-regulated signaling is illustrated by the early 
embryonic lethality of Ubc13-/- mice7,8. Recent studies using conditional tissue specific 
Ubc13-/- mouse models have shown an important role for this E2 in normal hematopoi-
esis7-9. Conditional knockout of the Ubc13 gene in bone marrow cells and thymocytes 
of adult mice led to mortality within two weeks9. The lethality was accompanied by a 
strong reduction of platelets and white blood cells (of myeloid and lymphoid origin) in 
the peripheral blood. These cytopenias were caused by bone marrow hypoplasia with a 
severe reduction of stem cells and progenitor cells.
These data demonstrate an important role for UBC13 in early hematopoiesis. 
However, no studies have been performed on later stages of differentiation. Furthermore, 
all data currently available originated from mouse studies. In this study, we investigated 
the role of UBC13 in myeloid differentiation using the human U937 monocytic cell 
line model. 
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Materials and Methods
Cell Lines 
HEK293T and HEK 293FT cells were cultured in DMEM medium (Invitrogen, 
Carlsbad, USA), supplemented with 10% non heat-inactivated FCS (Invitrogen), 
1% penicillin/streptomycin (MP biomedicals, Solon, USA), 0.1 mM Non-Essential 
Amino Acids (Invitrogen), 6 mM L-glutamine (Invitrogen) and 500 ng/mL geneticin 
(Invitrogen). NB4 and U937 cell lines were cultured in RPMI medium (Invitrogen) 
supplemented with 10% FCS and 1% penicillin/streptomycin. Cells were cultured at 
37°C and 5% CO2 in a humidified atmosphere. Granulocytic differentiation of NB4 
cells and monocytic differentiation of U937 cells was induced by 10-6 M ATRA (all-trans 
retinoic acid) or 100 ng/mL PMA (phorbol-12-myristate-13-acetate), respectively.
Cloning lentiviral inducible shRNA vectors 
Four independent short hairpin RNA (shRNA) sequences targeting UBC13 were 
cloned into the puromycin-resistant, tetracycline inducible pLKO.1 (pLKO.1-Tet-on-
puro) vector following the manufacturer’s protocol (Addgene, Cambridge, USA). In 
short, double stranded shRNAs were designed with flanking single stranded sequences 
compatible with AgeI and EcoRI sticky ends and a loop containing the XhoI restriction 
site. The sequences were ligated into the pLKO.1 backbone which was digested with 
AgeI and EcoRI. The following sense sequences were used for UBC13 shRNA construc-
tion: AATCCAGATGATCCATTAGCA (shRNA A; adapted from Matsuzawa et al.10), 
GTTGGGAAGAATATGTTTAGA (shRNA B; adapted from Xu et al.11), GGGACTTT-
TAAACTTGAACTA (shRNA C; adapted from Marteijn et al.12) and GCCCGAG-
CAGGGACTACATTT (shRNA D). A scrambled shRNA control was introduced in the 
pLKO.1-Tet-on-puro vector as negative control (CCATGCCTGCATTCTTCAT).
Lentivirus production
pLKO.1-Tet-on-puro vectors were co-transfected with the viral packaging vectors 
pLP1, pLP2 and pLP/VSVG (kindly provided by L. van Emst, Department of pediatric 
oncology, Radboud University Nijmegen Medical Centre, The Netherlands) in 
HEK293T or HEK 293FT cells using calcium phosphate. The medium was refreshed 
16h after transfection. Virus-containing supernatant was harvested 72h following 
transfection. 
Viral transduction
For lentiviral transduction, U937 cells were cultured on retronectin coated dishes in the 
presence of virus supernatant for 72h. Afterwards, transduced cells were selected with 1 
μg/mL puromycin for 14 days. shRNA transcription was induced by the addition of 2 
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μg/mL doxycycline 72h before starting PMA-induced (100 ng/mL) myeloid differentia-
tion. Differentiation was performed with continued doxycycline exposure.   
QPCR and Western blotting
For quantification of UBC13, MMS2 and UEV1A gene expression levels, total RNA 
was extracted using RNABee (AMS Biotechnology, Abingdon, UK). cDNA reactions 
were performed on 1 μg total RNA using M-MLV reverse transcriptase (Invitrogen). 
QPCR data were normalized to beta-ACTIN expression. Commercially available 
primer/probesets were used for QPCR of MMS2, UEV1A and beta-ACTIN (Applied 
Biosystems, Carlsbad, USA). For UBC13 QPCR, the following primers and probe were 
designed:  forward primer:   GAGCAGTGGAAGACCAACGAA; 
  reverse primer:   AGTGATGCACACTTGATGATCGTAT; 
  FAM-MGB probe:  ATAGAAACAGCTAGAGCATGGA.
To evaluate UBC13 protein expression, cells were lysed in RIPA lysis buffer 
(phosphate buffered saline with 1% Igepal CA-630, 0.5% Na-DOC, 0.1% SDS, 1 
mM MgCl2, and 10 μM ZnCl2), supplemented with benzonase (Novagen, Merck, 
Darmstadt, Germany) and complete protease inhibitor cocktail (Roche, Basel, 
Switzerland). Proteins were separated on SDS-polyacrylamide gels and transferred to 
PVDF membranes. Immunostaining was performed with primary antibodies directed 
against UBC13 (Invitrogen) and GAPDH (Abcam, Cambridge, UK) or β-ACTIN 
(Sigma, St. Louis, USA) as loading control. Horseradish peroxidase-coupled secondary 
antibodies were used and staining was visualized with enhanced chemiluminescence 
using a Chemidoc XRS+ system (Biorad, Hercules, USA).
Flow cytometric analysis
To quantify myeloid differentiation, CD11b expression at the cell membrane was 
measured by flow cytometry using PE-coupled antibodies (Beckman Coulter, Brea, 
USA). Apoptosis was measured by Annexin-V (VPS Diagnostics, Hoeven, The 
Netherlands) and 7AAD (Sigma) staining. To study cell cycle distribution, cells were 
harvested and incubated for 16h at 4°C in PI-solution (0.3 mM Sodium citrate, 0.1 mg/
mL RNAse A, 20 μg/mL Propidium Iodide (PI), 0.1% Triton X-100). DNA histograms 
were generated by measuring PI signals using flow cytometry.
Statistical analyses
Differences between conditions were statistically tested by two-sided student’s t-tests. A 
p-value <0.05 was considered significant.
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Results
UBC13 is downregulated during myeloid differentiation
Previous results suggested that UBC13 mRNA expression levels decreased during 
gefitinib induced granulocytic differentiation of promyelocytic HL60 cells13. To study 
whether this decrease was a general phenomenon of myeloid differentiation, other 
cell lines and differentiation inducing agents were tested. UBC13 protein levels were 
reduced after PMA-induced differentiation of myelomonocytic U937 cells (figure 6.1A, 
left panel). A similar decrease was observed in promyelocytic NB4 cells, which were dif-
ferentiated using ATRA (figure 6.1A, right panel). In NB4 cells, UBC13 mRNA levels 
were determined during differentiation. This showed a significant decrease in mRNA 
expression to approximately 20% after 96 hours of differentiation (figure 6.1B).
As UBC13 needs one of its cofactors MMS2 or UEV1a for activity, gene 
expression of these two cofactors was quantified during ATRA induced differentiation 
of NB4 cells to determine whether these were differentially regulated as well. Both genes 
0h 72
h
96
h
0
20
40
60
80
100
hours ATRA induction
U
B
C
13
 e
xp
re
ss
io
n 
(%
)
0h 72
h
96
h
0
20
40
60
80
100
hours ATRA induction
M
M
S
2 
ex
pr
es
si
on
 (%
)
0h 72
h
96
h
0
20
40
60
80
100
hours ATRA induction
U
EV
1A
 e
xp
re
ss
io
n 
(%
)
p=0.002
p=0.02
p=0.003
p=0.02
p=0.02
p=0.07
β-Actin
Ubc13
NB4
ATRA induction
0h 96h
β-Actin
Ubc13
U937
PMA induction
0h 72h
B
A
Figure 6.1: UBC13 and its cofactors are downregulated during myeloid differentiation
A. PMA-induced differentiation of U937 cells (left panel) and ATRA-induced differentiation of 
NB4 cells (right panel) led to decreased UBC13 protein expression. Cells were treated with 100 
ng/mL PMA or 10-6 M ATRA for 72h or 96h before cell lysates were prepared as indicated. Equal 
loading of lysates was demonstrated by β-ACTIN staining. B. ATRA-induced differentiation of 
NB4 cells led to decreased mRNA expression of UBC13 (left panel) and its cofactors MMS2 
(middle panel) and UEV1A (right panel). Cells were treated with 10-6 M ATRA for the indicated 
time, followed by RNA isolation and QPCR for the indicated genes. Gene expression was 
normalized to expression of the housekeeping gene beta-ACTIN (ΔCt). Data are represented as 
percentage 2-ΔΔCt compared to time point 0. P-values were calculated via student’s t-tests on ΔCt 
values (n=4).
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were significantly downregulated during differentiation. The level of downregulation of 
MMS2 was comparable to UBC13, while UEV1A displayed downregulation to a lesser 
extent (figure 6.1B). The two cofactors resemble each other for more than 90% at the 
protein level. As specific antibodies are currently unavailable, we were unable to test the 
individual downregulation at the protein level.
Knockdown of UBC13 in U937 cells decreased monocytic differentiation
To study the biological role of UBC13 during myeloid differentiation, lentiviral 
approaches for delivery and expression of UBC13 targeting short hairpin RNA sequences 
(shRNAs) were established. Lentiviral vectors with four independent doxycycline-
inducible shRNAs were tested for their ability to knockdown UBC13 protein levels in 
transduced U937 cells. As shown in figure 6.2, shRNA A, B and C efficiently knocked 
down endogenous UBC13 levels, while shRNA D showed no effect. Knockdown became 
evident after three days of doxycycline treatment and lasted for more than eight days 
(data not shown). As shRNA A, B and C expression resulted in UBC13 knockdown, 
subsequent studies were performed with these three shRNAs.
To test the effect of UBC13 silencing on monocytic differentiation, stably 
transduced U937 cells with inducible UBC13 shRNAs were differentiated towards 
the monocytic lineage using PMA. To induce differentiation in a UBC13 knockdown 
setting, U937 cells were first cultured for three days in the presence of doxycycline 
to induce knockdown, before starting differentiation by PMA addition. As read-out 
for differentiation, cell surface expression of the myeloid-specific marker CD11b was 
measured. UBC13 silencing did not affect CD11b expression levels in undifferentiated 
cells (data not shown). However, UBC13 silencing resulted in a significant decrease in 
CD11b expression four days after PMA-treatment compared to non-doxycycline treated 
controls and the scrambled control or non-transduced cells (figure 6.3). 
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Figure 6.2: Efficiency of UBC13 
silencing by independent shRNA 
constructs
Lentivirally transduced U937 cells with 
the indicated shRNAs or non-transduced 
cells (NT) were treated for 72h with 2 μg/
mL doxycycline (Dox) to induce shRNA 
transcription. UBC13 expression was 
visualized by SDS-PAGE and Western 
blotting using a UBC13-specific antibody. 
Silencing of UBC13 was evident after 
induced expression of shRNA A, B and C 
but not D. GAPDH staining was included 
to assess equal protein loading.
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Figure 6.3: UBC13 knockdown attenuates monocytic differentiation of U937 cells
A. Non-transduced (NT) U937 cells or cells transduced with the indicated shRNAs were cultured 
with or without 2 μg/mL doxycycline for 72h, followed by a 96h exposure to 100 ng/mL PMA 
in combination or not with doxycycline, as indicated. Differentiation was evaluated by CD11b 
expression analysis using flow cytometry. Histograms of CD11b expression on cells treated 
with or without doxycycline and PMA are shown. The dotted line represents non-doxycycline 
treated, non-differentiated cells. The light grey surface represents non-doxycycline, PMA-treated 
cells and the dark grey surface indicates doxycycline- and PMA-treated cells. Doxycycline-
treated, non-PMA treated cells were comparable to the dotted line (data not shown). B. The 
differentiation of doxycycline-induced cells transduced with shRNA A, B and C was significantly 
decreased compared to both non-transduced cells and scrambled controls (p<0.05, student’s 
t-test, indicated by asterisk). The ratio of the x-mean of CD11b expression after four days of 
PMA-treatment of doxycycline-treated versus non-doxycycline-treated cells per transduction was 
calculated for five biological replicates (represented as percentage of the non doxycycline-treated 
sample). Data are represented as mean plus SEM (standard error of the mean). 
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Ubc13 deletion leads to increased apoptosis of primary mouse hematopoietic 
precursor cells in vivo9. Therefore, we studied apoptosis and cell cycle progression in 
the U937 model. In undifferentiated proliferating cells, UBC13 silencing did not affect 
apoptosis or cell cycle progression, as no differences were observed between doxycycline 
treated versus non-treated cells transduced with UBC13 shRNAs, nor between UBC13 
silenced cells and scrambled controls (figure 6.4A). Apoptosis and cell cycle progression 
was also measured during PMA-induced differentiation. PMA-treatment induced 
apoptosis and a G1/G0 arrest in all cells, and we did not observe consistent differences 
in apoptosis rates and cell cycle progression between scrambled controls and UBC13 
silenced cells after PMA-induced differentiation (figure 6.4B+C).
Discussion
The E2 conjugating enzyme UBC13, which catalyses K63-ubiquitin chain formation, is 
essential for early stages of murine hematopoiesis9. Here, we studied the expression and 
role of UBC13 at later stages of myeloid differentiation using human cell line models. 
Both ATRA-induced granulocytic differentiation of NB4 cells and PMA-induced 
monocytic differentiation of U937 cells led to UBC13 downregulation. In combination 
with the previously reported downregulation of UBC13 mRNA levels during gefitinib-
induced granulocytic differentiation of HL60 cells13, these data suggest that UBC13 
downregulation is a common phenomenon during myeloid differentiation. It would be 
interesting to study whether the total amount of K63-linked ubiquitin chains decreases 
upon differentiation, and whether specific substrates are differentially modified. 
Figure 6.4: UBC13 knockdown does not affect apoptosis and cell cycle progression of 
U937 cells (previous page)
Lentivirally transduced U937 cells with indicated shRNAs or non-transduced cells (NT) were 
treated with 2 μg/mL doxycycline for 72h, followed by 48h culturing with or without 100 ng/mL 
PMA in combination with doxycycline, as indicated. Cell cycle progression was evaluated by PI 
(Propidium Iodide) staining and apoptosis by Annexin-V and 7AAD staining. A. Doxycycline-
induced UBC13 silencing did not affect cell cycle progression (upper panels) or apoptosis (lower 
panels) in non-differentiated U937 cells. No differences were observed between doxycycline 
treated versus non-treated cells (data not shown). B. 48h PMA treatment induced cell cycle 
arrest in G0/G1 phase. UBC13 depletion did not affect this arrest. The upper graph represents 
the cell cycle progression differences between cells transduced with different shRNAs and the 
effect of doxycycline-induced shRNA expression. To visualize the data, PI flow cytometry graphs 
of doxycycline-treated cells are shown below. C. UBC13 depletion did not affect PMA-induced 
apoptosis. The upper graph represents the differences in apoptosis between cells transduced with 
different shRNAs and the effect of doxycycline-induced shRNA expression. To visualize the data, 
Annexin-V/7AAD flow cytometry graphs of doxycycline treated cells are shown below. Data 
shown are a representative of three independent experiments.
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Unfortunately, the quality of currently available K63-specific antibodies is not sufficient 
to test this.  
The high expression of UBC13 in undifferentiated cells and its downregulation 
during differentiation might suggest a functional role for UBC13 in myelopoiesis. 
Several scenarios are conceivable. High expression of UBC13 might be necessary to 
retain an undifferentiated state and UBC13 downregulation is needed before differen-
tiation can take place. Alternatively, high UBC13 levels might be needed for the first 
steps of differentiation, but once the differentiation program is started, UBC13 function 
is dispensable, resulting in downregulation. To test these hypotheses, the functional role 
of UBC13 was studied using inducible UBC13 silencing constructs in U937 differentia-
tion assays. Silencing of UBC13 did not induce spontaneous differentiation of U937 
cells. On the contrary, UBC13 silencing reduced the PMA-induced differentiation of 
U937 cells, based on reduced CD11b expression after four days of PMA treatment. This 
indicates that high levels of UBC13 are needed for proper differentiation. However, 
differentiation was not completely blocked by UBC13 silencing. In this respect, the low 
residual UBC13 levels following gene silencing may have allowed low levels of differen-
tiation. The reduced CD11b expression upon differentiation after UBC13 silencing was 
not accompanied by reduced apoptosis levels. This observation was unexpected, as dif-
ferentiation of U937 cells induced by PMA is generally accompanied by apoptosis14. It 
would be interesting to study which mechanisms are regulated by UBC13 that are able 
to stimulate PMA-induced differentiation programs, while not affecting PMA-induced 
apoptosis and cell cycle regulation.
The role of K63-linked ubiquitin chains has been established in several pathways 
including DNA damage repair, NF-κB and MAP kinase signaling and receptor 
trafficking. K63-linked chains are known to induce internalization of several cellular 
membrane receptors15. We observed reduced membrane expression of CD11b upon 
UBC13 depletion, which is opposite to the expected effect if UBC13 would enhance 
the internalization of this receptor. To verify that the effect we observed is not due 
to a specific role of UBC13 in CD11b expression and/or trafficking, research in our 
laboratory is currently directed at confirming the results using other differentiation 
markers. Furthermore, additional studies such as NBT (Nitro Blue Tetrazolium) or 
phagocytic activity assays should be performed to study the effect of UBC13 silencing 
on the monocytic behavior of PMA-treated U937 cells.
Together with E3 ubiquitin ligases, UBC13 marks various proteins involved 
in NF-κB and MAP kinase signaling with K63-linked ubiquitin chains16,17. In these 
pathways, UBC13 depends on UEV1a as cofactor. Importantly, UEV1A showed 
comparable downregulation to UBC13 during differentiation in our experiments 
(≈80%, figure 6.1B). In mouse macrophages and B cells, UBC13 is needed for proper 
inflammatory responses. However, it depends on cell type and stimulus whether UBC13 
signaling is necessary for NF-κB and/or MAP kinase signaling7,8. Both NF-κB and MAP 
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kinase signaling are important for PMA-induced U937 differentiation, as inhibition of 
either pathway decreases differentiation18-21. This resembled the data following UBC13 
silencing described in this study. However, inhibition of both NF-κB and MAP kinase 
pathways decreased differentiation-induced apoptosis of U937 cells, which was not 
evident in our experiments. Additional studies investigating whether UBC13 silencing 
causes decreased activation of target genes of the NF-κB and MAP kinase pathways in 
PMA-treated U937 cells are required to show a potential direct effect of UBC13 on these 
pathways during differentiation. To gain better insight in additional pathways regulated 
by K63-linked ubiquitin chains during myeloid differentiation, future research should be 
directed at identification of the substrate proteins of UBC13-mediated ubiquitination.
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Abstract
The modification of proteins with ubiquitin is critical for many cellular processes. 
Typically, K63-linked ubiquitin chains positively affect downstream signaling, for 
example in NF-κB and DNA damage repair pathways. UBC13 is the E2 conjugating 
enzyme responsible for K63-linked ubiquitin chain formation. Recently, it has been 
shown that conditional knockout of Ubc13 leads to severe hematopoietic defects 
in mice. To fully understand the role of K63-linked ubiquitination in this process, 
knowledge on the modified substrates is needed. In this chapter, a novel method 
to isolate endogenous proteins modified with K63-linked ubiquitin chains is 
described. This method is based on immobilized GST-fusions of ubiquitin binding 
domains. Rap80-UIM (ubiquitin interacting motif ), Tab2-NZF (Npl4 Zinc finger) 
and a tandem-Tab2-NZF domain were used for the isolation of proteins modified 
with K63-linked chains. The Mud1-UBA (ubiquitin associated) domain with 
specificity for K48-linked chains served as a control. K63-ubiquitinated proteins 
were isolated by incubation of the immobilized K63-linkage specific domains 
with cellular extracts. The GST-fusion of tandem-Tab2-NZF showed the highest 
enrichment for modified proteins with K63-linked chains. Mass spectrometry was 
used to identify the purified proteins. Apart from ubiquitin, which was the most 
abundant protein in the mass spectrometric analysis, many other proteins were 
identified, including E3 ligases and proteasome subunits.
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Introduction
Many important biological processes, such as DNA damage repair, cell cycle progression 
and NF-κB signaling are regulated by ubiquitination1. In this posttranslational modifi-
cation of cellular proteins, ubiquitin is covalently conjugated to an internal lysine of the 
substrate protein. As ubiquitin itself contains seven lysines (K6, K11, K27, K29, K33, 
K48, K63), ubiquitin polymers can be formed by the covalent interaction of the donor 
ubiquitin C-terminus to an internal lysine of the acceptor ubiquitin. Consequently, 
proteins can be modified with single ubiquitin moieties, so-called mono-ubiquitination, 
or with ubiquitin chains (poly-ubiquitination)2.
K63-linked ubiquitin chains are important signaling factors by serving as a 
binding platform for downstream proteins3. The regulatory role of K63-linked ubiquitin 
chains has been shown in the DNA damage repair pathway, NF-κB and MAP kinase 
signaling and membrane receptor turnover4. UBC13 is currently the only E2 conjugating 
enzyme identified that specifically catalyzes K63-linked chains5,6. Conditional knockout 
of Ubc13 in mouse models leads to severe defects in early hematopoiesis, inducing 
mortality within two weeks7. Furthermore, a role for UBC13 in myelopoiesis has been 
described in chapter 6 of this thesis. However, the substrates of UBC13 ubiquitination 
that mediate its function in these processes are mainly unknown. In this chapter we 
describe a method to isolate and identify K63-ubiquitinated proteins using the binding 
specificity of different ubiquitin binding domains (UBDs) for K63-ubiquitin linkages.
Currently, cellular methods to study ubiquitin linkages rely on the overexpression 
of tagged-ubiquitin mutants lacking one or more lysines, followed by isolation of the 
modified proteins via the tag. The advantage of this technique is the possibility to use 
denaturing conditions for isolation, thereby disrupting all protein-protein interactions 
and only isolating ubiquitin covalently coupled to substrates. However, the mutation and 
the tag might influence ubiquitination. Furthermore, overexpressed mutant ubiquitin 
has to compete with endogenous ubiquitin, which is among the highest expressed 
proteins in a cell. Therefore, it is likely that in overexpression studies, poly-ubiquitin 
chains are composed of both wildtype and mutant ubiquitin moieties and data may 
therefore be misleading. 
Mass spectrometry (MS) has become the standard technique to identify ubiq-
uitination-sites in substrates, taking advantage of the covalent nature of this modifica-
tion. Trypsin digestion of ubiquitinated proteins results in the formation of peptides 
containing a miscleaved lysine with a double glycine (diG) remnant originating from 
the C-terminus of ubiquitin. This diG remnant causes a 114D shift of the unmodified 
peptide in the MS spectrum8. This property has been used in quantitative MS to 
determine the abundance of different ubiquitin chain linkages in several organisms, 
including human cell line models. This showed that the most abundant chains are 
K48-linked, followed by K11- and K63-linked chains. The presence of the other chains 
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is much lower9-11. Although MS can be used to identify the ubiquitinated lysine in 
proteins and to determine the cellular abundance of different chain conformations, it is 
unable to identify the type of ubiquitin chain attached to a specific protein in complex 
samples, as trypsin digestion destroys the substrate-chain architecture. Therefore, an 
additional purification step for the specific ubiquitin-linkage preceding MS analysis 
would be needed for global identification of substrates of specific chains.
Proteins that bind ubiquitin contain one of the many structural types of UBDs12. 
Many of these domains show specificity for particular ubiquitin chains or mono-
ubiquitin13,14. For some of these domains, structural data are available, illustrating their 
chain specificity. For example, the C-terminal Npl4 Zinc finger (NZF) domain of Tab2 
binds specifically to K63-linked chains using two distinct domains in the two adjacent 
ubiquitin moieties15,16. Tab2 uses a single NZF-domain of only 30 amino acids for 
K63-linkage binding. This is in contrast to Rap80, which uses two ubiquitin interacting 
motifs (UIMs) for the recognition of one K63-linkage17,18. We developed a method to 
purify endogenous proteins modified with K63-chain linkages based on these UBDs. 
The small UBDs (K63 specific: Tab2-NZF, Rap80-UIM, and as control, K48 specific: 
Mud1-UBA19 (Ubiquitin Associated)) were fused to GST and expressed in bacteria. The 
fusion-proteins were coupled to glutathione sepharose beads and used in pull-down 
experiments with human cell lysates, followed by the identification of isolated proteins 
via MS analyses. 
Materials and Methods
Cell Lines
U937 cells were cultured in RPMI medium (Invitrogen, Carlsbad, USA) supplemented 
with 10% fetal calf serum (FCS, Invitrogen) and 1% Penicillin/Streptomycin (MP 
biomedicals, Solon, USA). Hela cells were cultured in DMEM medium (Invitrogen) 
supplemented with 10% FCS and 1% Pen/Strep. All cells were maintained at 37°C and 
5% CO2 in a humidified atmosphere.
Constructs and transfection
For GST-fusion protein expression, the following constructs were used: pGEX-6p1, 
pGEX-6p1-Mud1_UBA (amino acid (aa) 293-332) and pOPINJ-Tab2_NZF-UBD (aa 
663-693) (kindly provided by Dr. Kulathu and Dr. Komander (Cambridge, UK))13,15. 
The pGEX-Rap80_UIM1/2 (aa 79-121) construct was kindly provided by Dr. Jetten 
(NIH, USA)20. To generate a tandem-Tab2_UBD construct, the NZF-UBD was 
PCR amplified from pOPINJ-Tab2_UBD either with flanking BamHI and HindIII 
restriction enzyme sites or with flanking HindIII and XhoI restriction enzyme sites 
including a linker encoding 5x Gly and 1x Val downstream of the HindIII site, upstream 
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of the UBD. Both PCR-products were cloned separately into the cloning vector pDrive 
(Qiagen, Venlo, The Netherlands) and subsequently combined into pGEX-6p1 as a 
tandem-Tab2 domain, interspersed by the six amino acid linker.
pcDNA3.1 with ubiquitin containing an N-terminal strep(II)-HA-tag was 
kindly provided by Dr. Nielsen (Copenhagen, Denmark)10. The HA-tag was removed 
by substituting HA-Ubiquitin flanked by SacII and NotI restriction sites by solely 
ubiquitin with the same flanking restriction sites. K11R, K48R and K63R mutations 
were introduced using the Quickchange XL Site-Directed Mutagenesis kit of Stratagene 
(Santa Clara, USA) according to the protocol supplied and the following primers: 
5’-gaccctgaccggcaggaccatcactctgg-3’ (K11R), 5’-aggctcatctttgcaggcaggcagctggaag-3’ 
(K48R), 5’-tctttctgactacaacatccagagagagtcgaccct-3’ (K63R). Constructs were sequenced 
to confirm mutation introduction. Wildtype or mutant ubiquitin fused to the Strep(II) 
tag was overexpressed in Hela cells using PEI transfection.
GST-fusion protein expression and isolation
GST-fusion UBD domains were expressed and purified as described elsewhere15. In 
short, pGex or pOPINJ vectors were transformed into the Escherichia Coli Rosetta 
2(DE3)pLacI bacterial strain (Novagen, Darmstadt, Germany). Bacteria were grown to 
OD 0.6, followed by induction of protein expression with 150 μM IPTG and 200 μM 
ZnSO4 for 16h at room temperature. Afterwards, bacteria were lysed by sonication in 
lysis buffer (270 mM sucrose, 50 mM Tris-HCl pH8, 10 mM Na2β-glycerophosphate, 50 
mM NaF, complete protease inhibitor cocktail (EDTA-free, Roche, Basel, Switzerland), 
1 mg/mL lysozyme, 0.1 mg/mL DNAse and 0.1% β-mercaptoethanol). Cleared lysates 
were incubated with glutathione sepharose beads (GE Healthcare, Waukesha, USA) 
for 2hr at 4°C. GST-coupled beads were washed six times with high salt buffer (500 
mM NaCl, 25 mM Tris-HCl pH8, 5 mM DTT), five times with low salt buffer (150 
mM NaCl, 25 mM Tris-HCl pH8, 5 mM DTT) and 3 times with TEND buffer (140 
mM NaCl, 25 mM Tris-HCl pH7.4, 2.7 mM KCl, 0.5% Igepal CA-630, 5 mM DTT, 
complete protease inhibitor cocktail (EDTA-free, Roche), and 1 mM PMSF). Purity 
and yield of GST-coupled beads was examined by SDS-PAGE of 2 μL beads followed by 
colloidal Coomassie blue staining21 (0.12% Coomassie G250 (Biorad, Hercules, USA), 
10% (NH4)2SO4, 10% H3PO4, 20% Methanol). 
Pull-down of purified ubiquitin chains
Small amounts of sepharose beads coupled to GST-UBDs (0.05μL≈0.25μg GST-
protein) were incubated with di-ubiquitin chains (di-Ub) or chains of 2-9 ubiquitin 
moieties (Ub2-9) of different chain conformations (K11, K48 and K63, Boston Biochem, 
Cambridge, USA) for 3hr at 4°C in pull-down buffer (150 mM NaCl, 50 mM Tris-HCl 
pH7.5, 5 mM DTT, 0.1% Igepal CA-630). Beads were subsequently washed five times 
in pull-down buffer and denatured in SDS loading buffer prior to SDS-PAGE and 
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Western blotting. Blots were probed with an antibody against total ubiquitin (clone 
6C1, Sigma-Aldrich, St. Louis, USA).
Pull-down of ubiquitinated proteins from cellular extracts
U937 or transfected Hela cells were lysed by sonication in pull-down buffer supple-
mented with complete protease inhibitor cocktail (EDTA-free, Roche), 0.5% benzonase 
(Novagen), 1 mM PMSF and 10 μM WP1130 (kindly provided by Dr. Donato, Ann 
Arbor, USA). Cleared lysates were incubated with UBD-sepharose beads for 3hr at 4°C. 
Beads were washed five times in pull-down buffer and denatured in SDS loading buffer. 
After SDS-PAGE and Western blotting, pull-down efficiency was evaluated by probing 
membranes with antibodies for total ubiquitin (Sigma-Aldrich), K11-ubiquitin chains 
(Millipore, Billerica, USA), K48-ubiquitin chains (Millipore) and K63-ubiquitin chains 
(Millipore), or Strep(II) (IBA, Göttingen, Germany).
Protein identification via tandem mass spectrometry
U937 pull-down samples were electrophoresed on an SDS-PAGE gel for 2.5 cm. 
Following colloidal Coomassie blue staining, gel fragments above the GST-proteins 
(>±36kD) were excised and cut into 1x1mm pieces. Gel pieces were destained in three 
rounds of consecutive equilibration in 50mM ammonium bicarbonate (ABC), 50% 
acetonitrile (ACN)/50% H2O and 100% ACN. Next, gel pieces were reduced in 10 mM 
DTT, followed by alkylation in 50 mM 2-chloroacetamide in 50 mM ABC. Proteins 
were in gel digested with trypsin (100 ng trypsin in 50 mM ABC per lane) for 16hr at 
37°C. Peptides were extracted from the gel pieces using 2% trifluoroacetic acid (TFA) 
followed by a second extraction in 80% ACN, 0.5% acetic acid, 1% TFA. Afterwards, 
peptides were purified using home-made Stage Tips as described22 and reconstituted 
in 0.5% acetic acid. For MS analysis, 20% (5μL) of the sample was injected onto a 15 
cm fused silica emitter (New Objective, Woburn, USA) packed with reversed phase 
ReproSil-Pur C18AQ 3μm resin (Dr. Maisch, Ammerbuch-Entringen, Germany) using 
0.5% acetic acid. Peptides were eluted from the column in a 60 minute linear gradient 
of 15 to 60% 80% ACN, 0.5% acetic acid using a nanoflow liquid chromatography 
(LC) system (Proxeon, Thermo Fisher Scientific, Waltham, USA). Tandem MS spectra 
were acquired by the linear ion trap for the top four most-abundant ions from each 
ICR cell precursor scan by collision induced dissociation (CID) with enabled dynamic 
exclusion to prevent repetitive analysis of peptide ions. Measurements were performed 
with a linear ion trap Fourier-transform ion cyclotron resonance mass spectrometer (7T 
LTQ FT Ultra, Thermo Fisher) as described23. 
Data was searched against the human Refseq database (release 44) with additional 
known contaminant sequences (e.g. trypsin and LysC) using Mascot software (v2.2, 
Matrix Science). A second database search was performed against a decoy database 
with reversed protein sequences for subsequent false discovery rate (FDR) calculations. 
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Parameters for the Mascot searches were 10 ppm precursor ion mass tolerance, 0.8 Da 
fragment ion mass tolerance, ESI-TRAP instrument fragment ions, tryptic specificity 
with a maximum of 2 missed cleavages, carbamidomethyl (cys) as fixed modification, 
and the following variable modifications: GlyGly (Lys), LeuArgGlyGly (Lys), and 
oxidation (Met). Validation of the peptide and protein identification data was performed 
according to Weatherly et al.24 using the in-house developed software tool PROTON 
[PROteomics TOols Nijmegen; Wessels et al., manuscript in preparation]. Briefly, this 
validation method uses the normal (true and false positives) and decoy (true negatives) 
database search results to calculate peptide identification score thresholds to achieve 
the specified 1% FDR for proteins identified using 1, 2, 3, 4, 5, and 6 or more unique 
peptides. Protein abundance values for valid protein identifications were calculated by 
the PROTON software as exponentially modified protein abundance index according 
to Ishihama et al.25.
Enrichment of diG-peptides for MS analysis
U937 cell lysate incubation with tandem-Tab2 immobilized beads, sample preparation, 
trypsin digestion and Stage Tip purification were performed as described above. 
Following Stage Tip purification, diG-peptides were purified using the PTMScan 
Ubiquitin Remnant Motif kit (Cell Signaling Technology, Danvers, USA)26, following 
the manufacturer’s protocol. In short, peptides were dissolved in 1.4 mL IAP buffer (50 
mM MOPS/NaOH, pH7.2, 10 mM Na2HPO4, 50 mM NaCl) and incubated with 
PTMScan diG-immunoaffinity beads for 30 min. at 4°C. After washing, peptides were 
eluted with 0.15% TFA, followed by concentration and purification using Stage Tips. 
MS analysis of the peptides was performed as described above.
Results
Tab2 binds preferentially to purified K63-linked ubiquitin chains
GST-UBD fusion proteins immobilized to glutathione beads were used to isolate specific 
ubiquitin chains. For capturing of K63-linkages, the NZF domain of Tab2 and tandem 
UIM domain of Rap80 were used and the UBA domain of Mud1 was used as a reference 
for capturing K48-linkages (supplemental figure 7.1)13,20. By performing pull-down 
experiments with purified di-ubiquitin (figure 7.1A) and longer chains of two to nine 
ubiquitin moieties with K48 or K63 linkages (figure 7.1B), we confirmed the preferen-
tial binding of Tab2 and Rap80 to K63-linked ubiquitin chains over K48-linked chains. 
Mud1 showed preferential binding to K48-linked chains, as expected. However, Mud1 
also showed binding to K63-linked chains, although the binding efficiency was much 
lower compared to K48-binding. Importantly, GST alone did not show any binding 
affinity for the tested ubiquitin chains.
Chapter 7
140
7
Next to K48- and K63-linked chains, K11-linked chains are the third most 
occurring type of chains9-11. We therefore also tested binding of the used domains 
to K11-linked di-ubiquitin chains. Interestingly, Tab2 was able to bind K11-linked 
chains, a property not described before (figure 7.1A). Rap80 and Mud1 did not bind to 
K11-linked di-ubiquitin. 
Of the two K63-linkage specific domains, Tab2 showed the highest efficiency 
in ubiquitin binding. We hypothesized that a tandem domain might increase binding 
even more. To test this, a GST-fusion of two Tab2-NZF domains interspersed by a six 
amino acid linker was cloned and bacterially expressed. Indeed, this domain showed 
higher affinity for K63-linked ubiquitin chains compared to the single domain (figure 
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Figure 7.1: Pull-down of K63-linked chains by Tab2, Rap80 and tandem-Tab2
A. 0.05 μL of purified GST-UBD fusion proteins immobilized to glutathione beads were 
incubated with 2 μg di-ubiquitin of different linkages (K11, 48 or 63). Pull-down samples were 
separated with SDS-PAGE and Western Blotting, and blots were stained for ubiquitin. Mud1 
showed specificity for K48-di-Ub. Rap80 showed specificity for K63 di-ub. Tab2 and tandem-
Tab2 (tTab2) bound to K63 di-Ub, but also to K11 di-Ub. A Ponceau staining is included to 
indicate the amount of GST-fusion protein used. B. Experimental setup as in A, except ubiquitin 
chains of different lengths (K482-9 and K632-9) were used. Mud1 bound preferentially to K48-
linked chains, with minor binding to K63-linked chains. Tab2, tandem-Tab2 (tTab2) and Rap80 
bound preferentially to K63-linked chains, although tandem-Tab2 showed low binding to K48-
linked chains as well.
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7.1B). However, it also interacted with K48-linked chains of three linkages or longer, 
albeit with lower efficiency compared to K63-linked chains. Tandem-Tab2 interacted 
with K11 di-ubiquitin in a comparable manner as the single Tab2 domain (figure 7.1A).
GST-UBDs bind to endogenous proteins modified with ubiquitin chains
The data described above showed efficient binding of the UBDs to purified ubiquitin 
chains, confirming previously described data15-19. To test whether the binding efficiency 
was sufficient to isolate ubiquitin chains attached to endogenous substrates from cellular 
extracts, we incubated the GST-UBD fusions with lysates of U937 cells. In figure 7.2A, 
it is shown that tandem-Tab2 and Mud1 showed the highest efficiencies to pull-down 
ubiquitinated proteins. Tab2 showed a modest efficiency in ubiquitinated substrate 
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Figure 7.2: Tandem-Tab2 efficiently isolated endogenous substrates of K63-linked 
ubiquitin chains
10 μg GST-UBD fusion protein immobilized on glutathione beads was incubated with 50 mg 
U937 lysate. After washing of beads, the pull-down samples were divided in four and following 
Western blotting membranes were stained for total ubiquitin (A), K63-linked poly-ubiquitin 
chains (B), K48-linked poly-ubiquitin chains (C), and K11-linked poly-ubiquitin chains (D). A 
Ponceau staining for GST-UBDs is shown below each antibody staining
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binding and Rap80 showed inefficient binding. The GST-control did not show any 
binding to ubiquitinated proteins.
To study the chain linkages present in the pull-down samples, we probed the 
samples with chain specific ubiquitin antibodies. Figure 7.2B shows that all GST-UBD 
fusion proteins were able to isolate K63-ubiquitinated proteins. Tandem-Tab2 displayed 
the highest efficiency to isolate K63-modified proteins. The Mud1 pull-down was most 
efficient for isolation of K48-linked chains, although all other tested GST-fusion UBDs 
showed binding to K48-chains (figure 7.2C). All UBDs except Rap80 captured proteins 
with K11-ubiquitin chains (figure 7.2D). For Mud1, this was unexpected, as Mud1 did 
not bind purified K11-linked di-ubiquitin (figure 7.1A).
Overexpression of K63R and K48R ubiquitin mutants confirms the binding specificity of 
tandem-Tab2 and Mud1
In the previous experiment, it was difficult to determine binding specificity of 
the domains, as stainings of different antibodies cannot be compared. To study the 
specificity of the UBDs for ubiquitinated proteins with different chain linkages, we 
overexpressed strep(II)-tagged ubiquitin mutants in Hela cells, followed by pull-down 
using GST-UBD beads. Overexpression of wildtype ubiquitin and mutants lacking one 
of the three lysines that are most abundant in cellular chains (K11, K48, K63)9-11 was 
tested. All mutants were incorporated into higher molecular weight proteins, indicating 
substrate-ubiquitination (upper left blot, figure 7.3) and pull-down efficiencies were not 
affected by the overexpression of the mutants (lower right blots, figure 7.3). Overex-
pressed strep(II)-tagged wildtype ubiquitin was inefficiently isolated by all UBDs, while 
the mutants were more efficiently isolated by tandem-Tab2 and Mud1. The pull-down 
efficiencies of Tab2 and Rap80 were insufficient to show binding to overexpressed 
strep(II)-tagged wildtype ubiquitin or mutants (data not shown). The binding affinity 
of tandem-Tab2 was lowest for strep(II)-tagged K63R ubiquitin, while K11R and K48R 
were more efficiently isolated. These data confirmed the preference of tandem-Tab2 
for K63-linked chains, although it was not 100% specific, indicated by the residual 
strep(II)-signal in the pull-down using K63R overexpression. Mud1 showed decreased 
pull-down efficiency of strep(II)-tagged K48R ubiquitin, confirming its specificity for 
K48-linked ubiquitin chains. 
Mass spectrometry identifies proteins isolated by the GST-UBD fusions
To identify the proteins that were isolated from U937 cellular extracts using the different 
GST-UBD fusions, tandem mass spectrometry was used. Samples from GST-UBD 
beads without incubation with U937 cellular extracts were included as negative control. 
The number of proteins identified per UBD pull-down are shown in table 7.1A, repre-
senting proteins that were identified in the pull-down using U937 lysates, but not in the 
negative control of the corresponding UBD. 
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To increase the number of protein identifications, we repeated the tandem-Tab2 
pull-down using a larger amount (150%) of U937 cellular extract. This increased the 
number of proteins identified by two-fold (see figure 7.4A). Importantly, of the 74 
unique proteins identified in the first experiment (excluding the proteins identified 
in the negative control), 67 (91%) were identified in the second experiment as well, 
indicating good reproducibility between experiments (figure 7.4A). 
To identify the common and unique proteins isolated by the different GST-UBD 
fusions, we compared the lists of proteins identified in the positive pull-down samples 
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Figure 7.3: Pull-down of UBDs with lysates overexpressing ubiquitin mutants
5 μg GST-UBDs immobilized on glutathione beads was incubated with approximately 5 mg 
Hela cell lysates transfected with Strep(II)-tagged wildtype ubiquitin or single Lysine to Arginine 
mutants, as indicated. Membranes were stained for Strep (overexpressed ubiquitin, upper 
panel) or total ubiquitin (lower panel). A Ponceau staining is included to demonstrate equal 
amounts of GST-fusion proteins. All Strep(II)-tagged ubiquitin constructs were expressed, with 
K48R-ubiquitin showing the lowest expression levels. Strep(II)-tagged wildtype ubiquitin was 
inefficiently pulled down.
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7 of GST, Mud1, Rap80 and tandem-Tab2 (of the larger input experiment) (figure 7.4B, table 7.1B). Among the isolated proteins E3 ubiquitin ligases and proteasome subunits 
were identified, representing enrichment of the ubiquitin system. 
Identification of diG-peptides of proteins isolated by GST-tandem-Tab2
In the mass spectrometric analysis of the pull-down samples, no diG-peptides represent-
ing modified lysines were found, except for internal ubiquitin linkages (data not shown). 
Recently, a novel method has been described to enhance the detection of diG-peptides by 
performing immunoprecipitation (IP) on trypsin digested peptides using a diG-specific 
antibody26,27. To test whether this method would enhance the identification of diG-
peptides following isolation of ubiquitinated peptides using GST-UBDs, we performed 
a diG-IP after tandem-Tab2 pull-down of U937 cellular extracts. The isolated peptides 
were identified using tandem-MS in an identical fashion as the previous experiment. 
A B
Figure 7.4: Protein identification of pull-down samples using mass spectrometry
A. Comparison of unique proteins identified in two independent experiments (tTab2.1 PD vs. 
tTab2.2 PD) using GST-tandem-Tab2 for pull-down of proteins from U937 cellular extracts. 
As negative control, proteins identified in a pull-down experiment using tandem-Tab2 without 
incubation with U937 cellular extracts are depicted as well (tTab2.1 –PD). In the second 
tandem-Tab2 PD sample, more proteins were identified due to larger input of U937 extracts. 
The overlap between the two experiments (excluding proteins identified in the negative sample as 
well) was more than 90% (67/74), based on the first experiment with less proteins identified. B. 
Comparison of proteins identified in the pull-down samples of GST-tandem-Tab2 (experiment 
2: see figure 7.4A), GST, GST-Mud1, GST-Rap80. The unique proteins included in this analysis 
were devoid of the proteins that overlapped with proteins identified in the negative control 
sample per condition (pull-down samples without U937 cellular extracts). The proteins in the 
different groups are listed in table 7.1B, excluding the proteins that were identified in the GST-
pull-down.
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The identified peptides are shown in table 7.1C. Although peptides representing internal 
ubiquitin linkages were abundant, only few diG-modified peptides of other proteins 
were identified. The proteins to which these peptides belonged were identified in the 
mass spectrometry analysis of the tandem-Tab2 pull-down before diG-IP as well.
GST GST-Mud1 GST-Rap80 GST-Tab2 GST-tandem 
Tab2
unique 
proteins
48 52 43 41 75
Table 7.1: Identified proteins by MS analysis of GST-UBD pull-down with U937 cellular 
extracts
A. Number of proteins identified*
*Proteins identified in pull-down samples with U937 cellular extracts, devoid of proteins identified in the negative 
control of the UBD without cellular extracts.
B. Unique proteins identified in specified pull-down samples (related to figure 7.4B)
Mud1+Rap80+ Rap80+ Mud1 Tandem-Tab2
tandem-Tab2 tandem- KCNAB2 RNF126 SLC25A5 ASNA1 SNRNP200 TCP1
UBC Tab2 DDX18 BFAR SLC25A6 WBP2 LGALS9 NOP56
ATP5A1 HSPH1 TOMM34 UBE3A VCP ATP1A1 HLTF KEAP1
LSP1 RASAL3 CORO6 AMFR HIST1H2BE KRT78 LMNA TOP2B
ACTN4 MYO1C DLTS RFWD3 HIST1H3D SCAMP3 PTDSS1 MFN1
CLTC CECR1 UBR4 CLINT1 AHCY LBR ESYT2
ANPEP HUWE1 DCD ATAD3A EIF2S3 CAD
Mud1+ KRT33B CUL1 HSPA1L COMMD9 PARP14 XPO1
tandem- cIAP1* MYADM FARSA LPCAT1 ACLY
Tab2 Rap80 PSMA4 C20orf4 IMPDH2 MCM6 LARS
RLIM CBR1 PSMD7 FADS2 TMEM201 ANXA2 FANCI
RNF115 HBB PSMC2 DHCR7 SLC1A5 EIF4A2 TRPM2
UBR5 APOA1 PSMC3 NAP1L1 CCRN4Lp PTOV1 ALB
PSMC1 TF PSMD11 ERLIN1 HADHB PARP1 SURF4
PKM2 PLK1 PSMD5 RPL30 PDK1 PRPF8 DIABLO
CORO1A SERPINA1 PSMD2 ATP5B LONP2 UBA1 PABPC1
HSPA5 GSN PSMD3 S100A9 RPN2 SUPT16H NAP1L4
BAG6 PSMD1 RPL11 TRRAP SHMT2 LMNB1
SQSTM1 PSMC5 HSP90AB1 CYHR1 KLHL12 RPN1
CCT7 HIST1H1E NASP PABPC4 FAR1 PARP4
HIST1H1B CLEC2B HSPA8 SLC12A9 RBM14-
SLC25A3 VPS13C RBM4
Grey colored, underlined protein: ubiquitin;
Bold, underlined proteins: E3 ligases;
Underlined proteins: 26S proteasome subunits; 
*cIAP1 is a described target for K63-linked ubiquitination31.
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Discussion
To study the role of K63-linked ubiquitin chains in different cellular processes, knowledge 
on the modified substrates is needed. In this chapter we show that GST-UBD fusion 
proteins can be used to isolate endogenous proteins modified with K63-linked ubiquitin 
chains. For the isolation of K63-linked ubiquitin chains, the UBDs of Tab2 and Rap80 
were used. The UBD of Mud1, which shows specific binding to K48-linked chains, 
served as a control. Pull-down experiments with commercially available synthetic 
ubiquitin chains confirmed the specificity of the different UBDs as described before 
(Tab2, Rap80: K63 chains, Mud1: K48 chains, figure 7.1)15-19. Binding of ubiquiti-
nated proteins was greatly enhanced using a fusion protein of two Tab2-NZF domains 
interspersed with a 6-amino acid linker, compared to the single domain (figure 7.1 and 
7.2A). 
Tandem-Tab2 GST-pull-downs with U937 cellular extracts resulted in the 
highest efficiency to isolate proteins modified with K63-ubiquitin chains (figure 7.2B), 
compared to the other domains tested. However, Western blot analysis using K11- and 
K48-linkage specific ubiquitin antibodies revealed the presence of these chains as well in 
tandem-Tab2 pull-down samples. Comparing different antibody signals is not feasible for 
the absolute quantification of the abundance of different chains. To study the specificity 
of tandem-Tab2 to pull-down proteins modified with K63-linked ubiquitin chains, 
we overexpressed tagged ubiquitin mutants lacking one lysine. Although tandem-Tab2 
C: Identified unique diG-peptides by tandem-Tab2 pull-down and diG-IP
protein diG-peptide*
Ubiquitin K6 1-MQIFVKTLTGK-11
Ubiquitin K11 7-TLTGKTITLEVEPSDTIENVK-27
Ubiquitin K11 7-TLTGKTITLEVEPSDTIENVKAK-29
Ubiquitin K29 28-AKIQDKEGIPPDQQR-42
Ubiquitin K48 43-LIFAGKQLEDGR-54
Ubiquitin K48 43-LIFAGKQLEDGRTLSDYNIQK-63
Ubiquitin K63 55-TLSDYNIQKESTLHLVLR-72
Ubiquitin-40S ribosomal protein S27a precursor (outside 
ubiquitin peptide sequence)
105-YYKVDENGKISR-116
Tubulin alpha-1C chain 157-LSVDYGKK-164
ADP/ATP translocase 2 141-LAADVGKAGAER-152
Histone cluster 1, H2aj 101-VTIAQGGVLPNIQAVLLPKK-120
Histone H2B type 1-C/E/F/G/I 118-AVTKYTSSK-126
*The position of the diG-peptide within the corresponding protein is indicated by the flanking numbers and the 
modified K is indicated by underlined italics.
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showed binding to ubiquitin chains containing K63R mutants, it showed less affinity 
to chains composed of this mutant compared to K11R and K48R mutants. This 
confirmed that tandem-Tab2 shows the highest affinity for K63-linked ubiquitin chains 
(figure 7.3). The residual binding of tandem-Tab2 to K63R ubiquitin mutants could be 
explained by non-specific binding of tandem-Tab2 to other chain conformations. Alter-
natively, a K63R mutant ubiquitin moiety could be incorporated in a K63-linked chain 
being the terminal ubiquitin. Such a chain would still be isolated by tandem-Tab2. Yet 
another possibility is the binding of tandem-Tab2 to proteins that are simultaneously 
modified with multiple ubiquitin chains of different chain conformations, of which one 
is wildtype K63-linked and the other chain includes the tagged K63R mutant.
Quantitative mass spectrometry using heavy labeled standards of internal 
ubiquitin linkages should be performed to absolutely quantify the specificity of the UBDs 
for different ubiquitin chains coupled to cellular proteins. Preliminary experiments in 
our laboratory showed that the linear dynamic range of detection of the heavy labeled 
peptide representing the K63-diG linkage was poor with a high limit of detection. In 
the mass spectrometry analyses of the different pull-down samples, the K63 diG-peptide 
signal did not reach the limit of detection, which made absolute quantification unreliable 
(data not shown).
Recent data have described the importance of the linker between UBDs for 
avidity and specificity of ubiquitin binding18,28. This was shown for tandem-UIMs 
(including the UIMs of Rap80) which use the two UIMs for binding of one K63-
linkage. The linker orients the two domains in a structural conformation for binding 
of the ubiquitin-linkage. Hence the composition and length of this linker determines 
the avidity and specificity towards K63-linked ubiquitin chains. Although the Tab2 
NZF-UBD binds one K63-linkage by itself, the nature of the linker in the tandem-Tab2 
protein might be of importance to enhance conformational orientation for binding of 
two consecutive K63-linkages within one chain. Future research should therefore be 
directed at optimizing linker composition and length.
Tab2 and tandem-Tab2 NZF-domains interacted with K11 di-ubiquitin, which 
has not been reported previously. Full-length Tab2 is involved in NF-κB activation, 
mediating downstream signaling upon binding to K63-ubiquitinated RIP117. Recently, 
it has been shown that RIP1 is modified with K11-chains during NF-κB signaling as 
well. NEMO showed affinity for these chains and thereby might regulate downstream 
signaling29. However, Tab2 binding to K11-linked chains was not addressed. Based on 
our results, it would be interesting to test whether Tab2 binding to K11-linked chains is 
also involved in regulating NF-κB signaling.
The MS analysis of the isolated proteins in the pull-down samples identified 
many common and unique proteins in the different UBD pull-downs. Among the 
identified proteins, several proteasome subunits and E3 ligases were present, indicating 
enrichment of the ubiquitin system. It was remarkable to find many proteasome 
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subunits in the pull-down using the K63-linkage specific tandem-Tab2. Although 
mono-ubiquitination has been identified on proteasomal subunits, K63-linked chains 
have not been reported30. One of the isolated E3 ligases, cIAP1 is believed to be a 
substrate for K63-linked ubiquitination31, which validates that the used approach can 
indeed isolate K63-substrates.
The pull-down experiments described here were performed under conditions 
with a relatively high concentration of the denaturing agent DTT (5 mM). However, 
complete elimination of non-covalent protein-protein interactions was likely not 
achieved. Therefore, proof of the ubiquitination status of the isolated proteins was 
needed to reliably conclude that they were ubiquitinated. In the MS analyses of the 
total trypsin digested samples of the different pull-down samples, no diG-peptides 
of proteins other than ubiquitin were identified. To enrich for the diG-peptides, a 
tandem-Tab2 pull-down sample of U937 cellular extracts was immunoprecipitated 
using a diG-specific antibody following trypsin digestion. The subsequent mass spec-
trometry analysis only identified few ubiquitinated peptides, including histone H2A and 
H2B. Remarkably, these two proteins are abundantly modified with mono-ubiquitin in 
cells32, although H2A poly-ubiquitination with K63-linked chains has been described 
during DNA damage repair33,34. Previous reports have demonstrated poor affinity of 
Tab2 to mono-ubiquitin15,16. Also in the experiments described here, we did not observe 
binding of tandem-Tab2 to mono-ubiquitin (notice the lack of free ubiquitin pools in 
tandem-Tab2 pull-down samples, figure 7.3). It would therefore be interesting to study 
whether H2A and H2B are modified with ubiquitin chains in non-stressed conditions 
as well. The described method in this chapter is a promising new technique to isolate 
K63-linked ubiquitination substrates, although further optimization is required to 
enhance the identification of isolated substrates.
Acknowledgements
The authors thank Lieke Egbers and Erik Dullink for help with the GST-purifications.
149
Isolation of K63-ubiquitinated proteins 
7
Reference List
1. Marteijn,J.A., Jansen,J.H., & van der Reijden,B.A. Ubiquitylation in normal and malignant hema-
topoiesis: novel therapeutic targets. Leukemia 20, 1511-1518 (2006).
2. Ikeda,F. & Dikic,I. Atypical ubiquitin chains: new molecular signals. ‘Protein Modifications: Be-
yond the Usual Suspects’ review series. EMBO Rep. 9, 536-542 (2008).
3. Haglund,K. & Dikic,I. Ubiquitylation and cell signaling. EMBO J. 24, 3353-3359 (2005).
4. Chen,Z.J. & Sun,L.J. Nonproteolytic functions of ubiquitin in cell signaling. Mol. Cell 33, 275-
286 (2009).
5. Andersen,P.L. et al. Distinct regulation of Ubc13 functions by the two ubiquitin-conjugating en-
zyme variants Mms2 and Uev1A. J. Cell Biol. 170, 745-755 (2005).
6. Hofmann,R.M. & Pickart,C.M. Noncanonical MMS2-encoded ubiquitin-conjugating enzyme 
functions in assembly of novel polyubiquitin chains for DNA repair. Cell 96, 645-653 (1999).
7. Wu,X., Yamamoto,M., Akira,S., & Sun,S.C. Regulation of hematopoiesis by the K63-specific 
ubiquitin-conjugating enzyme Ubc13. Proc. Natl. Acad. Sci. U.S.A 106, 20836-20841 (2009).
8. Kirkpatrick,D.S., Denison,C., & Gygi,S.P. Weighing in on ubiquitin: the expanding role of mass-
spectrometry-based proteomics. Nat. Cell Biol. 7, 750-757 (2005).
9. Xu,P. et al. Quantitative proteomics reveals the function of unconventional ubiquitin chains in 
proteasomal degradation. Cell 137, 133-145 (2009).
10. Danielsen,J.M. et al. Mass spectrometric analysis of lysine ubiquitylation reveals promiscuity at site 
level. Mol. Cell Proteomics. 10, M110 (2011).
11. Kaiser,S.E. et al. Protein standard absolute quantification (PSAQ) method for the measurement of 
cellular ubiquitin pools. Nat. Methods 8, 691-696 (2011).
12. Dikic,I., Wakatsuki,S., & Walters,K.J. Ubiquitin-binding domains - from structures to functions. 
Nat. Rev. Mol. Cell Biol. 10, 659-671 (2009).
13. Komander,D. et al. Molecular discrimination of structurally equivalent Lys 63-linked and linear 
polyubiquitin chains. EMBO Rep. 10, 466-473 (2009).
14. Raasi,S., Varadan,R., Fushman,D., & Pickart,C.M. Diverse polyubiquitin interaction properties of 
ubiquitin-associated domains. Nat. Struct. Mol. Biol. 12, 708-714 (2005).
15. Kulathu,Y., Akutsu,M., Bremm,A., Hofmann,K., & Komander,D. Two-sided ubiquitin binding 
explains specificity of the TAB2 NZF domain. Nat. Struct. Mol. Biol. 16, 1328-1330 (2009).
16. Sato,Y., Yoshikawa,A., Yamashita,M., Yamagata,A., & Fukai,S. Structural basis for specific recogni-
tion of Lys 63-linked polyubiquitin chains by NZF domains of TAB2 and TAB3. EMBO J. 28, 
3903-3909 (2009).
17. Sato,Y. et al. Structural basis for specific recognition of Lys 63-linked polyubiquitin chains by tan-
dem UIMs of RAP80. EMBO J. 28, 2461-2468 (2009).
18. Sims,J.J. & Cohen,R.E. Linkage-specific avidity defines the lysine 63-linked polyubiquitin-binding 
preference of rap80. Mol. Cell 33, 775-783 (2009).
19. Trempe,J.F. et al. Mechanism of Lys48-linked polyubiquitin chain recognition by the Mud1 UBA 
domain. EMBO J. 24, 3178-3189 (2005).
20. Yan,J. et al. Ubiquitin-interaction motifs of RAP80 are critical in its regulation of estrogen receptor 
alpha. Nucleic Acids Res. 35, 1673-1686 (2007).
21. Candiano,G. et al. Blue silver: a very sensitive colloidal Coomassie G-250 staining for proteome 
analysis. Electrophoresis 25, 1327-1333 (2004).
22. Rappsilber,J., Ishihama,Y., & Mann,M. Stop and go extraction tips for matrix-assisted laser desorp-
tion/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. Anal. Chem. 
75, 663-670 (2003).
23. Wessels,H.J., Gloerich,J., van der Biezen.E., Jetten,M.S., & Kartal,B. Liquid chromatography-
Chapter 7
150
7
mass spectrometry-based proteomics of Nitrosomonas. Methods Enzymol. 486, 465-482 (2011).
24. Weatherly,D.B. et al. A Heuristic method for assigning a false-discovery rate for protein identifica-
tions from Mascot database search results. Mol. Cell Proteomics. 4, 762-772 (2005).
25. Ishihama,Y. et al. Exponentially modified protein abundance index (emPAI) for estimation of ab-
solute protein amount in proteomics by the number of sequenced peptides per protein. Mol. Cell 
Proteomics. 4, 1265-1272 (2005).
26. Kim,W. et al. Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol. 
Cell 44, 325-340 (2011).
27. Xu,G., Paige,J.S., & Jaffrey,S.R. Global analysis of lysine ubiquitination by ubiquitin remnant im-
munoaffinity profiling. Nat. Biotechnol. 28, 868-873 (2010).
28. Sims,J.J. et al. Polyubiquitin-sensor proteins reveal localization and linkage-type dependence of 
cellular ubiquitin signaling. Nat. Methods 9, 303-309 (2012).
29. Dynek,J.N. et al. c-IAP1 and UbcH5 promote K11-linked polyubiquitination of RIP1 in TNF 
signalling. EMBO J. 29, 4198-4209 (2010).
30. Weissman,A.M., Shabek,N., & Ciechanover,A. The predator becomes the prey: regulating the 
ubiquitin system by ubiquitylation and degradation. Nat. Rev. Mol. Cell Biol. 12, 605-620 (2011).
31. Vallabhapurapu,S. et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in 
a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat. Im-
munol. 9, 1364-1370 (2008).
32. Weake,V.M. & Workman,J.L. Histone ubiquitination: triggering gene activity. Mol. Cell 29, 653-
663 (2008).
33. Doil,C. et al. RNF168 binds and amplifies ubiquitin conjugates on damaged chromosomes to al-
low accumulation of repair proteins. Cell 136, 435-446 (2009).
34. Stewart,G.S. et al. The RIDDLE syndrome protein mediates a ubiquitin-dependent signaling cas-
cade at sites of DNA damage. Cell 136, 420-434 (2009).
151
Isolation of K63-ubiquitinated proteins 
7
250kD
148kD
98kD
64kD
50kD
36kD
22kD
GST GST-
Mud1
GST-
Tab2
GST-
Rap80
GST-
tandem
Tab2
5 10
μg BSA
Supplemental figure 7.1: Purity of GST-UBD fusion proteins
GST-UBD fusion proteins were expressed in E.Coli and purified according to the materials and 
methods section. 2 μL of GST-fusion proteins coupled to glutathione beads were separated on 
10% SDS-PAGE gels. Proteins were visualized by Colloidal Coomassie blue staining. Aspecific 
binding of E.Coli proteins to the beads was very limited, and per μL beads, approximately 5μg 
GST-fusion was bound (compared to BSA lanes).
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Thesis objective
The posttranslational modification of cellular proteins with single ubiquitin moieties or 
poly-ubiquitin chains plays an important regulatory role in many biological processes. 
Also in hematopoiesis, ubiquitination plays multiple roles, for example in regulating 
transcription factor stability and immune responses. The objective of this thesis was to 
extend the knowledge on the role of ubiquitination in normal and malignant hema-
topoiesis. To achieve this, global top down and dedicated bottom up approaches were 
followed. On the one hand we focused on altered gene expression of proteins involved 
in ubiquitination in acute myeloid leukemia (AML) and breast cancer. Chapters three to 
five describe the results of these studies, identifying correlations of BRE expression with 
disease outcome in AML and breast cancer. On the other hand, studies were directed 
at substrate identification. The importance of the E2 conjugating enzyme UBC13 for 
normal hematopoiesis served as a starting point to study its contribution to myeloid dif-
ferentiation (chapter six) and to identify proteins that are ubiquitinated with UBC13-
dependent K63-linked ubiquitin chains (chapter seven). 
The strength of outlier analysis 
Chapters three to five describe the prognostic value of gene expression differences of the 
BRCA1-associated protein BRE in AML and breast cancer. This gene was identified via 
a gene expression outlier analysis in AML. In this analysis, genes were identified that 
were differentially expressed in a subgroup of the total AML cohort. The cut-off for 
outlier expression was defined as four times the standard deviation above or below the 
mean of the total cohort. The strength of this analysis lies in its unsupervised approach: 
it identifies genes that show deregulated expression in a small subset of patients, without 
bias of defining subsets before analysis (e.g. based on clinico-pathological factors). The 
disease outcome of the patients with outlier expression was compared to the remaining 
patients to identify correlations of outlier expression with outcome. Another frequently 
used approach to identify correlations between gene expression and disease outcome 
is the univariate Cox regression analysis. However, as outlier expression often occurs 
in small subsets of patients, the analysis of gradual expression differences by the Cox 
regression analysis will likely not identify prognostic correlations of the outlier genes, 
because statistical power of many samples that correlate with disease outcome is lacking 
for these genes. The application of outlier analysis has been useful in other types of 
cancer as well. A well known example is the identification of outlier expression of ERG 
and ETV1 in prostate cancer, which led to the discovery of a frequent chromosomal 
translocation in this cancer type1. 
The outlier analysis we performed identified other genes apart from BRE, 
including EVI1. High expression of this gene is a known poor prognostic marker in 
155
Discussion 
8
AML. Deregulated expression of this gene was identified twenty years ago as a result 
of chromosome 3q aberrations2. Since then it has become clear that this chromosomal 
aberration occurs in only 50% of the high EVI1 expressing cases. In chapter four, we 
showed that high EVI1 expression not resulting from 3q aberrations co-occurred with 
t(9;11) translocations which encode the MLL-AF9 fusion protein. High BRE expression 
also co-occurred with MLL-AF9. By comparing EVI1 and BRE expression levels in 
MLL-AF9 samples, we observed mutual exclusive expression of the two genes. The 
MLL-AF9 positive samples with high BRE expression showed similar global expression 
profiles, unlike the high EVI1 expressing samples that only showed modest similarities 
in expression profiles. This led to the conclusion that MLL-AF9 by itself likely does not 
provoke global expression changes. In combination with the observation that two known 
target genes of MLL-AF9 - MEIS1 and HOXA93 - were not expressed inextricably at a 
high level in individual MLL-AF9 positive AML patients, this indicates that regulation 
of gene expression in MLL-AF9 positive leukemia’s might rely on additional cofactors or 
cellular differentiation state.
In this thesis, we applied outlier expression analysis on ubiquitin-related genes, 
as the regulatory role of ubiquitination in malignant hematopoiesis was the focus of 
our research. Approximately 1,600 genes which were functionally or structurally linked 
to ubiquitination were included in our study. These genes were represented by 2,890 
probesets on the Affymetrix HG133 plus 2.0 array: approximately 5% of the total 
number of probesets. Performing outlier analysis on the remaining 95% will likely result 
in the identification of additional novel prognostic markers.
BRE as a novel cancer-related gene
BRE expression correlated with disease outcome in AML and breast cancer. Yet, 
differences were observed between both cancer types. In AML, BRE was highly expressed 
in a small subset of patients, while in breast cancer there was a gradual expression dis-
tribution. Furthermore, high BRE expression in non-radiotherapy treated breast cancer 
patients predicted an adverse disease outcome, which was opposite to the effect observed 
in AML and radiotherapy treated breast cancer patients. Interestingly, the two latter 
patient groups received therapy that induces DNA double strand breaks: radiotherapy 
for breast cancer patients and high doses of topoisomerase II inhibitors (e.g. idarubucin 
and etoposide) for AML patients. Given the role of BRE in DNA double strand break 
repair, it is tempting to speculate that BRE is involved in therapy responses. Before 
studying this hypothesis, it is important to confirm the gene expression differences at 
the protein level. Several antibodies directed against BRE were tested in our laboratory, 
however none of them yielded reliable results in overexpression experiments. Therefore, 
we have not been able yet to validate the high BRE expression at the protein level in 
patients samples.
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The function of BRE as enhancer of DNA double strand break repair seems 
contradictory to the favorable prognostic effect observed in patients treated with DNA 
damage inducing agents: one might expect that high BRE expression causes cellular 
resistance to radiotherapy and DNA damage inducing chemotherapy, thereby adversely 
affecting disease outcome. Indeed, BRE depletion renders cells more susceptible to 
radiotherapy induced cell death in several cell line models4,5. Similar unexplained con-
tradictory data have been described for other DNA damage repair factors, such as the 
Mre11/Rad50/Nbs1 complex, BRCA1 and ATM6-13. The data presented in this thesis 
warrant further studies on the role of BRE in therapy responses to better understand the 
double-faced characteristics of BRE. 
The failure of proper DNA damage repair can lead to loss of chromosomal 
integrity and consequently to malignant transformation. Given its role in the DNA 
repair pathway, BRE might therefore also function in cancer predisposition and/or cancer 
development. Furthermore, BRE also functions in death receptor mediated apoptosis14. 
Research on the role of BRE in malignant transformation onset and development is 
therefore needed, which should focus both on DNA damage repair and apoptosis. 
Expression regulation of the BRE chromosomal locus
Another interesting observation made in this thesis is the co-expression of RBKS and 
MRPL33 with high BRE expression in AML (figure 3.4). The three genes are clustered 
on chromosome two: MRPL33 and BRE are oriented in the same direction, while RBKS 
is located in between the other two genes on the opposite strand (figure 8.1). The genes 
may share common enhancer elements causing co-expression, potentially mediated 
through three-dimensional chromosomal conformations. Experiments that can detect 
3D DNA configurations are therefore needed to determine whether the co-expression 
of the genes is caused by shared common regulatory elements.
Chromosome 2
27,995,000 28,562,000
read-through
EST
position:
MRPL33
RBKS
BRE
MIR4263
CF594040
DA490081
BI915020
Figure 8.1: Read-through transcripts of BRE
The upper part of the graph represents the locus of the MRPL33, RBKS and BRE genes on 
chromosome 2. MRPL33 and BRE are sense oriented and RBKS antisense. The lower part of 
the graph represents examples of expressed sequence tags (ESTs) showing read-through from 
MRPL33 to BRE. Currently, 10 cases of MRPL33-BRE read-through ESTs have been reported 
in the UCSC database. 
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By analyzing expressed sequence tags (ESTs) of BRE, we observed ESTs that showed 
read-through from MRPL33 to BRE (figure 8.1). The development of deep-sequencing 
techniques has enabled the identification of read-through in cancer samples15,16, and 
might therefore be used in studying the read-through in high BRE expressing patients. 
Preliminary PCR results in our lab confirmed MRPL33-BRE read-through in several 
AML samples. It will be interesting to determine whether this read-through is specific 
for AML and other cancer types compared to normal tissue and if so, what the biological 
role of the MRPL33-BRE transcripts is. However, it is unlikely that this read-through 
is causing the high expression of the three genes, as the transcript does not include 
the antisense oriented RBKS gene. Studying the chromosomal composition of the BRE 
locus also revealed the presence of a microRNA in an intronic region of BRE (MIR4263, 
figure 8.1). Although experimental data on this microRNA are lacking, it is known that 
deregulated expression of microRNAs can contribute to the pathogenesis of cancer17. 
Therefore, determining the expression of microRNA 4263 in normal versus high BRE 
expressing samples is interesting. 
K63-linked ubiquitination in hematopoiesis
The regulatory role of K63-linked ubiquitin chains has been established in several 
important cellular pathways, such as DNA damage repair and NF-κB signaling. 
K63-linked chains are formed to mediate signaling pathways by serving as docking 
sites for protein complex formation, thereby stimulating downstream pathways. 
Tissue specific knockout of the K63-specific E2 conjugating enzyme UBC13 resulted 
in apoptosis of hematopoietic stem cells and early progenitors in mice. This caused 
a reduction of white blood cell numbers, including monocytes. In chapter six of this 
thesis, we studied whether UBC13 depletion affects human myeloid differentiation. 
Its downregulation during differentiation and the decreased differentiation capacity of 
UBC13-silenced U937 cells suggest a functional role for UBC13 during myeloid dif-
ferentiation. These data imply that high levels of UBC13 are needed to enable the onset 
of differentiation. NF-κB and MAP kinase pathways are necessary for proper U937 
differentiation18-21. Given the role for UBC13 in these pathways, it was unexpected that 
UBC13 silencing did not phenocopy the inhibition of NF-κB or MAP kinase pathways: 
inhibition of NF-κB and MAP kinase signaling reduces differentiation as well as 
differentiation-induced apoptosis, while UBC13 depletion only affected differentiation 
and not apoptosis. This suggests that the role of UBC13 is probably not restricted to the 
NF-κB and MAP kinase signaling pathways during myeloid differentiation. 
To study the exact functional role of UBC13 during myeloid differentiation, it is 
important to identify the proteins that are differentially modified with K63-ubiquitin 
chains. In chapter seven we developed a technique to specifically isolate K63-ubiquiti-
nated proteins. This technique is based on the interaction of ubiquitin binding domains 
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of Tab2 and Rap80 with K63-linked ubiquitin chains. The association of these domains 
to ubiquitin is relatively weak and short lived, displaying relatively high dissociation 
constants22. To enhance binding, we generated a tandem Tab2-NZF construct, which 
indeed significantly improved binding efficiency compared to the single Tab2-NZF 
domain. 
The Tab2-NZF domain by itself recognizes a single K63-linkage23,24. The 
increased affinity of a tandem construct might be caused by simultaneous binding of 
two linkages within one chain. In that view, the linker between the two tandem domains 
might be of importance to enable the structural conformation for binding two adjacent 
linkages. Recent data have indeed demonstrated the importance of the linker between 
K63-specific ubiquitin interacting motifs (UIMs) of Rap80 for binding specificity and 
affinity25. These domains differ from the Tab2-NZF domain as the tandem-UIM is 
needed for the recognition of a single K63-linkage. Nevertheless, further optimization of 
the linker in the tandem-Tab2-NZF domain might increase the binding and specificity 
towards adjacent K63-linkages.
Following isolation of K63-substrates, identification with mass spectrometry 
yielded information on potential substrates. Currently, it remains difficult to identify 
true ubiquitinated proteins via mass spectrometry as the abundance of diG-modified 
peptides is low in complex protein samples. Furthermore, clear ubiquitination consensus 
sequences are lacking, making it impossible to reliably predict ubiquitination sites26. 
Recent advances in purifying peptides with a ubiquitin remnant after trypsin digestion 
(via the diG-link) have greatly improved global profiling of ubiquitination27. However, 
this technique requires large amounts of cellular extracts to generate sufficient output. 
The tandem-Tab2 pull-down we performed prior to diG-IP of modified peptides 
likely did not provide sufficient input, hence explaining the identification of only few 
diG-peptides. 
A novel technique that might be very helpful in studying ubiquitination is the 
use of top-down mass spectrometry, which analyzes intact proteins in a tandem-MS 
fashion. This technique greatly enhances sequence coverage and identification of 
post-translational modifications28,29. Currently, this technique is not widely applied, 
because improvements need to be made for the analysis of complex biological samples. 
However, when solved, this technique holds great promise to enhance the detection of 
post-translational modifications. 
Concluding remarks
The goal of this thesis was to identify novel ubiquitin-regulators during normal and 
malignant hematopoiesis. On the one hand, research focused on genes and proteins 
regulating and catalyzing ubiquitination and on the other hand, it focused on substrates 
of this modification. Ideally, future studies should be directed at combining the two 
159
Discussion 
8
approaches. For example, deregulated expression of ubiquitin-related genes in AML, 
as presented in chapter three, could be compared with altered substrate ubiquitina-
tion identified via mass spectrometric analyses. Bioinformatic analyses of the combined 
results could then lead to the identification of novel deregulated pathways in AML 
mediated via ubiquitination.
The title of this thesis ‘Orchestrating the ubiquitin solos in the hematopoietic 
symphony’ might be interpreted as ubiquitin regulating processes on its own. However, 
I hope it is clear from this thesis that ubiquitin is the ultimate example of a team player: 
it needs other proteins to exert its function. This resembles the actual symphonic 
orchestra environment: no solo can exist without the underlying basis of the remaining 
instruments of the orchestra. This enables a moment of fame for the soloist, needed 
for symphony progression. Afterwards, the soloist retracts himself into the rest of the 
orchestra, just like the reversible, time-sensitive nature of ubiquitination. Writing 
the complete hematopoietic symphony in four years is an impossible task. Therefore, 
the symphony in this thesis remains an ‘Unvollendete Symphonie’, with many novel 
research questions for future orchestrators. 
Chapter 8
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Over the past ten years, multiple roles of ubiquitination have been described in the 
field of hematopoiesis. For example, the post-translational modification of important 
transcription factors with K48-linked ubiquitin chains regulates their proteasomal 
degradation during blood cell differentiation. In contrast, K63-linked chains are 
important activating regulators of immune responses and DNA damage responses. 
Aberrations of factors catalyzing ubiquitination have been identified in several types of 
leukemia and other hematopoietic malignancies. This made the ubiquitin proteasome 
system an interesting subject for novel targeted therapies, as discussed in chapter 1. 
This thesis describes several top down and bottom up studies, focusing on both the 
ubiquitination machinery and its substrates in normal and malignant hematopoiesis.
Acute Myeloid Leukemia is the most frequent type of acute leukemia in adults. 
The current five year overall survival is only 40%. Although many recurrent genetic 
aberrations correlate with disease outcome, the survival of patients within genetically 
defined subgroups still shows large variation. Therefore, novel prognostic markers are 
invaluable for improved classification and treatment decisions. 
Full knowledge on clinico-pathological factors is needed when studying correla-
tions of novel factors such as gene expression with disease outcome. Hence, fast and 
efficient screening methods are needed to rapidly identify clinico-pathological factors in 
large cohorts. Chapter 2 governs the application of High Resolution Melting (HRM) 
analysis as a fast and cost-effective technique for screening of the recently discovered 
IDH1 and IDH2 mutations in AML. HRM utilizes the dissociation behavior of double 
stranded DNA fragments. Small differences within PCR products, such as deletions 
or duplications of a few bases, or even single nucleotide substitutions can be readily 
identified. Indeed, HRM analysis was a reliable technique for hotspot IDH1 and IDH2 
mutation screening, with no false negative results and only a small percentage of false 
positive results. The combination of the closed post-PCR HRM technique with con-
firmation of only mutation variants by Sanger sequencing is a reliable, cost-effective 
and fast alternative compared to sequence analysis of all samples, especially when large 
patient cohorts need to be screened.
In chapter 3, we performed a study to identify deregulated expression of genes 
involved in ubiquitination with concomitant predictive value for disease outcome in 
AML. Via a so-called ‘outlier analysis’ we identified deregulated BRE expression in a 
subset of AML patients with favorable prognosis. This gene encodes a member of the 
BRCA1 E3 ligase complex, involved in DNA damage repair. High BRE expression 
co-occurred strongly with a myelomonocytic morphology (FAB M5) and MLL-AF9 
translocations. MLL-AF9 positive patients are currently classified as intermediate risk. 
Especially among these patients, high BRE expression predicted a very good prognosis, 
in contrast to normal BRE expression, which predicted a very poor prognosis. 
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Global expression profiling showed that AML samples with high BRE expression 
were almost completely confined to a previously uncharacterized cluster with similar 
expression profiles. These data suggest that these patients share an underlying mechanism 
that influences global gene expression. The presence of the MLL-AF9 translocation 
may not be the underlying cause, as its co-occurrence with the novel expression profile 
was only partial. Indeed, chapter 4 describes data indicating that there are at least two 
different subtypes of MLL-AF9 positive AML cases, one characterized by high BRE 
expression and the other characterized by high EVI1 expression, a poor prognostic 
marker for AML. The high expression of these two genes was mutually exclusive among 
MLL-AF9 positive patients, with only few patients showing low expression of both 
genes. Based on BRE and EVI1 expression, MLL-AF9 patients could be subdivided 
into a very good and a very poor prognostic subgroup. Diagnostic screening for the two 
genes would therefore improve risk stratification. However, BRE expression differences 
between patients with high or normal expression are small and it would be difficult 
to design a reliable diagnostic tool based on expression of this gene. In contrast, high 
EVI1 expressing patients are readily detected by currently used QPCR techniques and 
diagnostic screening for the combination with MLL-AF9 is therefore warranted.
The global gene expression profiles of MLL-AF9 positive patients with high 
EVI1 expression did not show strong similarities. These data confirmed the observation 
that MLL-AF9 positivity by itself does not provoke global gene expression changes. 
Moreover, in chapter 4 we showed that even well-studied direct targets of MLL-AF9 
were not necessarily highly expressed in all MLL-AF9 positive patients. These data 
indicate that the expression regulation in MLL-AF9 translocated patients may depend 
on additional factors, which could differ per patient or alternatively could depend on 
the leukemia’s cell of origin.
BRE is part of the BRCA1 E3 ligase complex, involved in DNA double strand 
break repair. As BRE depletion attenuates downstream signaling needed for proper 
DNA repair, BRE is functionally important for this complex. The BRCA1 complex 
is closely linked to breast cancer development: mutations in BRCA1 itself are a major 
cause of familial breast cancer. Furthermore, expression alterations, haplotypes or 
polymorphisms of BRCA1 and other complex members have been implicated in breast 
cancer susceptibility. In chapter 5 we therefore questioned whether BRE expression 
had prognostic impact in breast cancer. In a cohort of 229 breast cancer patients, 
BRE expression did not predict disease outcome. However, when the patient cohort 
was subdivided in radiotherapy treated and non-radiotherapy treated patients, BRE 
expression had prognostic impact in both subsets, albeit with opposite effects. In ra-
diotherapy treated patients, BRE expression predicted a favorable prognosis, while in 
non-radiotherapy treated patients, it predicted an adverse prognosis. Previously reported 
data showed radio-sensitivity of cell line models depleted for BRE. This is contradictory 
to the observation that high BRE expression correlated with a favorable disease outcome 
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in radiotherapy treated patients. Additional research is therefore needed to study the role 
of high BRE expression in radiotherapy responses in breast cancer. 
K63-linked ubiquitin chains are important regulators of signaling pathways such 
as the NF-κB pathway, which is constitutively activated in AML stem cells. The E2 
conjugating enzyme UBC13 is currently the only E2 conjugating enzyme identified 
with catalytic specificity for K63-ubiquitin chains. Previous research in conditional 
Ubc13-/- mice showed that this protein is crucial for survival of hematopoietic stem 
cells and early progenitors. The knockout mice died within two weeks after UBC13 
depletion, displaying a severe reduction of white blood cells, including monocytes. 
Chapter 6 is a result of specific studies on the role of UBC13 in myeloid differentiation 
using human cell line models. UBC13 appeared to be downregulated during myeloid 
differentiation of several cell lines. Also UBC13’s cofactors MMS2 and UEV1a were 
downregulated. Silencing of UBC13 diminished PMA-induced monocytic differentia-
tion of U937 myelomonocytic cells, as observed by decreased CD11b expression, while 
not affecting apoptosis or cell cycle progression. This indicates that UBC13 might be 
required for differentiation of U937 cells.
To gain better insight in the function of UBC13 during myeloid differentia-
tion, information on the modified substrates is needed. Currently, techniques to isolate 
endogenous proteins that are ubiquitinated with specific chain conformations are poorly 
developed. In chapter 7, we described a method to isolate K63-ubiquitinated proteins 
using a tandem repeat of the Tab2-ubiquitin binding domain, which specifically binds 
to K63-chains. After isolation of the modified proteins, mass spectrometry was used 
to identify the proteins. Additional research is needed to validate that the identified 
proteins were modified with K63-linked ubiquitin chains. Furthermore, the mass spec-
trometric analysis of the captured substrates could be optimized to further enhance the 
identification of K63-ubiquitinated substrates. When optimized, this technique would 
be very helpful to better understand the role of K63-linked ubiquitination, for example 
in UBC13-mediated U937 differentiation.
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Nederlandse samenvatting
Het bloed vormt één van de grootste organen in het lichaam en bestaat uit allerlei 
typen cellen met allemaal een eigen functie: de rode bloedcellen zorgen voor het 
zuurstoftransport van de longen naar alle delen van het lichaam, de bloedplaatjes spelen 
een rol in de bloedstolling bij verwondingen en de verschillende witte bloedcellen 
zorgen voor afweer tegen ziekteverwekkers. Al deze bloedcellen hebben een beperkte 
levensduur en daarom is het belangrijk dat er continu nieuwe bloedcellen aangemaakt 
worden. Er wordt geschat dat per minuut ongeveer 350 miljoen nieuwe bloedplaatjes, 
rode en witte cellen aangemaakt worden. Dit proces vindt plaats in het beenmerg en 
wordt hematopoëse genoemd. Aan de basis van dit proces staat de hematopoëtische 
stamcel. Deze stamcel deelt zich asymmetrisch: één van de dochtercellen blijft stamcel 
(daarmee wordt het totale aantal stamcellen op peil gehouden) terwijl de andere 
dochtercel zich differentieert (uitrijpt) tot een voorlopercel. Voorlopercellen delen zich 
veelvuldig en differentiëren uiteindelijk door naar de verschillende rijpe bloedcellen (zie 
figuur 1.1, blz. 12). De verhouding tussen celdeling en differentiatie is erg belangrijk 
om een optimale aanmaak van alle volwassen bloedcellen te garanderen. Verstoringen in 
de hematopoëse kunnen dan ook leiden tot een gebrek of overmaat aan bloedcellen. In 
ernstige gevallen kunnen verstoringen leiden tot het ontstaan van bloedkanker, ook wel 
leukemie genoemd.
Bij acute myeloïde leukemie (AML) is het differentiatieproces richting de myeloïde 
celtypen (zoals monocyten en granulocyten die betrokken zijn bij het niet-specifieke 
immuunsysteem) verstoord. In AML patiënten verliezen voorlopercellen hun capaciteit 
om uit te rijpen tot volwassen myeloïde cellen. Deze voorloper cellen hopen zich op 
in het beenmerg, en later ook in het bloed. In het beenmerg verdringen ze de gezonde 
cellen, waardoor uiteindelijk de aanmaak van gezonde volwassen bloedcellen verstoord 
wordt. Mogelijke symptomen van AML hangen hiermee samen: bloedarmoede door een 
gebrek aan rode bloedcellen, een slechte afweer door een gebrek aan witte bloedcellen en 
spontane bloedingen door een gebrek aan bloedplaatjes.
Eiwitten zorgen ervoor dat alle processen in een cel goed verlopen. Daarvoor zijn 
verschillende soorten eiwitten nodig: eiwitten die structuur aan een cel geven, eiwitten 
die signalen van buiten de cel doorgeven naar het binnenste van de cel, eiwitten die de 
activiteit van andere eiwitten reguleren, etc. De informatie voor de aanmaak van eiwitten 
ligt opgeslagen in het DNA van de cel. Door middel van transcriptie en translatie 
wordt deze informatie per eiwit (een gen) gereguleerd afgeschreven (dit noemen we 
genexpressie) wat leidt tot de aanmaak van de specifieke eiwitten.
Fouten in het DNA kunnen verkeerde informatie voor de eiwitproductie aan 
een cel doorgeven, waardoor processen als differentiatie en celdeling verstoord kunnen 
raken. DNA fouten vormen daarom vaak de oorzaak van AML. Bij deze ziekte komen 
veel verschillende DNA afwijkingen voor. De specifieke afwijking voorspelt de prognose 
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van de patiënt, die kan variëren van een voorspelde vijf jaar overleving van minder dan 
10% tot meer dan 80%. Echter, een groot gedeelte van de patiënten heeft geen van de 
bekende DNA afwijkingen. Bovendien varieert de overleving soms drastisch per patiënt 
binnen een groep patiënten met een bepaalde afwijking. Het is daarom noodzakelijk om 
het succes op therapie beter te voorspellen per patiënt zodat therapie daarop aangepast 
kan worden.
In de laatste tien jaar zijn defecten in een belangrijk eiwitregulatie proces - 
ubiquitinering - ontdekt bij AML (tabel 1.2, blz. 23). Nadat eiwitten aangemaakt zijn, 
kan de functie nog verder beïnvloed worden. Bijvoorbeeld door een eiwit naar een andere 
plek in de cel te verplaatsen, de structuur zo te veranderen dat andere eiwitten kunnen 
binden of door de afbraak te reguleren. Deze processen worden vaak post-translationeel 
gereguleerd door het betreffende eiwit te markeren met een ‘vlaggetje’. Eén van die 
vlaggetjes is ubiquitine. Dit kleine eiwitje kan aan een andere eiwit gekoppeld worden 
in de vorm van mono-ubiquitinering. Meerdere ubiquitines kunnen ketens vormen, 
zodat substraateiwitten ook gemarkeerd kunnen worden met poly-ubiquitine-ketens 
(zie figuur 1.2, blz. 19). Afhankelijk van het type keten dat gevormd wordt, heeft 
ubiquitinering van een eiwit verschillende uitkomsten. Ketens die gekoppeld worden 
via Lysine-48 (K48) van ubiquitine leiden tot afbraak van het gemodificeerde eiwit. 
Ketens gekoppeld via Lysine-63 (K63) leiden juist niet tot afbraak, maar tot activatie 
van processen, doordat deze ketens een bindingsplatform vormen voor andere eiwitten 
die hierdoor gerekruteerd worden en activerende signalen doorgeven.
Duizenden eiwitten spelen een rol in de cel en een groot deel van deze eiwitten 
wordt geubiquitineerd. Toch is ubiquitinering een uiterst specifiek proces, aangezien de 
modificatie van al die duizenden eiwitten individueel gereguleerd wordt. De eiwitten 
die verantwoordelijk zijn voor de uitvoer van deze modificatie zijn de zogenaamde E1 
ubiquitine activatie, E2 ubiquitine conjugatie en E3 ubiquitine ligase eiwitten (zie 
figuur 1.2, blz.19), waarbij de E2 het type keten dat gevormd wordt bepaalt en de E3 
substraatspecificiteit introduceert in het proces.
Het proces van ubiquitinering speelt een belangrijke rol in de hematopoëse en 
deregulatie van dit proces kan leiden tot leukemie (voor voorbeelden, zie tabel 1.2, 
blz. 23). Het doel van het promotieonderzoek beschreven in dit proefschrift was het 
bestuderen van gedereguleerde ubiquitinering in AML en de rol van K63-ubiquitine 
ketens tijdens myeloïde bloedceldifferentiatie. Hiervoor is gekeken naar de genexpressie 
van eiwitten die betrokken zijn bij het ubiquitinatie proces in AML patiënten. Daarnaast 
zijn cellijn experimenten uitgevoerd om te kijken naar de rol van K63-ubiquitine ketens 
tijdens myeloïde differentiatie en is een techniek opgezet om eiwitten die gemodificeerd 
zijn met deze ketens te isoleren en te karakteriseren.
Bij het identificeren van een prognostische waarde van gedereguleerde genexpressie 
in AML is het belangrijk te bepalen of de deregulatie samengaat met bekende afwijkingen 
in de bestudeerde patiënten, om zo te bepalen of de genexpressie een onafhankelijke 
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prognostische marker is. Snelle en effectieve methoden zijn daarom noodzakelijk om 
bekende moleculaire afwijkingen in kaart te brengen voor grote studie cohorten. In 
hoofdstuk twee wordt een nieuwe techniek getest om puntmutaties in de genen IDH1 
en IDH2 op te sporen. Mutaties in deze genen zijn recentelijk ontdekt in ongeveer 
20% van de AML patiënten. De techniek besproken in hoofdstuk twee is gebaseerd 
op verschillen in bindingsinteractie tussen dubbelstrengs DNA fragmenten met of 
zonder mutatie. De zogenaamde ‘High Resolution Melting’ (HRM) analyse blijkt een 
goede prescreening te zijn om gemuteerde samples te onderscheiden van ongemuteerde 
samples. Door het gebruik van deze techniek hoeven alleen de gemuteerde samples 
nog gesequenced te worden om de exacte puntmutatie te bepalen. Deze prescreening 
vermindert daarmee de totale benodigde sequencing-tijd drastisch.
In hoofdstuk drie wordt de identificatie van een nieuwe prognostische factor in 
AML beschreven: genexpressie van het eiwit BRE, een eiwit betrokken bij DNA schade 
herstel. Het gen BRE komt hoog tot expressie in een kleine subgroep van AML patiënten. 
Deze patiënten vertonen een goede overleving. Hoge BRE expressie gaat in meer dan 
50% van de gevallen gepaard met een translocatie van chromosoom 9 en 11 (t(9;11)), 
wat resulteert in een MLL-AF9 fusiegen. In de huidige diagnostiek worden MLL-AF9 
positieve patiënten geclassificeerd als ‘gemiddeld risico’. Echter, uit ons onderzoek blijkt 
dat patiënten met deze chromosomale translocatie opgesplitst kunnen worden in een 
groep met zeer goede vooruitzichten (gekarakteriseerd door hoge BRE expressie) en een 
groep met extreem slechte prognose (gekarakteriseerd door normale BRE expressie).
Hoofdstuk vier beschrijft onderzoek naar de verschillen tussen MLL-AF9 
positieve patiënten met hoge en normale BRE expressie, aangezien slechts de helft van de 
MLL-AF9 positieve patiënten hoge BRE expressie vertoont. Hoge expressie van het gen 
EVI1 komt ook frequent voor bij patiënten met MLL-AF9 translocaties. Hoge expressie 
van dit gen is een bekende marker voor slechte prognose in AML. Binnen MLL-AF9 
positieve patiënten komt hoge expressie van EVI1 dan ook niet samen voor met hoge 
BRE expressie. Op basis van deze data concluderen we dat de groep van MLL-AF9 
positieve patiënten niet meer gezien moet worden als een groep met ‘gemiddeld risico’, 
maar dat het belangrijk is deze groep op te splitsen in een goed en slecht risico groep. 
Daarom is diagnostische bepaling van BRE en/of EVI1 expressie in de toekomst van 
belang.
BRE maakt onderdeel uit van een E3 ubiquitine ligase eiwitcomplex waarin ook 
het BRCA1-eiwit aanwezig is. Dit complex is betrokken bij dubbelstrengs DNA schade 
herstel. BRE is nodig voor complex formatie en wanneer BRE afwezig is, is het vermogen 
van een cel om DNA schade te herstellen verminderd. Verschillende afwijkingen in 
het BRCA1 complex zijn betrokken bij borstkanker ontwikkeling, zoals de mutaties 
in BRCA1 zelf die voorkomen bij erfelijke vormen van borstkanker. Een correlatie van 
BRE met borstkanker was echter tot op heden niet beschreven. In hoofdstuk vijf laten 
we zien dat BRE expressie ook bij deze kankervorm een prognostische betekenis heeft. 
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In een cohort van 229 patiënten voorspelde hoge BRE expressie in de tumor een goede 
of slechte prognose afhankelijk van het type therapie waarmee een patiënt behandeld 
werd: bij behandeling met radiotherapie (bestraling) voorspelde hoge BRE expressie 
een goede uitkomst. Bij therapie zonder radiotherapie bleek hoge BRE expressie juist 
een slechte uitkomst te voorspellen. Radiotherapie induceert een bepaalde vorm van 
DNA schade, die ook wordt geïnduceerd door de chemotherapie die wordt gegeven als 
therapie bij AML. Aangezien de functie van BRE in het repareren van dit type schade 
ligt, zou vervolgonderzoek uitgevoerd moeten worden om te bepalen of de mate van 
BRE expressie een functionele rol speelt bij de cellulaire reactie op therapie in deze 
patiënten.
De koppeling van K63-gelinkte ubiquitine ketens aan een cellulair eiwit biedt een 
platform voor interactie met andere eiwitten, en daarmee worden cellulaire processen 
geactiveerd. Deze ketens spelen een rol bij DNA schade herstel, immuunreacties en 
celmembraan-receptor internalisatie. UBC13 is het E2 ubiquitine conjugerend eiwit dat 
verantwoordelijk is voor de koppeling van deze ketens. Muizen die dit eiwit missen, zijn 
niet levensvatbaar en conditionele uitschakeling van dit eiwit in het hematopoëtische 
systeem leidt tot mortaliteit binnen twee weken. Dit eiwit is dus erg belangrijk voor 
een goede bloedcel ontwikkeling. Echter, de exacte processen in de hematopoëse die 
gereguleerd worden door UBC13 zijn nog onbekend.
In hoofdstuk zes wordt onderzoek beschreven naar de rol van dit eiwit tijdens 
de myeloïde differentiatie richting monocyt. Tijdens differentiatie van verschillende 
cellijnen richting myeloïde uitrijping nam de expressie van UBC13 af, wat suggereert 
dat hoge expressie wellicht een rol speelt bij de eerste stappen van differentiatie, maar 
voor verdere uitrijping niet nodig is. Wanneer de expressie van UBC13 artificieel omlaag 
werd gebracht voordat differentiatie werd geïnduceerd, bleek de differentiatie minder 
goed te verlopen. Dit lijkt inderdaad aan te tonen dat hoge UBC13 expressie nodig is 
voor de eerste stappen van myeloïde differentiatie.
Om de rol van UBC13 in de hematopoëse beter te begrijpen, is het belangrijk de 
substraten van UBC13-gemedieerde K63-ubiqutinering te identificeren. In hoofdstuk 
zeven wordt een techniek beschreven om deze onbekende substraten te isoleren 
en identificeren. Met behulp van eiwitdomeinen die specifiek K63-gelinkte ketens 
binden, werden K63-geubiquitineerde eiwitten uit cellulaire lysaten gevist en daarna 
gekarakteriseerd met behulp van massa spectrometrie. Alhoewel het op dit moment nog 
moeilijk blijkt om aan te tonen dat de geviste eiwitten daadwerkelijk een K63-keten 
bevatten, belooft deze techniek een goede aanvulling te zijn in het onderzoek naar 
specifieke ubiquitine ketens. Verder onderzoek zou zich moeten richten op optimalisatie 
van de massa spectrometrische identificatie van de gemodificeerde eiwitten.
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Een promotie is net als een lange bergwandeling met hoge toppen en diepe dalen. 
Gelukkig heb ik de afgelopen jaren een hoop mensen om me heen gehad met wie ik 
de toppen en dalen samen heb kunnen beklimmen. Mede dankzij jullie allemaal is het 
eindresultaat een boekje waar ik trots op kan zijn. Echter, dit boekje is maar relatief: het 
vertegenwoordigt maar een klein deel van alles wat ik geleerd heb als onderzoeker. 
Bert, als eerste wil ik jou bedanken. Jouw onvermoeide enthousiasme heeft me 
keer op keer weer door moeilijke tijden heen geloodst. Ik denk dat onze eigenwijsheid 
ons gemotiveerd heeft om de wetenschappelijke discussies telkens weer op te zoeken, 
wat leidde tot ambitieuze, maar goed doordachte plannen. Je hebt me altijd de vrijheid 
gegeven om het soort onderzoek te doen waar mijn hart ligt, terwijl je er toch zorg 
voor droeg dat mijn promotie niet in gevaar kwam door mij te ‘dwingen’ tot een aantal 
zijprojecten. Alhoewel ik hier soms met enige tegenzin aan begon, ben ik erg dankbaar 
dat je volgehouden hebt, want de BRE-onderzoekslijn had ik niet willen missen.
Joop, jouw kritische mening vanaf de zijlijn en resultaatgerichte werkhouding 
heb ik altijd zeer gewaardeerd. Daarnaast hebben onze gesprekken over mijn verdere 
wetenschappelijke carrière mij erg geholpen om de stap te wagen om als postdoc in het 
buitenland aan de slag te gaan. Ik hoop dat je ondanks je drukke agenda nog veel AIOs 
zo kunt blijven helpen.
Als scheikundige stond de klinische hematologie ver van mij vandaan als 
beginnende AIO. Daarom ben ik blij met jou als promotor, Theo. Jij hebt me elke keer 
weer alert kunnen maken op de klinische relevantie van het detaillistische werk waarmee 
we ons in het lab bezighouden.
Saskia, als paranimf sta je vandaag naast me. Een mooie afsluiting van een 
geweldige samenwerking. Wat was ik blij met jou als analist! Geen proef was je te lastig 
en ik kon altijd op je rekenen, zelfs toen ik op het laatst thuis aan mijn proefschrift 
werkte. Ach, wanneer je zoveel kilometers samen hebt gewandeld door de eindeloze 
maïsvelden als training voor de Nijmeegse 4daagse, dan stelt labwerk toch ook eigenlijk 
niets voor ;-).
Laurens, ook al ben je alweer een tijd weg van onze afdeling, jij bent toch degene 
die me geïntroduceerd heeft in de ubiquitine en Triad1 wereld. Je hebt een hoop 
praktische kennis aan mij doorgegeven, waar ik veel aan gehad heb. Ik heb bewondering 
voor je relaxte werkhouding. Ook naast het werk heb ik veel plezier gehad aan onze 
fietstochtjes, klimuitjes en etentjes op de Floraweg. Hopelijk zet je nog eens wat klassieke 
muziek aan, ook als ik niet meer in de buurt ben om je uit te nodigen voor concerten.
Een speciaal woord van dank gaat uit naar alle studenten die in de afgelopen 
vier jaar met mij gewerkt hebben. Sanne, Tamara, Lieke, Hilke, Dieke, Erik, en Inge: 
bedankt voor jullie geweldige inzet. Ik heb altijd veel lol beleefd aan jullie begeleiding. 
Jullie open blik heeft mij vaak gedwongen mijn tunnelvisie opzij te zetten. Helaas is 
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niet al jullie inspanning terug te lezen in dit proefschrift, maar ik hoop dat ik jullie heb 
kunnen overtuigen dat dat nou eenmaal bij onderzoek hoort.
Davide, a year after I started, you arrived as a new member of the Triad1 clan. 
With your Italian spirit, you dived into functional studies on Triad1. Although I bullied 
you around cleaning up your mess, we had a lot of great scientific discussions on Triad1. 
I am looking forward to the Triad1-Bub1 break throughs! Keep me updated.
Jimmy, binnen de ubiquitine groep stond jouw onderzoek het verst van het mijne 
vandaan. Toch heb ik veel aan jouw input gehad, niet alleen over onderzoekszaken, maar 
zeker ook over allerlei computertechnische zaken. Bedankt voor alle instant hulp bij het 
maken van figuren.
Zonder hulp van ‘De Diagnostiek’ zouden veel van mijn projecten niet gelukt 
zijn. Adrian en Evelyn, altijd enthousiast als jullie waren, was het nooit een probleem 
om nog snel wat PCR experimentjes in jullie planning toe te voegen. Louis, jouw PCR 
kennis is vaak van pas gekomen als ik weer eens een lastige primer nodig had. Marion, 
Ellen, Patricia, Sandy en Laura, ook jullie wil ik bedanken voor alle gezelligheid en hulp.
Peter, onze samenwerking is helaas maar van korte duur geweest. Toch hebben 
we in die korte tijd leuk samengewerkt, en ik heb onze muziekgesprekken erg leuk 
gevonden. Hopelijk kun je nog vele jaren op het lab hematologie werken en genieten 
van een rustig en gezond leven.
Saskia L, Leonie en Thessa, naast de gezelligheid op het lab, hebben wij samen 
letterlijke hoogtepunten beleefd in de klimhal en op de klimtochtjes naar Duitsland en 
Frankrijk. Hopelijk lukt het om nog een klimuitje te plannen voordat ik naar Canada 
vertrek, maar dan het liefst zonder een dag regen in de kayak. Thessa, heel veel geluk met 
de nieuwe telg in jullie gezinnetje.
Maaike, uiteraard mag jij niet ontbreken in dit dankwoord. Wat een steunpilaar 
ben jij voor iedereen om je heen! Je kaartjes hebben me vaak een hart onder de riem 
gestoken. Ik heb de hele collectie nog thuis liggen. Ik hoop dat je je draai helemaal gaat 
vinden als kinderarts en ik heb er alle vertrouwen in dat jouw proefschrift ook snel af 
gaat komen.
Ook alle andere collega’s van de moleculaire unit wil ik bedanken voor de 
geweldige tijd. Gorica, wat hebben we een hoop lol gehad in ons hokje. Ik ga ons lijflied 
nog vaak draaien. Hopelijk komt er snel weer iemand om onze kamer op te vullen, nu 
vis Joop er ook niet meer is om je gezelschap te houden. Ruth, ik hoop dat je als lab 
oudste nog een hoop AIOs kunt helpen met je praktische trucjes. Mariam, Leilei and 
Pedro, thank you for the multicultural atmosphere in the lab. All the best with finishing 
your PhDs.
Buiten onze eigen moleculaire unit, heb ik ook veel hulp gehad van andere units. 
Iedereen erg bedankt hiervoor. Speciaal wil ik de hele GVL unit bedanken voor alle 
gezelligheid. Ik heb niet zoveel in de Aesculaaf kunnen zitten als ik misschien gewild 
had, maar het was altijd gezellig met jullie. Een speciaal woord van dank heb ik voor 
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Rob. Jouw FACS hulp is van onmisbare waarde voor dit lab. Ook de vrijdagse hardloop-
uurtjes zal ik niet vergeten.
Tijdens mijn promotie heb ik met veel mensen samen kunnen werken, zowel 
binnen als buiten Nijmegen. Hans, Maurice en Jolein, bedankt voor de introductie in 
de mass spec wereld. Helaas is ons project niet zo mooi verlopen als we gewild hadden, 
maar dankzij jullie heb ik heel veel kennis opgedaan die ik in de toekomst verder hoop 
toe te passen. Mathijs en Peter, jullie open samenwerking heeft geleid tot twee mooie 
publicaties over BRE expressie in AML. I would also like to thank Lars for his help on the 
BRE MLL-AF9 project. Vanuit het AML veld heb ik even een uitstapje gemaakt naar het 
borstkanker onderzoek. Paul en Marloes, bedankt voor jullie hulp hierbij. Helaas heeft 
het functionele werk niet direct iets opgeleverd. Ik hoop dat het paper met de klinische 
data in een mooi journal terechtkomt. Ook al is het Triad1 werk uiteindelijk niet in mijn 
proefschrift terecht gekomen, ik wil toch graag de samenwerking met Titia en Judith 
hier vermelden. De werkoverleggen over ons favoriete eiwit waren altijd erg constructief 
en ik heb veel geleerd van jullie moleculaire insteek. Ik hoop dat het HOIP-HOIL paper 
snel geaccepteerd wordt (als het niet al gebeurd is ten tijde van mijn promotie).
Naast de mensen die direct betrokken zijn geweest bij mijn promotieonderzoek, 
wil ik ook alle mensen bedanken die hebben gezorgd voor de nodige afleiding van het 
werk. In het bijzonder wil ik ‘t Pendada kwintet bedanken. Marleen, Inge, Rutger en 
Tom: wat hebben wij een hoop lol gehad samen. De twee FIMU-reizen waren misschien 
het hoogtepunt, maar de repetities waren voor mij ook altijd een feest en een welkome 
afleiding. Sorry dat ik nu naar de andere kant van de wereld vertrek. Hopelijk komt er 
een Canadese tour aan in de toekomst! Inge en Marleen, jullie waren toch wel een beetje 
mijn steun en toeverlaat. De weekendjes Riga en Istanbul waren geweldig, laten we het 
snel een keer overdoen in Toronto.
Alle studievrienden, bedankt voor de gezellige etentjes. Het is altijd fijn om 
met gelijkgestemden over het AIO-leven te kunnen zeuren. Sanne, ik ben erg blij dat 
jij vandaag mijn paranimf bent. Hopelijk komt jouw boekje ook snel af. Liesbeth, 
Toronto-New York is maar een kippeneindje. We komen elkaar snel een keer opzoeken, 
en wie weet maak ik dan een tussenstop in Boston bij Judith.
Tenslotte wil ik mijn familie bedanken voor alle steun. Het doet me verdriet dat 
Tante Cora er vandaag niet bij is, ik weet hoe trots ze geweest zou zijn. Als jongste telg van 
het Noordermeer-gezin, ben ik blij dat ik me nu ook onder de Doktoren mag scharen. 
Wanneer zouden we nou eens voor die nationale wetenschapsquiz gevraagd worden? 
Minke, Jan Willem, Edo, Joanna, Daan, Maren, Simon, Hasse en Arthur, ik ga jullie 
allemaal erg missen in Canada, maar kijk nu alweer uit naar de scheikundegesprekken 
onder het kerstdiner (Sorry Mam, Jan Willem, Edo en Joanna). Pap en Mam, bedankt 
voor jullie steun in alles. Het was heerlijk om af en toe bij jullie te kunnen uitpuffen als 
ik het allemaal niet meer zag zitten. Ik hoop dat jullie lekker kunnen gaan genieten van 
je pensioen en ik hoop jullie vaak te verwelkomen in Canada.
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